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Abstract 
Gene therapy is a potent and versatile nano-medicine strategy in the treatment of cancer. 
Of the many tools currently used in this application, short-interfering RNA (siRNA) are among 
the most commonly employed due to their ability to silence oncogenic mRNA with high precision 
and potentially induce cancer cell apoptosis through the RNA interference (RNAi) pathway. Our 
work revolves around silencing the Glucose-Regulated Proteins (GRPs) whose expressions are 
upregulated in cancerous tissues and are implicated in altering the proliferative, pro-survival, and 
anti-apoptotic pathways within these tumors. 
Chapter 2 highlights a novel role that GRP78 has in cell-cell adhesion and its implication 
in tumors (multiple myeloma, MM and prostate cancer, PCa) that target the bone as a primary 
metastatic site. Using siRNA to silence GRP78, a concomitant downregulation of a mesenchymal 
cell-adhesion marker, N-cadherin, was observed in multiple myeloma and prostate cancer cell 
lines. Upon further investigation with an epithelial prostate cancer cell line, PC3, it was noted that 
the GRP78 silencing led to concomitant downregulation of E-cadherin and subsequent 
upregulation of TGF-b1 and Snail-2. Interestingly, TGF-b1 expression has been correlated with 
EMT and the upregulation of N-cadherin, suggesting that our findings indicate a novel function of 
GRP78 in which it can modulate the expression of adhesion molecules in a manner that supersedes 
the natural pathways that regulate their expression in PCa. Furthermore, the PC3 cells treated with 
GRP78 siRNA produced drastic changes in their morphology from their normal elongated shape 
to a more rounded shape which resulted in a reduction in their adhesion to an osteoblast (bone cell) 
monolayer in an N-cadherin dependent manner. These results help establish a novel correlation 
between GRP78 and N-cad in MM and PCa cells and present GRP78 as an ancillary regulator of 
markers associated with the EMT pathway andin the adhesion properties of PCa to the bone. 
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Chapter 3 discussed the application of a synthetic methodology that led to the production 
of linear, V-shape and Y-shape RNA templates, the latter two by the incorporation of a unique 
branchpoint ribouridine synthon. In this application, the RNA templates were used to hybridize 
complementary RNA strands that self-assembled into higher order nanostructure formulations. 
These formulations were designed to adopt genetically encoded shapes that resulted in siRNA 
hybrids that targeted multiple GRPs (GRP78, GRP94, GRP75). Moreover, they were capable of 
inducing synergistic knockdown of the GRPs in multiple tumor types (endometrial, breast, 
cervical) while being relatively inactive in a non-cancerous lung cell line. This established that the 
self-assembled siRNA nanostructures as a more potent anti-cancer gene therapy tool as compared 
to a cocktail of linear siRNAs, administered separately. Moreover, siRNA bioconjugates based on 
the V- and Y-shape RNA templates were designed to incorporate multi-functionality to the siRNA 
constructs and improve their scope of applications. A theranostic FITC-siRNA bioconjugate was 
synthesized and provided a unique opportunity to track cell uptake, localization, and mechanism 
of action. A self-assembly approach facilitated the incorporation of multi-FITC containing 
siRNAs, that resulted in greater sensitivity (up to 72 hours post transfection) relative to their singly 
labeled counterparts due to the enhanced signaling effect. Sense strand functionalization provided 
the most potent GRP KD effects (50-95%) which translated to the most significant cell death 
effects (20-95%) within a model PC3 PCa cell line. Furthermore, amphiphilic fatty acid- siRNA 
bioconjugates were generated to potentially improve the permeability of the siRNA across the cell 
membrane. The C16 (palmitic acid) and C18 (oleic acid) conjugated siRNAs were able to elicit 
GRP78 knockdown, albeit to a moderate extent (~30-40%). Sense strand functionalization and 
self-assembly to linear, V-, and Y-shape antisense templates afforded constructs containing a 
single, double, or triple palmitamide that also failed to improve GRP knockdown. Cellular uptake 
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studies performed by flow cytometry with a chimeric fluorophore –fatty acid siRNA bioconjugate 
revealed limited cell uptake, and/that rapidly dissipated within 24hrs post transfection. 
Furthermore, DLS and TEM analysis showed large aggregate particles with sizes upwards of 1 µm 
which we propose altogether inhibited cell uptake and RNAi activity.  
Chapter 4 of this thesis illustrates a unique method for targeting cells for siRNA delivery. 
The cell targeting peptides (CTPs) function to target and bind to a cell surface receptor, in this case 
PSMA, found on the surface of PCa cells. Moreover, the incorporation of poly(cationic) cell 
penetrating peptides (CPPs), such as poly(arginine), can have the dual functionality of condensing 
siRNA by favorable electrostatic interactions and facilitating cell uptake within the target cell. A 
lead model peptide sequence, PSMA-1, was functionalized with short oligo(arginine) sequences 
(R6 and R9). The PSMA-1 peptide was able to effectively bind to PSMA+ LNCaP cells with a 
limited amount of nonspecific binding to a PSMA- PC3 cell line. The R6 variant was shown to 
efficiently complex and release siRNA according to a gel shift assay, yet no GRP78 KD was 
detecte mRNA and protein levels of expression within the PC3 or LNCaP cells. Flow cytometry 
revealed that the FITC-PSMA-1-R9 peptide showed limited cell uptake when bound with siRNA. 
DLS and TEM analysis showed large particle sizes (1-2 µm), polydisperse particle distributions, 
negative surface charge densities and aggregation, all of which prevented cell uptake of the 
peptide:siRNA complexes when compared to siRNA complexed with a commercial transfection 
reagent. Together, this thesis will serve to highlight the biological evaluation of novel siRNA 
formulations for the study of GRP function in cancer. 
 
KEYWORDS: siRNA, Glucose Regulated Proteins (GRPs), Prostate Cancer, N-cadherin, 
Adhesion, siRNA nanostructures, siRNA bioconjugates 
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Chapter 1: General Introduction into the Applications of siRNA in RNAi 
Based Gene Therapy 
 
1.1 Discovery of RNAi  
RNA interference (RNAi) is a potent biological process that serves as a regulator of gene 
expression by suppressing  protein expression and degrading  targeted mRNA. One of the first 
major examples of modern RNAi applications were pioneered by Andrew Fire, et al. when they 
demonstrated an effective and specific inhibition of the uncoordinated (unc-22 and unc-54) genes 
in C. elegans muscle through the production of antisense RNA. In this application, DNA segments 
of the genes were placed in reverse orientation inside of plasmid vectors designed to produce RNA 
in body wall muscle. The constructs led to an observed a loss of wild-type motor function in  test 
worms and an apparent loss of unc-22 protein via immunoimaging. They further provided genetic 
evidence for an antisense mechanism, confirming that homology between an inverted region and 
the wild- type chromosome was necessary for the disruption of gene function.1 
Guo and Kemphues further complemented Fire’s findings on antisense RNA for their work on 
the par-1 gene in C. elegans, a major protein involved in the worms’ embryonic development. 
Upon injection of exogenous DNA constructs containing either the sense or antisense sequence of 
the par-1 gene into C. elegans, they observed more than 50% of the embryos were terminated in 
both cases. While the results from the antisense vectors were consistent with an antisense inhibition 
mechanism complete with cell division patterns characteristic of par-1 loss of function mutations, 
the sense vectors also induced unexplainable par-1 phenotypic changes among the test worms’ 
progeny. They summarized that, unlike the antisense constructs, the effects of the sense vectors 
seemed to be restricted to a putative translated region of the gene and may function on separate 
and unique mechanisms.2 
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Years later, Fire and Mellow set out to investigate the underlying mechanism of the interfering 
RNA. Building on previous work in C. elegans,1 mixtures of RNA-producing DNA vectors 
containing the sense and antisense sequences for the unc-22 and unc-54 genes were injected into 
the worms. To their surprise, the expressing complementary RNA sequences elicited a far more 
potent loss in motor function in the worm’s muscle compared to solely the antisense or sense 
sequences (100% for dsRNA vs 1-11% for ssRNA) and even at 120-fold lower doses of dsRNA, 
the same loss in function was observed (~30%) (Figure 1.1). From their investigation, they made 
three major claims about the observed RNA interference (RNAi) pathway: 1) targeting exon 
regions of the intended gene is essential as targeting intronic or promoter regions had little to no 
effect, 2) mRNA is the likely target for RNAi, and 3) the dsRNA-mediated interference could 
easily cross cellular boundaries. They concluded that this process likely exists as a mechanism 
used by organisms for physiological gene silencing and could extend into other invertebrates and 
vertebrates as well.3  Fire and Mellow were awarded the Nobel Prize in Physiology or Medicine 
in 2006 for their discovery of the RNAi pathway. 
 
Figure 1.1  Phenotype responses in C. elegans after injection with dsRNA- producing DNA 
vectors. Fluorescent labeling of the muscle along the body cavity in wild-type (A-C) that is 
diminished after injection with dsRNA (G-I). Adapted from Fire, A.;  Xu, S.;  Montgomery, M. 
K.;  Kostas, S. A.;  Driver, S. E.; Mello, C. C., Nature 1998, 391 (6669), 806-811.3 with permission 
from Springer Nature. 
Nature © Macmillan Publishers Ltd 1998
8
letters to nature
808 NATURE | VOL 391 | 19 FEBRUARY 1998
striated muscle cell3. Semiquantitative correlations between unc-22
activity and phenotype of the organism have been described8:
decreases in unc-22 activity produce an increasingly severe twitch-
ing phenotype, whereas complete loss of function results in the
additional appearance of muscle structural defects and impaired
motility.
Purified antisense and sense RNAs covering a 742-nucleotide
segment of unc-22 had only marginal interference activity, requiring
a very high dose of injected RNA to produce any observable effect
(Table 1). In contrast, a sense–antisense mixture produced highly
effective interference with endogenous gene activity. The mixture
was at least two orders of magnitude more effective than either
single strand alone in producing genetic interference. The lowest
dose of the sense–antisense mixture that was tested, ,60,000
molecules of each strand per adult, led to twitching phenotypes in
an average of 100 progeny. Expression of unc-22 begins in embryos
containing ,500 cells. At this point, the original injected material
would be diluted to at most a few molecules per cell.
The potent interfering activity of the sense–antisense mixture
could reflect the formation of double-stranded RNA (dsRNA) or,
conceivably, some other synergy between the strands. Electrophoretic
analysis indicated that the injected material was predominantly
double-stranded. The dsRNA was gel-purified from the annealed
mixture and found to retain potent interfering activity. Although
annealing before injection was compatible with interference, it was
not necessary. Mixing of sense and antisense RNAs in low-salt
concentrations (under conditions of minimal dsRNA formation) or
rapid sequential injection of sense and antisense strands were
sufficient to allow complete interference. A long interval (.1 h)
between sequential injections of sense and antisense RNA resulted
in a dramatic decrease in interfering activity. This suggests that
injected single strands may be degraded or otherwise rendered
inaccessible in the absence of the opposite strand.
A question of specificity arises when considering known cellular
responses to dsRNA. Some organisms have a dsRNA-dependent
protein kinase that activates a panic-response mechanism10. Con-
ceivably, our sense–antisense synergy might have reflected a non-
specific potentiation of antisense effects by such a panicmechanism.
This is not the case: co-injection of dsRNA segments unrelated to
unc-22 did not potentiate the ability of single unc-22-RNA strands
to mediate inhibition (data not shown). We also investigated
whether double-stranded structure could potentiate interference
activity when placed in cis to a single-stranded segment. No such
potentiation was seen: unrelated double-stranded sequences located
59 or 39 of a single-stranded unc-22 segment did not stimulate
interference. Thus, we have only observed potentiation of inter-
ference when dsRNA sequences exist within the region of homology
with the target gene.
The phenotype produced by interference using unc-22 dsRNA
was extremely specific. Progeny of injected animals exhibited
behaviour that precisely mimics loss-of-function mutations in
unc-22. We assessed target specificity of dsRNA effects using three
additional genes with well characterized phenotypes (Fig. 1, Table
1). unc-54 encodes a body-wall-muscle heavy-chain isoform of
myosin that is required for full muscle contraction7,11,12; fem-1
encodes an ankyrin-repeat-containing protein that is required in
hermaphrodites for sperm production13,14; and hlh-1 encodes a C.
elegans homologue of myoD-family proteins that is required for
proper body shape and motility15,16. For each of these genes,
injection of related dsRNA produced progeny broods exhibiting
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Figure 1 Genes used to study RNA-mediated genetic interference in C. elegans.
Intron–exon structure for genes used to test RNA-mediated inhibition are shown
(grey and filled boxes, exons; open boxes, introns; patterned and striped boxes,
59and39untranslated regions.unc-22. ref. 9,unc-54, ref.12, fem-1, ref.14, andhlh-1,
ref.15). Each segment of a gene tested for RNA interference is designatedwith the
name of the gene followed by a single letter (for example, unc22C). These
segments are indicated by bars and upper-case letters above and below each
gene. Segments derived from genomic DNA are shown above the gene; seg-
ments derived from cDNA are shown below the gene. NLS, nuclear-localization
sequence; MtLS, mitochondrial localization sequence.
a
b
c
d
e
f
g
h
i
Control RNA (ds-unc22A) ds-gfpG RNA ds-lacZL RNA
A
d
u
lt
L
1
A
d
u
lt
Figure 2 Analysis of RNA-interference effects in individual cells.Fluorescence
micrographs show progeny of injected animals from GFP-reporter strain PD4251.
a–c, Progeny of animals injected with a control RNA (double-stranded
(ds)-unc22A). a, Young larva, b, adult, c, adult body wall at high magnification.
These GFP patterns appear identical to patterns in the parent strain, with
prominent fluorescence in nuclei (nuclear-localized GFP–LacZ) and mitochondria
(mitochondrially targeted GFP). d–f, Progeny of animals injected with ds-gfpG.
Only a single active cell is seen in the larva in d, whereas the entire vulval
musculature expresses active GFP in the adult animal in e. f, Two rare GFP-
positive cells in an adult: both cells express both nuclear-targeted GFP–LacZ and
mitochondrial GFP. g–i, Progeny of animals injected with ds-lacZL RNA:
mitochondrial-targeted GFP seems naffected, while the nuclear-targeted GFP–
LacZ is absent from almost all cells (for example, see larva in g). h, A typical adult,
with nuclear GFP–LacZ lacking in almost all body-wall muscles but retained in
vulval muscles. Scale bars represent 20mm.
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1.2 siRNA Structure and Function in RNAi Pathway 
There are numerous non-coding RNAs (ncRNAs) that have been established as important 
regulators of gene expression.4,5 Prokaryotes use small antisense RNAs (asRNAs) to bind and 
inhibit the expression of target mRNA into functional proteins. Likewise, various small ncRNAs 
are active as inhibitors of gene regulation in eukaryotes, with the most prominent being 
microRNAs (miRNAs) and small interfering RNA (siRNAs) which can both activate the RNAi 
pathway6-8.  
While structurally and functionally similar, these two classes of small ncRNAs do have some 
unique characteristics. miRNAs are generally considered to evoke RNAi through an endogenous 
pathway, i.e  synthesized within the cell. They are transcribed as long primary miRNA transcripts 
(pri-miRNA) which are partially cleaved by a microprocessor complex in the nucleus yielding a 
stem-loop pre-miRNA. This pre-miRNA is transported to the cytoplasm and further processed by 
a nuclease enzyme called Dicer into a small 19-25 nucleotide (nt) dsRNA consisting of an active 
strand and an inactive passenger strand (Figure 1.2).9, 10  
While they can still be produced naturally by the enzymatic action of Dicer from long dsRNAs, 
siRNAs are generally considered to be exogenous RNAs (not synthesized within cells and 
introduced as external agents).9,11 They are introduced into the cytoplasm of the cells via a cationic 
polymer formulation that can condense the siRNA into small, discrete particles and facilitate their 
transient permeability across the cell membrane.12, 13 siRNAs are short dsRNAs ranging from ~20-
25nt in length with a well-defined structure consisting of a phosphorylated 5’-end and a 
hydroxylated 3’-end typically containing a 2nt overhang. These small dsRNA also consist of an 
active guide strand and inactive passenger strand.14, 15 
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Table 1.1 Structural and functional differences between siRNA and miRNA. Reprinted from 
Ahmadzada, T. R., G.; McKenzie, D. Biophysical Reviews 2018, 10, 69-86.9 with permission from 
Springer Nature. 
 
In particular, siRNA activates the RNAi pathway through a ribonucleoprotein effector complex 
known as RISC – RNA Induced Silencing Complex.16 Once in the cytoplasm, the siRNA are 
incorporated into the RISC complex where Ago2, an Argonaute protein containing a ribonuclease, 
RNAse III type domain, identifies the active guide antisense strand of the siRNA duplex and 
degrades the passenger sense strand. 17-19 The loaded RISC complex uses the antisense RNA strand 
as a template to recruit and bind to complementary mRNA which is then rapidly degraded by the 
Ago2 protein at cleavage sites determined by the 5’ end of the siRNA strand.20, 21 Importantly, 
siRNA have near perfect complementarity to their target mRNA resulting in very specific 
knockdown of genes which is in stark contrast to miRNA which may target many mRNAs (Figure 
1.2).9 Cleavage of target mRNA by siRNA mediated RNAi prevents its translation into protein 
which may diminish cell function and viability. In this manner, the RNAi strategy can target nearly 
any gene, including silencing detrimental gene transcripts as a treatment option for a variety of 
genetic diseases.22, 23 The modern advances in this field from its discovery by Fire and Mellow has 
(passenger) strand. siRNAs are regarded as exogenous RNAs
that enter the endogenous RNAi pathway. miRNAs, on the
other hand, are endogenous RNAs produced from within the
cells, expressed as long primary miRNA transcripts (pri-
miRs) from miRNA genes (Sioud 2015). After partial cleav-
age by the microprocessor complex in the nucleus, the stem-
loop pre-miRNA is exported to the cytoplasm, where it is
further processed by Dicer into a double-stranded RNA
consisting of the active, or mature, strand and the inactive
passenger strand. The mature miRNA is incorporated into
the RISC to initiate gene silencing. In contrast to the perfect
complementarity between an siRNA and its target mRNA, an
miRNA has imperfect complementarity, mostly within the
seed sequence at its 5′ end (Carthew and Sontheimer 2009).
In terms of silencing and potential clinical use, a key dif-
ference between siRNAs and miRNAs is that an siRNA is
specific for a single target site in a single mRNA, and, there-
fore, inhibits the expression of one target gene, whereas an
Table 1 Differences between siRNA and miRNA
siRNA miRNA
Occurrence Occurs naturally in plants and animals.
It is currently unknown whether or
not they occur naturally in mammals.
Occurs naturally in plants and animals.
Mean length Approx. 21–22 nt Approx. 19–25 nt
Complementarity t
o target mRNA
100% perfect match; therefore, siRNAs
knock down specific genes, with
minor off-target exceptions.
Not exact; therefore, a single miRNA
may target up to hundreds of mRNAs.
Biogenesis Regulate the same genes that express
them.
Expressed by genes whose purpose is
to make miRNAs, but they regulate
genes (mRNAs) other than the ones
that expressed them.
Action Cleave mRNA. Inhibit or replace translation of mRNA.
Function Act as gene silencing guardians in plants
and animals that do not have antibody-
or cell-mediated immunity.
Regulators (inhibitors) of genes (mRNAs)
Fig. 1 Gene silencing using siRNA or miRNA mimics. Once the siRNA
or miRNA mimic has been introduced into the cytoplasm of the cell, it is
unwound and the active antisense strand (green) is incorporated into the
RISC. This leads to gene silencing via two distinct mechanisms, depend-
ing on the extent of base pairing between the antisense strand and the
target mRNA. With siRNA on the left, the complete homology between
the antisense and target mRNA (yellow) leads to site-specific cleavage
and degradation of the mRNA. In contrast, the partial sequence identity
between the active miRNA strand and its mRNA target leads to inhibition
of translation, decapping, and subsequent mRNA degradation
72 Biophys Rev (2018) 10:69–86
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since evolved RNAi into a modern, precise, and efficient technology for screening and silencing 
targeted genes in a wide range of applications.  
 
 
Figure 1.2. RNAi mechanism of action induced by siRNA or miRNA. Reprinted from Wilson, R.; 
Doudna, A., Annu Rev Biophys 2013, 42, 217-239.16 with permission from Annual Reviews. 
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1.3 Applications of siRNA in Cancer Gene Therapy 
The high efficiency and specificity of siRNA in silencing target genes have made them 
interesting and promising therapeutic candidates in the treatment of genetic disorders, including 
cancer. Genetic mutations are common throughout the tumor lifespan and may function as genetic 
markers for targeting and silencing the progression of the disease.24 These tumor promoting genes, 
oncogenes, are defined as mutated genes related to tumor progression, can lead to altered protein 
function, amplification of specific gene products, deletions which alter the abundance of a 
particular protein, and alternate splicing leading to novel cancer proteins, oncoproteins.25,26 
However, not all of these mutations are direct causes of cancer, 27 rather, there is a small minority 
of mutations that act as “drivers” of tumor progressions that, once determined, offer a therapeutic 
regimen in the treatment of specific cancers (Figure 1.3).  
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Figure 1.3. Frequency of mutations in selected genes of various cancers. Reprinted with 
permission from Elsevier: Dancey, J.;  Bedard, P.;  Onetto, N.; Hudson, T. Cell 2012, 148, 409-
420.24 
 
RNAi technologies have become a focal point, especially in the treatment of difficult 
oncoprotein targets which may not be targetable through conventional drug treatment 
approaches.28 Furthermore, a major advantage of using RNAi technology is  the ability to target 
multiple genes among various cellular pathways.29 (Table 1.2). This not only may lead to a 
practical therapy, but may also serve as a screening assay to identify important oncogene targets 
in specific cancer types. 
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Pathway Target Gene  
Cell Adhesion Matrix 
metalloproteinase30 
Apoptosis Bax31 
Bcl-232, 33 
Angiogenesis Focal Adhesion Kinase34  
Signaling  H-Ras32, K-ras35 
PLK-136 
TGF-b32 
STAT337 
EGFR38, 39 
PKC-a32 
Cell-Cell 
Communication 
VEGF32 
Lipid Metabolism Fatty Acid Synthase40 
Table 1.2. siRNA gene targets in cancer. Adapted with permission from Springer Nature: 
Devi, G.R. Cancer Gene Therapy. 2006, 13(9), 819-826.41 
 
 Despite the array of potential targets for siRNA in a cancer gene therapy approach, they 
are limited in their translation to clinical use by a few key obstacles. First, siRNAs are not 
intrinsically stable in the cellular cytosol and are rapidly degraded by resident nucleases. Secondly, 
siRNAs are not cell permeable and require chemical carriers to cross the plasma membrane of 
cells. These carriers, also referred to as transfection reagents are also affected by notable 
limitations, including delivery efficiency, uptake and release profiles and toxicity.  Together, these 
limitations reduce the siRNA resident time at desired cellular target, thereby limiting their 
efficiency and potency often leading to higher dose concentrations, which increases the propensity 
for the siRNA to exhibit off-target side effects despite their high mRNA sequence specificity.42  
 
1.4  Modified siRNA for Pre-Clinical and Clinical Applications 
Native, non-modified siRNAs are at a clinical disadvantage due to their poor pharmacokinetic 
properties in vitro and in vivo. A majority of the main siRNA drugs in development now 
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incorporate a variety of chemical modifications that have been validated to increase siRNA 
stability and potency.43 Solid phase oligonucleotide synthesis provides a unique site-specific 
approach for siRNA modification using modified RNA phosphoramidites that can influence 
biological activity, thermodynamic stability, and nuclease resistance.44,45  
These chemically modified siRNAs (cm-siRNAs) typically fall into one of two broad 
categories: backbone modifications or base modifications. Backbone cm-siRNAs contain 
modifications either in the sugar ribose ring or along the phosphodiester bonds between the 
nucleosides. The most prevalent cm-siRNAs in this class often involve chemical substitutions at 
the 2’-OH in the ribose ring in order to confer oligonucleotide stability from degradation. These 
modifications include: 2’-O-Methyl (2’-OMe), 2’-deoxy, 2’-Fluro, 2’-aminoethyl, 2’-
methoxyethyl, and 2’-methylene bridged Locked Nucleic Acids (LNA).46-48 These 2’-OH 
modifications have been shown to moderately increase the stability of the cm-siRNAs without 
significantly affecting gene silencing.48-50 Furthermore, site-selective incorporation and/or 
replacement of the phosphodiester backbone with phosphothioate or boranophosphonate linkages 
have also been promising modifications in increasing the stability and gene silencing activity of 
cm-siRNAs.51 Interestingly, these modifications can also have positive effects on off-target gene 
silencing, as studies on 2’O-Me and LNA cm-siRNAs have shown that even a single incorporation 
increased the specificity of the siRNA activity.52, 53  
Base modifications change the natural structure and affects base-pairing of the nucleobases 
adenine, cytosine, guanine, and more commonly, uracil (A, C, G, U). Therefore, they are less 
relevant in practical therapeutic applications. However, this class of cm-siRNAs have contributed 
to the basic understanding of the siRNA induced silencing method and off-target side effects.54 
These modifications include: 2’-uracil, hypoxanthine, pseudouridine, and dihydrouridine, which 
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when incorporated at selective positions in the sequence provide varying effects on siRNA hybrid 
stability and gene silencing activity.55,56  
Despite the wide variety of modifications that can be made, the incorporation of too many 
changes can significantly reduce the efficiency of the siRNA.57 This results in the careful design 
of cm-siRNAs with a balance between type, location and extent of modifications included within 
the sequence to maintain siRNA hybrid stability and gene silencing activity. The modern 
development of siRNA therapeutics includes more than 20 cm-siRNAs in different phases of 
clinical trials. For example, cm-siRNAs SPC2996 and EZN3042, targeting Bcl-2 and survivin,  
reached phase II and I for the treatment of leukemia and various solid tumors, respectively.58-60. 
Recently, a new database, siRNAmod, facilitated the identification of 128 unique modifications 
within nearly 5000 experimentally validated cm-siRNAs, in addition to descriptions of , their gene 
targets, and their silencing efficiency.43 Tools like this will prove to be invaluable for the 
development of stable, potent, and safe siRNA based formulations that can effectively translate 
from the bench into the clinic.  
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 Figure 1.4. Common siRNA chemical modifications to increase  potency and/or stability. A) 2’ 
substitutions in the ribose ring. B) Locked Nucleic Acids (LNA). C) phosphothiorate linkage. D) 
phosphoboranate linkage. E) psuedouridine. F) Dihydrouridine Images were drawn in 
ChemBioDraw. 
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1.5 siRNA Cell Uptake, Trafficking, and Release for RNAi Activity 
There are a number of cellular obstacles that delivery systems must overcome in order to 
promote efficient siRNA delivery and release. First, the delivery system must be amenable to a 
proper administration route. For example, oral ingestion is not preferred as many cancer target 
sites are not accessible through an oral route as well as intestinal stability and distribution across 
the epithelial gut wall into the circulatory system must be taken into consideration.61 Therefore, 
intravenous injection (IV) or infusion injections are the most common methods, with IV having 
the added benefit of bypassing metabolism clearance from the liver and kidney.  
The second obstacle is the vascular barrier. The delivery systems must condense siRNA into 
small, discrete nanoparticle formulations (≤ 80nm) in order to diffuse through the capillary 
vasculature found in the circulatory system and into solid tumors.62 Nanocarrier delivery systems 
can take advantage of a phenomenon called the enhanced permeability and retention effect (EPR). 
In this mechanism, the access and accumulation of siRNA into target cellular areas, must fulfill 
the particle size requirement.63 Furthermore, siRNA drugs are excreted through the kidneys which 
have a filtration barrier of roughly 8nm. Delivery systems which can condense the siRNA 
formulation to sizes less than 25nm can effectively address a large portion of this obstacle.64,65 The 
sizes of the siRNA nanoparticle formulations are also important in mitigating their encapsulation 
and destruction by phagocytes. In this scenario, large size formulations (> 100nm) or aggregates 
formed from high lipophilicity or electrostatic interactions can lead to the siRNA elimination by 
phagocytosis.66 
Thirdly, the delivery systems must be able to efficiently penetrate the cell plasma membrane 
and release the siRNA into the cytoplasm where it can activate the RISC complex. Both siRNA 
and the plasma membrane have an inherent negative charge due to the phosphodiester backbone 
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and integral phospholipids, respectively, that restricts transient diffusion across the membrane for 
siRNA. Many delivery formulations contain polycationic moieties to function as both a handle to 
condense and mask the siRNA, but also to enhance the interaction with the cell membrane. 
Typically, carrier mediated-endocytosis is the main mechanism for siRNA uptake into the cell and, 
preferably, should allow for the release of the siRNA before the late stage endosomes merge with 
lysosomes containing digestive enzymes that can lead to siRNA degradation.67 Mechanistically, 
this can happen in one of two ways. Cationic moieties in the formulation can further increase the 
acidity by absorbing native protons and destabilizing the endosome membrane allowing for 
release. Likewise, once fused with the lysosome, they can act as a proton sponge and drastically 
change the osmotic pressure within the organelle until it ruptures leading to the release of the 
siRNA.68 
Lastly, the delivery systems must limit an immune response upon administration. Specifically, 
they should not include any components that may be immunogenic, or invoke any unwanted or 
unseen side effects.69,70 The mononuclear phagocyte system (MPS) is a branch of the immune 
system that relates to blood cell turnover and defense against microorganisms. As such, 
particularly large siRNA formulations as well as highly charged aggregates can incite the MPS to 
phagocytose the treatment before reaching its target.66 While chemical modifications such as the 
2’OMe nucleosides can help diminish  immunogenicity on shorter (up to 23 nt) siRNA, care must 
be taken that the whole formulation remains stable, inert, and safe. 
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Figure 1.5 Graphical illustration of siRNA complexation by a nanoparticle carrier, entry into the 
cell, and subsequent endosomal release into the cytoplasm for RNAi activity. Image reprinted 
with permission granted by the Creative Common Attriubtion License: Mihaila, R.; et al. 
Molecular Therapy: Nucleic Acids. 2017, 7. 
 
1.6  siRNA Delivery Systems  
Various delivery systems have been developed to safely and effectively introduce siRNA 
within their cell targets and circumvent the difficulties and limitations in administering siRNA 
based therapies. The use of nanoparticle formulations have revolutionized the field. They are 
sought after due to the tunable range of particle sizes that can be achieved, their inertness, their 
enhanced resident circulation time, their tunable stability and release profiles, and in some cases, 
their ability for multifunctionality.62 They can be classified broadly into two categories: 
soft/organic or hard/inorganic. The organic nanoparticles are derived from both natural and 
synthetic sources and encompass liposomal, nanoemulsions, dendrimers, and polymer 
formulations. Liposomes a very common delivery agent and typically include amphiphilic and 
charged surfactants such as 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC) or 1,2-dioleoyl-
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3-trimethylammonium-propane (DOTAP) to help with payload entrapment. These liposomal 
formulations are often cationic and can complex with the siRNA and easily interact with the cell 
surface.72 However, they’ve been found to have a wide range of cytotoxic and immunostimulatory 
side effects which has limited their use over the years.73,74 Regardless, these types of carriers have 
found their way into clinical applications with several FDA-approved formulations for the delivery 
of therapeutics including a chemotherapy drug, doxorubicin.75 Moreover, a DOPC-based 
nanoliposome has been used in a Phase I clinical trial to deliver siRNA into solid tumors.72 The 
inorganic nanoparticles are non-biodegradable and consist typically of metals, metal oxides, or 
hard carbon-based materials. One important example of this category is the loading of siRNA onto 
gold nanoparticles which have the added benefit of being inherently anti-angiogenic with anti-
tumor properties.62 
Polymer-based delivery systems, also known as polymeric nanoparticles, have gained 
recent traction due to their flexible and tunable properties including biodegradability, hardness, 
aqueous solubility, and functionality. For example, they can be designed for particular stability 
and release profiles which often involves a multimolecular scaffold including the incorporation of 
cationic, hydrophilic, and hydrophobic moieties.78 These systems can also be bio-responsive, 
containing components that can assemble and release particles based on stimuli of the 
microenvironment which is especially important in the release of siRNA from their delivery 
formulation. The cationic components are commonly found as secondary and tertiary amines with 
polyethylenimine (PEI) being a model system that has been successfully used both in vitro and in 
vivo. Other commonly used polymer components include cyclodextrin, poly(D,L-lactide) (PLA), 
and poly(D,L-lactide-co-glycolide) (PLGA), all of which have been used to varying extents in 
murine models and clinical trials.77 
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Another important class of delivery systems are the targeted delivery systems. These 
formulations contain one moiety that is specific to a particular cell or tissue and will guide and 
internalize the siRNA to its target, typically by a receptor mediated endocytosis pathway. This has 
been found successful with ligands such as folate and transferrin conjugated covalently to the 
delivery system.78, 79 Similarly, peptide-based delivery systems are bio-compatible formulations 
that can function to target and internalize siRNA within cells. Cell penetrating peptides (CPPs) 
have been shown to improve the delivery of siRNA across the cell membrane  in vitro and in 
vivo.80,81 Moreover, they exhibit minimal toxicity or immunostimulatory effects and can 
effectively form ionic complexes with siRNA along with  their release intracellularly.82,83 
Similarly, cancer targeting peptides (CTPs) allow for the targeted delivery of siRNA by targeting 
a specific receptor on the cell surface similarly to folate targeting the folate receptor. However, 
compared to traditional ligands, CTPs can target a much wider range of receptors, so long as an 
appropriate peptide sequence can be found, commonly, through phage display.84 CTPs have led to 
the development of potent anti-cancer bioconjugates with good pharmacokinetic properties and 
multi-functionalities. For example, RGD, is a short peptide that is known to bind to cell surface 
localized integrin receptors on solid tumor tissues and has been conjugated to fluorescent probes 
for in vivo imaging of mice85. Moreover, Leutinizing-hormone releasing hormone (LHRH) has 
been conjugated with the chemo-drug camptothecin and this resulted in accumulation specifically 
in a human ovarian carcinoma mouse xenograft with minimal dispersion in the surrounding tissues 
and amplification of the apoptotic effects of the drug at the tumor site.86. Taken together, CTPs 
and CPPs can be formulated with siRNA leading to a delivery system that is both efficient and 
specific. They provide a safe alternative to the conventional methods of siRNA delivery and 
circumvent many of the limitations associated with the non-selective forms of gene delivery. 
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Figure 1.6. Various nanoparticle delivery system components for siRNA delivery. Image 
reprinted with permission from Elsevier: Young, S.W.S.; Stenzel, M.; Yang, J.L. Crit. Rev. 
Oncol. Hematol. 2016. 98, 159-169.87  
 
1.7 The Glucose Regulated Proteins – An Oncogenic Target 
The glucose-regulated proteins (GRPs) are enzymes localized in the lumen of the endoplasmic 
reticulum (ER) or the mitochondria where they function mainly as chaperone proteins, guiding the 
folding and unfolding of newly synthesized proteins. This makes them intrinsically vital to proper 
cell function, homeostasis, proliferation, and survival. As such, they also serve as the main sensors 
for misfolded proteins and can trigger the unfolded protein response (UPR) under physiological or 
pathological cellular stress conditions. This pathway is then responsible for the mitigation of the 
stress or to signal for programmed cell death under prolonged stress conditions.88 Moreover, non-
ER bound GRPs, such as those localized on the mitochondria or on the cell surface, can function 
differently and also direct cell signaling.89 
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Figure 1.7 GRP localization and function. Images adapted with permission from Springer 
Nature: Lee, A.S. Nat. Rev. Cancer 2014, 14, 263-276.88 
 
Of the various GRPs, the focus of this work is based on GRP78, GRP94, and GRP75. Glucose-
regulated protein of 78kDa (GRP78), also referred as the immunoglobulin heavy chain binding 
protein (BiP), is a heat shock protein primarily localized in the ER where it serves as a master 
regulator of ER homeostasis and the UPR.90 In its native state, GRP78 is bound to the ER 
transmembrane proteins PERK, ATF-6, and IRE-1 and prevents their activity in initiating the UPR. 
When exposed to cellular stress, GRP78 dissociates from these signal transducers which are then 
able to activate their signaling cascades in an effort to regain homeostasis.91 ATF-6 is translocated 
to the golgi and cleaved into its active form that functions as a transcription factor to upregulate 
the expression of proteins such as the GRPs that enhance ER folding capabilities.91,92 PERK, upon 
GRP78 dissociation, dimerizes and is phosphorylated into its active form that slows the rate of 
gene transcription to prevent the further accumulation of proteins until the stress has been 
reduced.91,93 Similarly, IRE-1 activates and splices a short 26-base intron segment from the mRNA 
encoding for the X-box binding protein (XBP-1). This spliced protein then functions as a 
transcription factor to regulate the expression of ER chaperones and folding proteins.91,94 In the 
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event that these branches of the UPR activated by GRP78 cannot return the cell to normal function, 
it then signals for apoptosis through the CHOP/Caspase signaling cascades.89 
GRP78 upregulation is commonly associated with tumor cell progression, drug resistance, 
metastasis, and adhesion.95-97 Silencing of GRP78 in the HepG2 liver carcinoma cell line resulted 
in a noticeable increase in tumor cell death (15%) with other studies showing that downregulation 
of GRP78 can inhibit tumor growth through the induction of apoptosis.98-100 Oncogenic GRP78 
expression is dysregulated and often translocated to the cell surface where it is associated with 
pathological stress typically related with the tumor microenvironment and signals for the survival 
and progression of the tumor.101,102 Therefore, it serves as a viable gene therapy target by silencing 
its overexpression, minimizing cancer progression, and potentially regaining normal cell function.  
Glucose-regulated protein of 94kDa, GRP94, is closely related to GRP78 in its function as an 
ER chaperone. Oncogenic GRP94 is similarly upregulated and helps to prevent apoptosis in cancer 
cells.103 Moreover, its expression is often directly correlated with that of GRP78 and is involved 
in a compensation mechanism in which dysregulation of GRP78 induces the expression of GRP94 
in order to maintain a high function chaperone activity for cancer cell proliferation. Silencing of 
GRP94 in patient multiple myeloma samples triggered apoptosis by inhibiting the Wnt-survivn 
pathway.104,105 This implicates GRP94 as a promotor, with GRP78, of tumor survival and 
progression. 
GRP75, also known as mortalin, is an interesting chaperone in that it is most closely associated 
with maintaining mitochondrial homeostasis through the mitochondrial UPR (mtUPR). 
Suppression of GRP75 has been shown to activate this version of the UPR, increase mitochondrial 
stress and fragmentation, reduce human mitochondrial mass ex vivo, and ultimately increase the 
rate of cellular apoptosis. Moreover, it has been found to interact with the well-known tumor 
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suppressor p53, altering its function and affecting the rate of cell apoptosis.107 Together, these 
studies provide a solid ground of evidence highlighting the GRPs as good candidates for siRNA-
based gene therapy mainly due to their overexpression and oncogenic activity. 
           
Table 1.3 Differential expression of the GRPs in a variety of cancer cell types. Reprinted with     
permission from Kozuch, S. PhD. Dissertation, Seton Hall University, 2018 who adapted it from 
Springer Nature: Lee, A.S. Nat. Rev. Cancer 2014, 14, 263-276.88 
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GRP 75, 78 and 94 in endometrial, cervical and breast cancer resulted in potent GRP knockdown 
and cell death relative to a non-tumorigenic cell line which displayed normal GRP expressions.  
 
Table 3.1 Overexpression of GRPs in different cancer types. Adapted with permission from 
Springer Nature: Lee, A.S. Nat. Rev. Cancer 2014, 14, 263-276. 
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1.8 Thesis Objectives  
This thesis highlights significant advances in the application of cm-siRNA, and the 
development of novel delivery strategies. The basis of our applications centers on the identification 
of the Glucose Regulated Protein, 78 kilodaltons (GRP78) as an important oncoprotein that is over-
expressed and cell surface localized on a wide range of tumor cells. We have designed linear and 
higher order V- and Y- shape siRNAs targeting not only GRP78, but the other main resident GRP 
chaperones, GRP94 and GRP75, that have been found to be over-expressed in tumors and act as 
main executors of the unfolded protein response (UPR), a system that is related to endoplasmic 
reticulum (ER) stress. In the absence of normal GRP function under ER stress conditions, 
cellstypically undergo apoptotic responses triggering a series of cell death pathways. Thus, our 
main objective is to target and silence the GRPs in cancer, in order to synergistically activate tumor 
cell apoptosis as well as investigate the effect this silencing activity on other important biological 
pathways related to tumor survival and metastasis.  
 Chapter 2 describes relationship correlation in between GRP78 and the mesenchymal 
maker and adhesion protein N-cadherin (N-cad) in cancers that originate in or metastasize to the 
bone. Delivery of linear siRNAs against GRP78 into multiple myeloma (MM) and prostate cancer 
(PCa) cells resulted in concomitant knockdown of both GRP78 and N-cad protein expression 
levels. Further investigation resulted in drastic changes in the expression of proteins involved in 
the epithelial to mesenchymal (EMT) pathway and cellular adhesion in PCa cells. Moreover, 
GRP78 knockdown (GRP78 KD) reduced the adhesion of PCa to osteoblasts in a co-culture 
environment, likely implicating this important UPR chaperone in the metastasis of PCa to the bone 
(Figure 1.9). 
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Figure 1.8 Graphical representation of the effect GRP78 silencing has on N-cad expression in PCa 
and its adhesion to osteoblasts. Drawn in Chemdraw. 
 
 Chapter 3 will focus on the evaluation of cm-siRNA resulting in the generation of V-, and 
Y-shape siRNAs that can simultaneously target and silence multiple oncogene targets. These 
multi-GRP silencing siRNAs have also been further functionalized by self-assembly and 
conjugation approaches for the generation of new cm-siRNA with improved structure-anti-cancer 
activity relationships. The higher order V- and Y-shape siRNAs self-assembled into discreet 
siRNA nanostructures adopting various sizes and shapes (Figure 1.9a) according to TEM and 
DLS measurements. These nanostructures targeted the above-mentioned resident GRPs in a small 
GRP78 Silencing
Osteoblasts
PCa Cells
N-cadherin
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panel of cancer cell lines. In the AN3CA endometrial cancer cells, the higher order siRNA 
nanostructures demonstrated a more potent and longer lasting silencing effect compared to the 
linear siRNA. Furthermore, a Y-shape siRNA construct targeting GRP78, GRP94, and GRP75 
elicited significant GRP KD (50-95%) and synergistic tumor cell death (50-60%) in endometrial, 
cervical, and breast cancer cell lines. Conjugation approaches were next developed to include 
functionalized linear, V-, and Y-shape siRNAs with FITC and palmitamide, respectively 
functioning as theranostic probes or self-delivering agents (Figure 1.9b). The bioconjugates 
expanded the repertoire of functionally diverse cm-siRNAs while improving their applications in 
anti-cancer activity.   
 
Fig 1.9 Graphical representation of linear, V-, and Y-shape siRNA constructs. A) Nanostructures 
derived from template guided self-assembly. B) Covalent bioconjugation strategy for introduction 
of fatty acid or fluorescent probes. Images adapted with permission from John Wiley and Sons: 
Cultrara, C.N.; Shah, S.; Kozuch, S.D.; Patel, M.R.; Sabatino, D. Chem Biol Drug Des. 2018.108 
 
 Chapter 4 will discuss the generation of a CTP:siRNA formulations targeting the Prostate 
Specific Membrane Antigen (PSMA) receptor found on PCa cells. In this application, the lead 
CTP will be functionalized with a polyarginine sequence in order to effectively condense siRNA 
into small, discrete nanoparticle formulations that can internalize selectively within PSMA 
A) B)
  24 
 
expressing PCa cells. Once internalized, the multi-GRP targeting siRNAs are expected to trigger 
potent GRP silencing leading to apoptosis in PCa cells. In this manner, the bifunctional CTPs may 
function as effective and selective delivery systems for a wide range of siRNAs, including those 
adopting the higher-order V- and Y-shape nanostructures (Figure 1.11). As such the CTP:siRNA 
are anticipated to provide a tumor-targeting gene therapy strategy. 
 
Figure 1.10 siRNA complex formation with novel PSMA targeting CTP/CPP hybrid. Drawn in 
ChemDraw. 
 
 
 
+
PSMA CTP Oligo Arginine CPP
  25 
 
References 
1. Fire, A.;  Albertson, D.;  Harrison, S. W.; Moerman, D. G. Development 1991, 113 (2), 
503-514. 
2. Guo, S.; Kemphues, K. J. Cell 1995, 81 (4), 611-620. 
3. Fire, A.;  Xu, S.;  Montgomery, M. K.;  Kostas, S. A.;  Driver, S. E.; Mello, C. C. Nature 
1998, 391 (6669), 806-811. 
4. Mattick, J. S. PLOS Genet 2009, 5, e1000459. 
5. Grosshans, H.; Filipowicz, W. Nature 2008, 451, 414-416. 
6. Esteller, M. Nat. Rev. Genet. 2011, 12, 861-874. 
7. Elbashir, S. M.;  Harborth, J.;  Lendeckel, W.;  Yalcin, A.;  Weber, K.; Tushcl, T. Nature 
2001, 411, 494-498. 
8. Hannon, G.; Rossi, J. Nature 2004, 431, 371-378. 
9. Ahmadzada, T.;  Reid, G.; McKenzie, D., Biophys. Rev. 2018, 10, 69-86. 
10. Sioud, M., Methods Mol. Biol. 2015, 1218, 1-15. 
11. Bernstein, E.;  Caudy, A.;  Hammond, S.; Hannon, G. Nature 2001, 409, 363-366. 
12. Dalby, B.;  Cates, S.;  Harris, A.;  Ohki, E.;  Tilkins, M.;  Price, P.; Ciccarone, V. Methods 
2004, 33, 94-103. 
13. Jensen, K.;  Anderson, J.; Glass, E. Vet. Immunol. Immunopathol. 2014, 158, 224-232. 
14. Zamore, P.;  Tushcl, T.;  Sharp, P.; Bartel, D. Cell 2000, 101, 25-33. 
15. Vermeulen, A.;  Behlen, L.;  Reynolds, A.;  Wolfson, A.;  Marshall, W.;  Karpilow, J.; 
Khnorova, A. RNA 2005, 11 , 674-682. 
16. Wilson, R.; Doudna, A. Annu Rev Biophys 2013, 42, 217-239. 
17. Siomi, H.; Siomi, M. C. Nature 2009, 457 , 396-404. 
18. Preall, J.;  He, Z.;  Gorra, J.; Sontheimer, E. Current Biology 2006, 16, 530-535. 
19. Gregory, R.;  Chendrimada, T.;  Cooch, N.; Shiekhattar, R. Cell 2005, 123, 631-640. 
20. Elbashir, S. M.;  Lendeckel, W.; Tushcl, T. Genes Dev. 2001, 15, 188-200. 
21. Elbashir, S. M.;  Martinez, J.;  Patkaniowska, A.;  Lendeckel, W.; Tuschl, T. EMBO J. 
2001, 20, 6877-6888. 
22. Agrawal, N.;  Dasaradhi, P.;  Mohmmed, A.;  Malhorta, P.;  Bhatnagar, R.; Mukherjee, S. 
Microbiol. Mol. Biol. Rev. 2003, 67, 657-685. 
23. Rossi, J.; Kim, D. Nature 2007, 8, 173-184. 
24. Dancey, J.;  Bedard, P.;  Onetto, N.; Hudson, T. Cell 2012, 148, 409-420. 
25. Stratton, M. R. Science 2011, 331, 1553-1558. 
26. Wong, K. M.;  Hudson, T. J.; McPherson, J. D. Annu. Rev. Genomics Hum. Genet. 2011, 
12, 407-430. 
27. Pleasance, E. D.;  Cheetham, R. K.;  Stephens, P. J.;  McBride, D. J.;  Meynert, A.;  Jones, 
D.;  Lin, M. L.;  Ordonez, G. R.;  Bignell, G. R.; et al. Nature 2010, 463, 184-190. 
28. Wu, S. Y.;  Lopez-Berestein, G.;  Calin, G. A.; Sood, A. K., Sci. Transl. Med. 2014, 6, 
240ps7. 
29. Burnett, J. C.; Rossi, J. J. Chem Biol 2012, 19 , 60-71. 
30. Sanceau, J.;  Truchet, S.; Bauvois, B. J Biol Chem 2003, 278, 36537-36546. 
31. Grzmil, M.;  Thelen, P.;  Hemmerlein, B.;  Schweyer, S.;  Voigt, S.;  Mury, D.; Burfeind, 
P. Am J Pathol 2003, 163, 543-552. 
32. Yin, J. Q.;  Gao, J.;  Shao, R.;  Tian, W. N.;  Wang, J.; Wan, Y. Exp. Ther. Oncol. 2003, 3, 
194-204. 
  26 
 
33. Futami, T.;  Miyagishi, M.;  Seki, M.; Taira, K. Nucleic Acids Res. Suppl. 2002, 2, 251-
252. 
34. Duxbury, M. S.;  Ito, H.;  Benoit, E.;  Zinner, M. J.;  Ashley, S. W.; Whang, E. E. Biochem. 
Biophys. Res. Commun. 2003, 311, 786-792. 
35. Lois, C.;  Refaeli, Y.;  Qin, X. F.; Van Parijs, L. Curr. Opin. Immunol. 2001, 13, 496-504. 
36. Spankuch-Schmitt, B.;  Bereiter-Hahn, J.;  Kaufmann, M.; Strebhardt, K. J. Natl. Cancer 
Inst. 2002, 94 , 1863-1877. 
37. Konnikova, L.;  Kotecki, M.;  Kruger, M. M.; Cochran, B. H. BMC Cancer 2003, 3, 23. 
38. Nagy, P.;  Arndt-Jovin, D. J.; Jovin, T. M. Exp. Cell. Res. 2003, 285, 39-49. 
39. Zhang, M.;  Zhang, X.;  Bai, C. X.;  Chen, J.; Wei, M. Q. Acta. Pharmacol. Sin. 2004, 25, 
61-67. 
40. De Schrijver, E.;  Brusselmans, K.;  Heyns, W.;  Verhoeven, G.; Swinnen, J. V. Cancer 
Res 2003, 63, 3799-3804. 
41. Devi, G. R. Cancer Gene Therapy 2006, 13, 819-826. 
42. Bora, R. S.;  Gupta, D.;  Mukkur, T. K.; Saini, K. S. Mol. Med. Rep. 2012, 6, 9-15. 
45. Lam, J. K.;  Chow, M. Y.;  Zhang, Y.; Leung, S. W. Mol Ther Nucleic Acids 2015, 4, e252. 
46. Wang, J.;  Lu, Z.;  Wientjes, M. G.; Au, J. L. A. J. AAPS 2010, 12 (4), 492-503. 
47. Bakhtiyari, S.;  Haghani, K.;  Basati, G.; Karimfar, M. H. Ther. Delivery 2013, 4 (1), 45-
57. 
48. Kanasty, R.;  Dorkin, J. R.;  Vegas, A.; Anderson, D. N. M., 12 (11), 967-77., Nat. Mater 
.2013, 12 (11), 967-977. 
49. Tatiparti, K.;  Sau, S.;  Kashaw, S. K.; Iyer, A. K. Nanomaterials 2017, 7 (4), 77. 
50. Wang, J.;  Mi, P.;  Lin, G.;  Xiang, Y.;  Wang, J.;  Liu, G.; Chen, X. Advanced drug delivery 
reviews 2016, 104, 44-60. 
43. Ahmad Dar, S.;  Thakur, A.;  Qureshi, A.; Kumar, M. Sci. Rep. 2016, 6 20031. 
44. Wilson, C.; Keefe, A. D. Curr. Opin. Chem. Biol. 2006, 10, 607-614. 
45. Gaglione, M.; Messere, A. Mini Rev. Med. Chem. 2010, 10, 578-595. 
46. Elmen, J. et. al. Nucleic Acids Res 2005, 33, 439-447. 
47. Prakash, T. P. et. al. J Med Chem 2005, 48, 4247-4253. 
48. Soutschek, J. et. al. Nature 2004, 432, 173-178. 
48. Aboul-Fadi, T. Current medicinal chemistry 2005, 12, 2193-2214. 
49. Chiu, Y. L.; Rana, T. M. RNA 2003, 9, 1034-1048. 
50. Layzer, J. M. et. al. RNA 2004, 10, 766-771. 
51. Detzer, A.; Sczakiel, G. Curr. Top. Med. Chem. 2009, 9, 1109-1116. 
52. Jackson, A. L.;  Burchard, J.;  Leake, D.;  Reynolds, A.;  Schelter, J.;  Guo, J.;  Johnson, J. 
M.;  Lim, L.;  Karpilow, J.;  Nichols, K.;  Marshall, W.;  Khvorova, A.; Linsley, P. S. RNA 2006, 
12, 1197-1205. 
53. Puri, N.;  Wang, X.;  Varma, R.;  Burnett, C.;  Beauchamp, L.;  Batten, D. M.;  Young, M.;  
Sule, V.;  Latham, K.;  Sendera, T.;  Echeverri, C.;  Sachse, C.; Magdaleno, S. Nucleic Acids Symp 
Ser (Oxf). 2008, 52, 25-6 
54. Peacock, H.;  Kannan, A.;  Beal, P. A.; Burrows, C. J., J. Org. Chem. 2011, 76, 7295-7300. 
55. Somoza, A.;  Silverman, A. P.;  Miller, R. M.;  Chelliserrykattil, J.; Kool, E. T. Chemistry 
2008, 14, 7978-7987. 
56. Sipa, K. et. al. RNA 2007, 13, 1301-1316. 
57. Choung, S.;  Kim, Y. J.;  Kim, S.;  Park, H. O.; Choi, Y. C. Biochem. Biophys. Res. 
Commun. 2006, 342, 919-927. 
  27 
 
58. Lares, M. R.;  Rossi, J. J.; Ouellet, D. L. Trends Biotech. 2010, 28, 570-579. 
59. Dürig, J.;  Dührsen, U.;  Klein-Hitpass, L.;  Worm, J.;  Hansen, J. B.;  Ørum, H.; 
Wissenbach, M. Leukemia 2011, 25 , 638-647. 
60. Raetz, E. A. et. al. J Pediatr Hematol Oncol 2014, 36, 458-463. 
61. Haussecker, D. J. Control Release 2014, 195, 49-54. 
62. Tatiparti, K.;  Sau, S.;  Kashaw, S. K.; Iyer, A. K. Nanomaterials 2017, 7 (4), 77 
63. Wang, J.;  Mi, P.;  Lin, G.;  Xiang, Y.;  Wang, J.;  Liu, G.; Chen, X. Advanced drug delivery 
reviews 2016, 104, 44-60. 
64. Jarad, G.; Miner, J. H. Curr Opin Nephrol Hypertens 2009, 18, 226-232. 
65. Huang, Y.;  Hong, J.;  Zheng, S.;  Ding, Y.;  Guo, S.;  Zhang, H.;  Zhang, X.;  Du, Q.; 
Liang, Z. Mol. Ther. 2011, 19, 381-385. 
66. Moghimi, S. M.;  Hunter, A. C.; Murray, J. C. Pharmacol Rev 2001, 53, 283-318. 
67. Appelqvist, H.;  Wäster, P.;  Kågedal, K.; Öllinger, K. J Mol Cell Biol. 2013, 5, 214-226. 
68. Sonawane, N. D.;  Szoka, F. C.; Verkman, A. S., J Biol Chem 2003, 278, 44826-44831 
69. Jackson, A. L.;  Burchard, J.;  Schelter, J.;  Chau, B. N.;  Cleary, M.;  Lim, L.; Linsley, P. 
S. RNA 2006, 12, 1179-1187. 
70. Judge, A. D.;  Sood, V.;  Shaw, J. R.;  Fang, D.;  McClintock, K.; MacLachlan, I. Nature 
Biotechnol. 2005, 23, 457-462. 
71. Mihaila, R.; et al. Molecular Threapy: Nucleic Acids. 2017, 7. 
72. Ozpolat, B.; Sood, A.; Berestein-Lopez, G. Adv Drug Deliv Rev. 2014, 66, 110-116 
73. Dokka, S.; Toledo, D.; Shi, X.; Castranova, Y.; Rojanaskaul, Y. Pharm Res. 2000, 17(5), 
521 
74. Spagnou, S.; Miller, M. Biochemisty. 2004, 43, 13348-13356 
75. Petros, R.A.; DeSimone, J.M. Nat Rev Drug Discov. 2010, 9(8), 615-627 
76. Semple, S. C.;  Akinc, A.;  Chen, J.;  Sandhu, A. P.;  Mui, B. L.;  Cho, C. K.;  Sah, D. W. 
Y.;  Stebbing, D.;  Crosley, E. J.;  Yaworski, E.; et. al,  Nature Biotechnol. 2010, 28, 172-176. 
77. Wang, J.; Xu, C. Asian Journal of Pharmaceutical Sciences. 2015, 10, 1-12 
78. Lee, D.J.; et al. Bioconjug. Chem. 2017, 28(9), 2393-2409 
79. Simoes, S.; Slepushkin, V.; Gaspar, R.; de Lima, M.C.; Duzgunes, N. Gene Ther. 1998, 5, 
955-964 
80. El-Andaloussi, S.;  Holm, T.; Langel, U., Curr. Pharm. Des. 2005, 11, 3597-3611. 
81. Deshayes, D.;  Morris, M. C.;  Divita, G.; Heitz, F., Cell Mol. Life 2005, 16, 1839-1849. 
82. Boisguérin, P.;  Deshayes, S.;  Gait, M. J.;  O'Donovan, L.;  Godfrey, C.;  Betts, C. A.;  
Wood, M. J.; Lebleu, B. Adv. Drug. Del. Rev. 2015, 87, 52-67. 
83. Lehto, T.;  Kurrikoff, K.; Langel, U. Expert Opin. Drug Disc. 2012, 9, 823-836. 
84. Kay, B. K.;  Kasanov, J.; Yamabhai, M. Methods 2001, 24, 240-246. 
85. Kwon, S.; Ke, Shi.; Houston, J.; Wang, W.; Wu, Q.; Li, C.; Sevick-Muraca, E. Molecular 
Imaging. 2005, 4(2), 75-78 
86. Dharap, S. S.;  Wang, Y.;  Chandna, P.;  Khandare, J. J.;  Qiu, B.;  Gunaseelan, S.;  Sinko, 
P. J.;  Stein, S.;  Farmanfarmaian, A.; Minko, T. PNAS 2005, 102 , 12962-12967. 
87. Young, S.W.S.; Stenzel, M.; Yang, J.L. Crit. Rev. Oncol. Hematol. 2016, 98, 159-169. 
88. Lee, A.S. Nat. Rev. Cancer 2014, 14, 263-276.  
89. Wu, J.; Kaufman, R. J. Cell Death Differ. 2006 13, 374–384. 
90. Lee, A.S. Trends Biochem Sci. 2001 26(8):504-510 
91. Wang, M.; Wey, S.; Zhang, Y.; Ye, R.; Lee, A.S. Antioxid Redox Signal. 2009, 11(9), 
2307-2316 
  28 
 
92. Haze, K.; Yoshida, H.; Yanagi, H.; Yura, T.; Mori, K. Mol Biol Cell. 1999,10(11):3787-
3799. 
93. Harding, H.P.; Zhang, Y.; Ron, D. Nature. 199, 397(6716),271-274. 
94. Yoshida, H.; Matsui, T.; Yamamoto, A.; Okada, T.; Mori, K. Cell. 2001, 107(7):881-891. 
95. Chang, Y.J.; Huang, Y.P.; Li, Z.L.; Chen, C.H. PLoS One. 2012, 7(4):e35123  
96. Mhaidat, N.M.; Alzoubi, K.H.; Almomani, N.; Khabour, O.F. Cancer Biomark. 2015, 
15(2):197-203.  
97. Zhang, L.; Li, Z.; Fan, Y.; Li, H.; Li, Z.; Li, Y. Int J Biochem Cell Biol. 2015, 64,202-211. 
98. Pi, L.; Li, X.; Song, Q.; Shen, Y.; Lu, X.; Di, B. Oncol Lett. 2014, 7(3):685-692.  
99. Suzuki, T.; Lu, J.; Zahed, M.; Kita, K.; Suzuki, N. Arch. Biochem. Biophys. 2007, 468, 1- 
14  
100. Maina, A; Blackman, B.A.; Parronchi, C.J.; Morozko, E.; Bender, M.E.; Blake, A.D.; 
Sabatino, D. Bioorg. Med. Chem. Lett. 2013, 23, 5270-5274.  
101. Gonzalez-Gronow M; Selim, M.A.; Papalas, J.; Pizzo, S.V. Antioxid Redox Signal. 2009 
11(9):2299-306.  
102. Quinones, Q.J.; de Ridder, G.G.; Pizzo, S.V. Histol Histopathol. 2008 23(11):1409-16.  
103. Reddy, R.K.; Lu, J.; Lee, A.S. J. Biol. Chem. 1999 274, 28476–28483.  
104 Hua, Y. et al. Clin. Cancer Res. 2013, 19, 6242–6251.  
105. Wadhwa, R. et al. J. Biol. Chem. 1998, 273, 29586–29591.  
107. Wadhwa, R. et al. Exp. Cell Res. 2002, 274, 246–253.  
108. Cultrara, C. N.;  Shah, S.;  Kozuch, S. D.;  Patel, M. R.; Sabatino, D. Chemical Biology 
and Drug Design 2018, 1-12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  29 
 
Chapter 2: GRP78 Modulates Cell Adhesion Markers in Prostate Cancer and 
Multiple Myeloma Cell Lines1  
 
2.1 Abstract 
siRNA technologies have had a widespread impact in the treatment of various disorders, 
particularly in cancer. As such, siRNAs have been developed as gene therapeutic agents, and also 
in their ability to promote RNAi screening of various gene targets implicated in the translation of 
detrimental proteins involved in disease progression. This chapter will discuss the anti-cancer 
effects of an anti-GRP78 siRNA in prostate cancer (PCa) and multiple myeloma (MM) cell lines. 
Moreover, this study aims to define the functional role of GRP78 on drug treatment sensitivity, 
cell adhesion and metastatic spread to resident bone tissues in these important cancer types. 
Glucose regulated protein 78 (GRP78) is a resident chaperone of the endoplasmic reticulum and a 
master regulator of the unfolded protein response under physiological and pathological cell stress 
conditions. GRP78 is overexpressed in many cancers and is involved in the regulation of various 
signaling pathways including tumor initiation and proliferation, as well as adhesion, invasion and 
metastatic spread to secondary organs. GRP78 can also regulate cell survival and initiate apoptotic 
pathways to either prevent further damage caused by a particular stress or to alter a cell’s 
responsiveness to anticancer drugs.  
Tumors that reside or metastasize to the bone and bone marrow (BM) space can develop pro-
survival signals through their direct adhesive interactions with stromal elements in the BM niche 
leading to drug treatment resistance. Here, we report a direct correlation between GRP78 and the 
adhesion molecule N-cadherin (N-cad), known to play a critical role in the adhesive interactions 
of MM and metastatic PCa within the bone microenvironment. N-cad mRNA and protein 
expression levels were evaluated upon silencing GRP78 in the MM.1S MM and the PC3 metastatic 
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PCa cell lines. Furthermore, we investigated the effects of GRP78 knockdown (KD) on PC3 cells 
including other epithelial-mesenchymal (EMT) transition markers, morphological changes and 
their adhesion properties to osteoblasts (OSB) cells. We found that GRP78 KD led to concomitant 
downregulation of N-cad at the protein levels of expression in both tumors types. In PC3 cells, 
GRP78 KD significantly decreased E-cadherin (E-cad) expression likely associated with the 
induction in TGF-b1 expression. Furthermore, GRP78 KD also triggered drastic changes in PC3 
cells morphology and decreased their adhesion to OSB cells dependent, in part, to the reduced N-
cad expression. This implicates GRP78 as a modulator of cell adhesion markers in MM and PCa 
which may lead to a clinical underscoring of GRP78 as a potential therapeutic target to reduce the 
adhesive nature of metastatic tumors to the bone niche. 
 
2.2 Introduction 
       Tumor cells that reside or metastasize to the bone and BM can develop pro-survival 
interactions with stromal cells, including osteoblasts (OSB) at the endosteum, through adhesion 
molecules. Resistant malignant stem cells can remain moderately protected within the bone 
microenvironment during treatment and later re-initiate growth to from reoccurring tumors.2-4 In 
particular, we have shown that N-cad is a necessary mediator of CD138+ patient-derived multiple 
myeloma (MM) cells’ adhesion to the endosteum, and that shRNA mediated down-regulation of 
N-cad in OSB decreased MM-OSB adhesive interactions, restricting the ex vivo survival of these 
tumor cells5. These adhesive interactions are considered to be major factors in which cancer cells 
remain “dormant” and escape the cytotoxic effects of therapeutic agents. This mechanism of drug 
resistance has been described in MM, as well as in disseminated/metastatic prostate cancer (PCa) 
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cancer.6-8 Bone is a preferred site for PCa metastases, and currently no curative treatments exist 
once the tumor is established within this niche.9-11 
         The 78 kDa glucose-regulated protein (GRP78) is a chaperone protein that serves as the main 
sensor for misfolded proteins in the endoplasmic reticulum (ER) and triggers the unfolded protein 
response (UPR).12 Moreover, GRP78 regulates intracellular signaling events associated with 
embryonic development, aging, pro-apoptotic/survival mechanisms, Ca2+ homeostasis and 
insulin/IGF-1 signal transduction.12 GRP78 is expressed ubiquitously in all cell types and is 
located primarily in the endoplasmic reticulum where it chaperones protein folding activity. It can 
also be found in the mitochondria where it interacts with pro-survival and apoptotic executors and 
also at the cell surface where it initiates various  cell signaling pathways, including those associated 
with oncogenic activity.13 In cancer, GRP78  is commonly overexpressed and associated with 
tumor initiation, drug resistance, proliferation, adhesion and invasion to resident tissues resulting 
in metastatic spread.13,14 GRP78 has also been found to be highly active in osteoblastic, androgen-
independent prostate cancer15 which suggests that it might play a pivotal role in the interaction of 
PCa cells with OSB. It was found to play a critical role in the adhesion and invasion of 
hepatocellular carcinoma16 and MM17 and can potentiate resistance against cytotoxic 
chemotherapy in PCa cells.18 Furthermore, it is also overexpressed in a quiescent MM cell sub-
population resistant to treatment.19, 20 Of note, GRP78 has been correlated with the expression of 
EMT markers N-cad, E-cad and  b-catenin, respectively in colon cancer and hepatocellular 
carcinoma.16, 21, 22  While high levels of N-cad have been linked to poor prognosis of MM patients23, 
24 and to PCa metastasis in castration resistant models 25, no studies have examined the potential 
interplay between GRP78 and N-cad in MM and PCa for modulating tumor-bone adhesion. 
Similarly, GRP78 overexpression can affect the EMT signaling pathways related to Snail/Slug and 
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TGF-b/smad that are closely associated with metastasis of epithelial tumors.16, 22 Classically, an 
EMT is associated with the upregulation of mesenchymal markers such as N-cad and vimentin 
along with parallel downregulation of the epithelial marker E-cad. 26, 27  
 
2.3 Chapter Objectives 
This thesis chapter focuses on the use of GRP78 siRNA to investigate a novel correlation 
between GRP78 and N-cad in MM and PCa cells. N-cad expression has been shown to be directly 
proportional to GRP78 levels in hepatocellular carcinoma and colorectal cancer. 16, 22 Furthermore, 
circulating levels of N-cad have been linked to poor prognosis of MM patients,23,24 while 
upregulation of this molecule was linked to PCa metastasis and castration resistance.25  Together 
these findings served as basis for our hypothesis, implicating GRP78 and N-cad as important 
markers involved in tumor adhesion and metastasis of PCa with bone tissue.  In order to investigate 
this purported correlation, an siRNA cocktail will be reverse transfected into MM and PCa cell 
lines in order to evaluate the relationship between GRP78 and related markers of cell adhesion and 
the EMT pathway. Quantitative analyses at the genetic and protein levels of expression will be 
evaluated by Real Time Polymerase Chain Reaction (RT-qPCR) and western blot, respectively. 
siRNA treatment will also be used in order to determine the functional role of GRP78 on PCa 
cells’ morphology and adhesion to bone-derived OSB cells. Importantly, these results may 
contribute to a better understanding of the underlying survival properties conferred by cell-cell 
adhesion interactions, aiding in the development of more effective therapeutic strategies against 
cancers that interact with the bone niche.10, 28-31 These results and data presented in this chapter are 
adapted with permission from the authored publication found in BMC Cancer : Cultrara, C. N.;  
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Kozuch, S. D.;  Ramasundaram, P.;  Heller, C. J.;  Shah, S.;  Beck, A. E.;  Sabatino, D.; Zilberberg, 
J., BMC Cancer 2018, 18 (1), 1263. doi: 10.1186/s12885-018-5178-8 
2.4 Results and Discussion 
2.4.1 GRP78 silencing leads to concomitant N-cad downregulation in MM.1S and PC3 cell lines 
Initially, the basal GRP78 and N-cad levels were analyzed by western blot and revealed 
comparable expressions of these proteins in MM.1S and PC3 cancer cell lines (Appendix fig. 1). 
While GRP78 upregulation is well documented in many cancers,15,19, 20 MM and PCa cells often 
display aberrant N-cad expressions.24, 25, 32, 33 An optimized siRNA transfection protocol found 
suitable for suspension (MM.1S) and adherent (PC3) cell lines was used to assess the effects of 
GRP78 KD on the expression levels of N-cad. A commercial GRP78-silencing siRNA was 
transfected with the TransIT-X2® dynamic delivery system that is compatible with the transfection 
of suspension and adherent cells.34 The suspension nature of MM.1S cells makes them inherently 
more difficult to transfect, therefore, we doubled the siRNA concentrations (to 100 nM) and used 
multiple GRP78 silencing siRNAs, in combination, to provide a more effective GRP78 KD in 
these cells. While this concentration was adequately tolerated (Appendix Fig 2), only a ~40% 
(P<0.05) decrease in GRP78 protein levels was achieved, compared with ~ 70% KD (P<0.001) in 
PC3 cells using only 50 nM of the same siRNA cocktail (Fig. 1A)..  
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Figure 2.1 Relationship between GRP78 and N-cad in MM.1S and PC3 cells upon GRP78 KD. 
siRNA cocktail (100 nM and 50 nM) against GRP78 or a control siRNA were transfected into 
MM.1S and PC3 cells, respectively. Total mRNA and protein levels were analyzed at 48 hrs and 
72 hrs, respectively. A) Western blots of endogenous GRP78 and N-cad protein expression after 
GRP78 silencing. B) Protein expression quantification. Target protein levels were normalized 
against the loading control GAPDH and compared with the control, non-targeting siRNA. Blot 
bands and quantitative values are presented as the mean ± SD and representative of 3 separate 
trials. Western blot analysis for MM.1S and PC3 cells were performed independently. *P<0.05 
and ***P<0.001 in MM.1S cells and ****P<0.0001 and **P<0.01 in PC3 cells for GRP78 and N-
cad, respectively. C) qRT-PCR analysis of relative mRNA levels for GRP78 and N-cad upon 
GRP78 silencing. Target mRNA levels are relative to the control siRNA and represented as the 
mean fold change ± SD of 3 separate trials. *P<0.05 in MM.1S cells and ***P <0.001in PC3 cells 
for GRP78. 
 
Two other MM cell lines; MM.1R and RPMI 8226, were also transfected. Similarly, no 
significant knockdown of GRP78 was observed under optimized conditions (Fig 2.2A) likely due 
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to the known challenges of transfecting non-adherent MM cells.35 Despite this difference in 
GRP78 KD efficiency, the MM.1S and PC3 cell lines exhibited significant decreases in N-cad 
protein levels although without changes in N-cad mRNA transcript levels (Fig. 2.1B & C), 
suggesting a preferential downregulation of N-cad translation over transcriptional modulation. 
Regardless, the decrease in N-cad protein expression level implies that a regulatory relationship 
between these two biomarkers exists in MM.1S and PC3 cells (Fig 2.1). Of note, only one of three 
MM cell lines (MM.1S) assayed showed appreciable GRP78 KD at high dose (100 nM) 
concentrations of siRNA. This demonstrates not only the difficulty of siRNA based gene silencing 
in MM, but also the dependence of MM on this important regulator of the ER/UPR system.36 
Alternatively, highly concentrated and long-lasting siRNA transfections (100 nM, 24-72hr) 
rendered further follow-up experiments unfeasible since the MM.1S cells were susceptible to 
apoptosis under these prolonged treatment conditions (Fig 2.2B) 
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Figure 2.2 Viability assay of MM.1S cells after siRNA transfection. A) GRP78 silencing in 
MM.1R and RPMI 8226 MM cell lines. 100 nM siRNA cocktail against GRP78 or a control siRNA 
were transfected into each cell line. Total mRNA levels were analyzed at 48 h. qRT-PCR analysis 
of relative mRNA levels for GRP78 and N-cad upon GRP78 silencing. Target mRNA levels are 
relative to the control siRNA and represented as the mean fold change ± SD of 3 separate trials. 
B) Viability assay of MM.1S cells after siRNA transfection. 100 nM siRNA cocktail or a control 
siRNA were transfected into MM.1S cells and analyzed by flow cytometry over 72 hrs. Histograms 
are representative of 3 independent trials at each time point. 
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Moreover, the cancer cell lines studied (i.e., MM.1S and PC3 lines) did not manifest cell 
membrane bound GRP78 and have been shown in other reports to lack surface GRP78 under 
specified culture conditions.37 Thus, our results likely indicate a role for cytosolic rather surface 
GRP78 on N-cad expression. However, surface expression of GRP78 has been observed in varying 
tumor cell lines and with ER stressors known to upregulate surface GRP78 expression allowing 
for potential future studies aimed at investigating the effects of exogenous GRP78 blocking 
antibodies on N-cad activity.37 Likewise, additional methods35 may be needed  to fully characterize 
the functional relationship in between GRP78 and N-cad among multiple MM and PCa cell lines.  
 
2.4.2 Oncomine cDNA Microarray analysis  
We queried the Oncomine microarray repository to find any correlations in the expression 
profiles of HSPA5 (GRP78) and CDH2 (N-cad) in patient samples. Oncomine is a cancer 
microarray database and web-based data mining platform whose objective is to perform genome 
wide expression analysis and compare a cancer’s target profile against that of healthy tissue. One 
major advantage of this platform is that the analysis can be set to clinically important limits such 
as membrane bound or known gene-drug target pairs which can help discover new therapy 
strategies.38 All MM tumor tissue samples in these studies were accessed from BM aspirates from 
newly diagnosed patients. Patients in Dickens’ et. al study received autologous transplantation 
following induction by either a cyclophosphamide, thalidomide and dexamethasone (CTD) 
chemotherapy regiment for younger fit participants or cyclophosphamide, vincristine sulfate, 
Adriamycin, and dexamethasone (CVAD) chemotherapy regimen for older, unfit participants, 
while no indication of treatment was presented for the Zhan and Agnelli cohorts. The analyzed 
PCa tumor tissue samples ranged in origin from patients with elevated PSA (>2.5ng/mL) but non-
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confirmed cancer, prostatectomy samples, xenograft biopsies, primary organ tumor, and 
metastasized samples including bone, lymph node, and lung. Only one PCa trial indicated that 
patients had received no prior treatment.  HSPA5 was overexpressed in 6/15 (40%) PCa studies 
(fold change ranging between 1.029-3.095, P<0.05) and 2/3 (66%) MM studies (fold change of 
1.095 and 1.513, P<0.05). HSPA5 gene rank between 2-24% in PCa and was in the top 13% in the 
2 MM studies with significant fold change. CDH2 was overexpressed in 1/17 PCa studies (fold 
change of 1.193, P<0.05) and a gene rank of 14%, and 2/4 MM studies (fold change of 1.094 and 
3.411, P<0.05) and gene rank of 25% and 12% respectively. Results are summarized in Tables 2.1 
and 2.2. 
ONCOMINE cDNA microarray analysis summary for MM 
Multiple Myeloma       
Study P-value 
Fold 
Change 
Tumor Tissue 
Samples 
Healthy Tissue 
Samples 
Gene 
Rank* 
        
HSPA5       
Zhan 8.87E-06 1.513 74 37 (plasma) top 13% 
Dickens 1.15E-08 1.095 84 84 (leukocyte) top 13% 
        
CDH2       
Zhan 3.84E-06 3.411 74 37 top 12% 
Agnelli 0.04 1.094 133 5 top 25% 
 
Table 2.1 ONCOMINE was searched using the following filters:  Gene: HSPA5 (GRP78) or 
CDH2 (N-cad), Analysis Type: Cancer vs. Normal Analysis, Cancer Type: prostate cancer or 
multiple myeloma. *Gene rank denotes the extent of significance out of all genes assayed; i.e. what 
percentage of genes whose upregulation has a more significant p-value as compared to the gene of 
interest 
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ONCOMINE cDNA microarray analysis summary for PCa 
Prostate Carcinoma        
Study P-value 
Fold 
Change 
Tumor Tissue 
Samples 
Healthy Tissue 
Samples 
Gene 
Rank* 
        
HSPA5       
Welsh 1.91E-07 1.958 25 9 top 2% 
Singh 1.14E-04 3.095 52 50 top 4% 
TCGA 1.12E-06 1.026 126 61 top 9% 
0.001 1.029 45 61 top 20% 
Vanaja 0.004 1.586 27 8 top 15% 
Taylor 0.013 1.169 131 29 top 17% 
Grasso 0.029 1.158 59 28 top 24% 
        
CDH2       
Arredouani 0.014 1.193 13 8 top 14% 
 
Table 2.2 ONCOMINE was searched using the following filters:  Gene: HSPA5 (GRP78) or 
CDH2 (N-cad), Analysis Type: Cancer vs. Normal Analysis, Cancer Type: prostate cancer or 
multiple myeloma. *Gene rank denotes the extent of significance out of all genes assayed; i.e. what 
percentage of genes whose upregulation has a more significant p-value as compared to the gene of 
interest. 
 
 For MM, the fold change was small likely because plasma cells and leukocytes (used as 
comparison samples) are secretory cells that also have high basal levels of the UPR markers.39 
CDH2 on the other hand was only significantly upregulated in one PCa study. That 
notwithstanding, a study describing the de novo expression of N-cad using two parameter 
immunofluorescence showed that this protein was expressed in high-grade human PCa, whereas 
no expression was found in normal prostatic tissue.40 Likewise, circulating N-cad has also been 
associated with poor MM prognosis 23, supporting an underlying relationship between N-cad and 
GRP78 in the progression of both tumor types.     
 
  40 
 
2.4.3 Effect of ER Stressors on GRP78 and N-cad expression in MM.1S 
The UPR is highly upregulated in MM cells due to their secretory nature.36,41,42 The lack 
of a strong transcriptional downregulation in the MM.1S cells prompted us to evaluate how the 
expression profiles of GRP78 and N-cad would be affected in the presence of acute drug challenge. 
The ER stress inducers Bortezomib (Btz) and thapsigargin (Tg); both of which are known to 
stimulate GRP78 expression and are used as current clinical treatments. Btz is a proteasome 
inhibitor that has been clinically approved for the treatment of MM while Tg is a Ca2+-ATPase 
inhibitor that causes the accumulation of unfolded proteins. Both cause intense ER stress by either 
preventing protein turnover or sequestering inactive proteins destined for removal. This stress 
induces the expression of ER chaperones, like GRP78, and forces it into action to either remove 
the stress or enable apoptotic pathways. Due to this, we wanted to examine whether ER stress 
would sensitize MM.1S cells to siRNA transfection, leading to a more robust KD effect. Btz 
triggered the upregulation of GRP78 mRNA expression levels by ~3.0 fold (P<0.01 ) while Tg, 
led to a greater (~7.0-fold, P<0.001) increase in GRP78 mRNA transcript levels. Conversely, both 
ER stress inducers were found to downregulate N-cad mRNA expression levels. We performed a 
follow up transfection of  BTZ treated MM.1S cells with GRP78-silencing siRNA (Fig. 2.3B) 
which interestingly resulted in GRP78 mRNA KD as well as concomitant N-cad mRNA KD.  
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Figure 2.3 Effect of ER stress on GRP78 and N-cad mRNA levels in MM.1S cells. A) Effect of 
ER stress inducers on MM.1S cells. Cells were treated with 10 nM bortezomib (BTZ) or 1 nM 
thapsigargin (Tg). qRT-PCR analysis was performed after 18 h of consecutive treatment. **P<0.01 
and ****P<0.001 for GRP78 with BTZ treatment and Tg treatment vs. vehicle control (DMSO), 
respectively. ****P<0.0001 for N-cad with both BTZ and Tg treatment vs. vehicle control 
(DMSO). B) GRP78 silencing after BTZ treatment. MM.1S cells were treated overnight with 10 
nM BTZ followed by treatment with 100 nM siRNA cocktail against GRP78. qRT-PCR analysis 
was performed 48 hrs post-transfection. ***P<0.001 and P<0.05 for GRP78 and N-cad vs. BTZ 
only treatment, respectively. All target mRNA levels are represented as the mean fold change ± 
SD of 3 separate trials. 
 
 
BTZ has been found to suppress the expression of N-cad 43 but little is known about the 
effects of Tg on this molecule. N-cad expression has been associated with intracellular Ca2+ flux, 
so inhibition of the ATPase-dependent Ca2+ flux by Tg may be correlated with its effects on N-
cad transcription levels.44 Nevertheless, when MM.1S cells were pre-treated with BTZ followed 
by GRP78 siRNA transfection, GRP78 KD caused an additional decrease in N-cad (Fig 2.3B) 
gene expression. Of note, siRNA treatment did not affect genetic levels of N-cad (Fig 2.1C) but 
the combination of ER stressors (i.e., drug treatments) and siRNA transfection did induce 
significant downregulation in N-cad mRNA levels, suggesting that ER stressors (such as that 
induced by BTZ) may sensitize MM cells to siRNA treatment. This strategy may be a potential 
clinically viable approach to facilitate the transfection of UPR dependent cancer cells. 
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2.4.4  GRP78 silencing has no significant effect on the expression of related GRPs in PC3 cells nor 
causes cytotoxicity. 
In combination with GRP78, GRP94 and GRP75 are important ER chaperones and 
regulators of cell homeostasis.45,46 Their overexpression has been linked to tumor progression, 
metastasis and survival in multiple cancer types.45,46 Because GRPs work in concert and are closely 
related in function, we hypothesized that GRP78 KD could potentially have an associated effect 
on the client chaperones GRP94 and/or GRP75. To test this hypothesis, we measured mRNA and 
protein levels of GRP94 and 75 upon GRP78 KD in PC3 cells. Interestingly, GRP78 KD strongly 
increased GRP94 mRNA levels (~2.7-fold, P<0.001) but no changes were detected in GRP94 
protein expression. GRP78 downregulation had no effect on the levels of GRP75 mRNA or protein 
expressions (Fig. 2.5 A,B,C) 
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Figure 2.4. Effects of GRP78 silencing on GRP94 and GRP75 in PC3 cells. 50 nM siRNA cocktail 
against GRP78 or control siRNA were transfected into PC3 cells. Total mRNA and protein levels 
were analyzed at 48 h and 72 h, respectively. A) Western blot of GRP protein expression after 
GRP78 silencing. B) Protein expression analysis. Target protein levels were normalized against 
the loading control GAPDH and compared to control siRNA. Blot bands and quantitative values 
are presented as the mean ± SD and representative of 3 separate trials. C) qRT-PCR analysis of 
relative mRNA levels GRPs upon GRP78 silencing. Target mRNA levels are relative to the control 
siRNA and represented as the mean fold change ± SD of 3 separate trials. ***P <0.001 for GRP94. 
D) Viability assay PC3 cells after siRNA transfection. 50 nM siRNA cocktail or a control siRNA 
were transfected into PC3 cells and analyzed by flow cytometry at 48 and 72 hrs. Histograms are 
representative of 3 independent trials at each time point. 
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 Work done in C. elegans has proven that a compensatory mechanism exists between nine 
different ER chaperones, of which GRP78 and GRP94 were included.47 GRP94’s activity is not 
replicative of GRP78 and tends to gain function when GRP78 is absent.48 GRP78 knockdown, 
inactivation, or altering its cellular localization in mammalian cells have all be been reported to 
induce the expression of GRP94.49-51 However, the reverse is not true as studies have shown 
GRP94 knockdown does not always induce the expression of GRP78 or other chaperones.52 
Interestingly, we observed this regulatory compensation by a strong transcriptional increase in 
GRP94 upon silencing of GRP78 in PC3. Yet, there was no increase in the protein expression 
suggesting that either 1) the cells had mitigated the stress caused by the initial knockdown and had 
no need for excess GRP94, or 2) the lack of GRP78 effectively suppressed the protein folding and 
no functional GRP94 was expressed despite the high transcriptional levels. Conversely, neither the 
transcript or protein expression levels of GRP75 were affected. Despite being an ER chaperone, 
GRP75 also functions as a crosstalk mediator between the ER and the mitochondria and its 
knockdown in neuroblastoma cells activated the mitochondrial stress response.53 However, 
increased GRP75 expression has been shown to promote cytotoxicity in different cancer models. 
The lack of a compensatory reaction of GRP75 in response to our treatment also falls in line with 
the lack of cytotoxicity commonly observed in GRP78 suppressed cells. The PC3 model may not 
be as reliant on the ER chaperones or as sensitive to the effects of the UPR even over prolonged 
stress (i.e 72hrs). This prevents simple knockdown of the ER chaperones as an effective treatment 
strategy for PCa in terms of cell death, yet as shown, may have significant effects on other 
important pathways related to tumor progression. In fact, GRP94 knockout has been shown to 
disrupt cell adhesion of liver cells in mice.54 Knockdown of multiple GRPs in combination may 
be a potentially potent way of increasing the therapeutic nature of this treatment.  
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2.4.5 GRP78 silencing has significant effects on the expression of EMT related markers in PC3 
cells.  
We next investigated the effects of GRP78 silencing on members of the EMT signaling 
pathway, in which N-cad is a major marker. The EMT of epithelial cells is partly characterized by 
elevated levels of N-cad, with concomitant suppression of E-cad, ultimately enabling a more 
migratory and invasive tumor phenotype.55 GRP78 expression has been linked to cancer 
progression and metastasis in part through its effects on EMT markers in PCa.56 Induction of 
GRP78 has been shown to trigger EMT in colorectal cancer cells, while GRP78 KD using shRNA 
reversed the EMT by suppressing N-cad and upregulating E-cad expression levels, referred to as 
a “cadherin switch.” 22  However, using our GRP78-silencing approach, GRP78 KD in PC3 cells 
resulted in significant decreases of both N-cad and E-cad (Fig. 2.1 & Fig. 2.5) protein levels. In 
addition, we also investigated other EMT markers such as TGF-b and snail/slug. 27 We found a 
significant upregulation in TGF-b1 expression (~100%, P<0.01), suggesting a potential role for 
GRP78 as an important regulator of EMT markers in metastatic PCa. While not statistically 
significant, changes in b-Catenin and Snail-2 were also observed and may have important 
biological implications (Fig. 2.5). Once more, due to the inherent difficulties associated with 
transfection of suspension cells, MM cells were not used for this part of the study. The EMT 
process is controlled, in part, by the transcription factor Snail-2 which acts as a strong repressor of 
E-cad.57,58 GRP78 KD induced Snail-2 expression (Fig 2.5) which may account for the 
downregulation of E-cad.  
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Figure 2.5  Analysis of markers related to EMT after GRP78 silencing. 50 nM siRNA cocktail 
against GRP78 or control siRNA were transfected into PC3 cells and total protein levels analyzed 
72 hrs post-transfection. A) Western blot of EMT markers. B) Protein expression analysis. Target 
protein levels were normalized against the loading control GAPDH and compared to control 
siRNA. Blot bands and quantitative values are presented as the mean ± SD and representative of 
3 separate trials. **P<0.01 for TGF-b1 and *P<0.05 for E-cad. 
 
        GRP78 overexpression, its localization to the cell surface, and its association with Cripto 59, 
60 have been correlated with the activation of the TGF-b pathway. 61 TGF-b is a multifunctional 
cytokine which regulates prostate cell growth and epithelial cell proliferation.62, 63  However, active 
TGF-b exists mainly as an extracellular matrix protein which can function both as a tumor 
suppressor or as a key player in promoting tumorigenesis in advanced cancers. 61-65 We showed 
that in PC3 cells, GRP78 KD induced a strong and significant increase in TGF-b1 protein 
expression; consistent with our findings, induction of Snail-2 expression has been credited to TGF-
b associated pathways.66 While we observed TGF-b1 upregulation and the expected downstream 
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effects that this molecule has on Snail-2 and E-cad, we found that GRP78 silencing decreased N-
cad expression in PC3 cells. TGF-b1 upregulation is typically reported to be accompanied by N-
cad upregulation,22 hence our results suggest that N-cad expression is highly dependent on GRP78 
in this cell line and its regulation via GRP78 KD may supersede the effects of TGF-b1; i.e., N-cad 
was downregulated in spite of the fact the TGF-b1 expression was significantly increased upon 
GRP78 KD. This may indicate a unique mechanism in which GRP78 KD can directly modulate 
the expression of certain adhesion and EMT molecules. We also showed that downregulation of 
GRP78 did not change the protein expression levels of other chaperone GRPs nor cause 
cytotoxicity in PCa. These results confirm that the observed effects on the EMT markers were 
GRP78-dependent and not the result of global changes in closely related chaperones that also 
maintain ER homeostasis. 
2.4.6 GRP78 silencing changes the morphology of PC3 cells and reduces their adhesiveness to 
OSB 
A co-culture assay with PC3 and hFOB 1.19 OSB cells was developed to test whether 
GRP78 silencing would translate into reduced adhesion to bone cells, due to the concomitant 
suppression of related adhesion and EMT markers. OSB were cultured to confluence in a 96-well 
plate. PC3 cells were initially transfected with GRP78 silencing siRNA and then cultured on top 
of the OSB monolayer. Parallel co-cultures were treated with the anti-N-cad mAb CG-4, known 
to neutralize its function.67 Dramatic changes in morphology of the PC3 cells following GRP78 
silencing were observed, indicated by a shift from a flatter, elongated shape to a rounded 
configuration. We also noticed a lower cell density in these wells 18 hrs after transfection. 
However, no significant changes in morphology were observed when cultures were incubated with 
an N-cad NAb (Fig 2.6). 
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Figure 2.6 Morphological changes in PC3 cells after GRP78 KD. Cells were harvested 48 hrs 
post-transfection and re-seeded on a 24-well plate. Changes in morphology were analyzed 24 hrs 
after seeding. Bright-field microscope images (10x magnification) of cellular morphology 
containing 4 representative fields of view from 3 separate trials. Black arrows denote cells with 
rounded morphology and red arrows denote elongated cells. ***P< 0.001 compared to control 
(untreated) cells. Scale bar = 10 µm. 
 
Importantly, transfected PC3 cells were found to be less adhesive to OSB, as determined by a small 
but significant increase (>10%) in the number of cells collected in the supernatant relative to the 
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untreated control wells. Likewise, the N-cad NAb treatment reduced the co-cultured PC3 adhesion 
to OSB by [ ~10% ] (Fig. 2.7B). These data support a functional role for GRP78 and N-cad in 
mediating cell-cell adhesive interactions in between PCa and OSB cells. Ultimately, the cells were 
found to be less adherent to OSB, relative to untreated control cells, supporting the hypothesis that 
GRP78 KD and suppression of N-cad could significantly inhibit PCa cell-based adhesion to bone. 
In a comparable manner N-cad NAb treatment also diminished PCa adhesion to OSB (Fig. 2.7) 
highlighting the specific role N-cad plays in this phenomenon. That notwithstanding, other 
adhesion molecules have been reported to play a role in PCa-bone interaction,68 potentially 
accounting for the only moderate decrease in PC3 adhesion to OSB in our assays.  
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Figure 2.7 Functional changes in PC3 adherence to OSB after GRP78 KD or incubation with a N-
cad NAb clone CG-4 (N-cad NAb). PC3 cells were fluorescently labeled and re-seeded into 96-
well plates with confluent OSB 48 h post-transfection. Percentage of adhered cells was determined 
24 hrs after co-culture.  A) Representative image of PC3+OSB co-culture. Left = brightfield, right 
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= composite. B) Fluorescent images of labeled PC3 cells in supernatant after being removed from 
the co-culture and are representative of 3 independent trials. *P<0.05 and ***P< 0.001 compared 
to control (untreated) cells for the N-cad NAb or the GRP78 siRNA, respectively. Scale bar = 50 
µm. 
 
2.5 Conclusions  
        We have established a novel correlation between GRP78 and N-cad in MM and PCa cells and 
present GRP78 as an ancillary regulator of markers associated with the EMT pathway and its 
implications in the adhesion properties of PCa to the bone/BM niche. Our data suggest that 
downregulation of GRP78 may represent a suitable therapeutic intervention strategy for 
modulating tumor-microenvironment adhesive interactions leading to tumor progression and drug 
resistance. In summary, our results warrant additional investigations to further unravel the 
molecular interactions by which GRP78 asserts adhesion regulation, given its primary role as a 
master regulator of the UPR in the ER.  
 
2.6 Methods and Materials 
2.6.1 ONCOMINE Data Mining 
The ONCOMINE repository (www.oncomine.com) is a repository of cDNA microarrays. 38 
We searched ONCOMINE using the following filters:  Gene: HSPA5 (GRP78) or CDH2 (N-cad), 
Analysis Type: Cancer vs. Normal Analysis, Cancer Type: prostate cancer or multiple myeloma. 
A summary table containing fold change and significance (P<0.05) for each comparison are 
presented as log2 median-centered intensity as reported by ONCOMINE.  
 
2.6.2 Cell Culture 
        MM.1S (MM cell line, ATCCÒCRL-2974), MM.1R (MM cell line, ATCCÒ CRL-2975), 
RPMI 8226 (ATCCÒ CCL-155), PC3 (bone metastatic PCa cell line, ATCCÒ-CRL-1435), and 
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hFOB 1.19 (OSB cell line, ATCC® CRL-11372) were purchased from ATCC. MM cell lines were 
cultured in high glucose RPMI-1640 medium supplemented with 15% fetal bovine serum (FBS), 
2.5 mM of L-glutamine and 1% penicillin/streptomycin. PC3 cells were cultured in RPMI-1640 
medium containing 10% FBS, 2.5mM of L-glutamine and 1% penicillin/streptomycin. Both cell 
lines were cultured at 37°C in a humidified tissue culture incubator containing 5% CO2. hFOB 1.19 
cell medium consisted of 1:1 mixture of Ham's F12 Medium Dulbecco's Modified Eagle's Medium, 
with 2.5 mM L-glutamine, 10% FBS and 0.3 mg/ml G418 (Sigma-Aldrich). These cells were 
maintained and propagated at 33°C and 5% CO2 except during co-culture experiments which were 
conducted at 37°C. All cell lines were checked periodically for mycoplasma using MycoAlert™ 
Mycoplasma Detection Kit (Lonza). Authentication of cell lines was performed by STR DNA 
profiling analysis conducted by the Molecular Resources Facility at Rutgers University. Cell 
populations were frozen after 3 passages from the time of initial receipt and growth and were 
discarded after 30 passages. 
 
2.6.3 ER Stress Induction 
       For ER stress induction, MM.1S cells were seeded at a density of 7.5x105- 1.0x106 cells/well 
in a 24-well plate. Cells were treated for 18 hrs with 10 nM bortezomib (BTZ) (Caymen 
Chemicals),  1nM thapsigargin (Tg) (Sigma-Aldrich) or dimethyl sulfoxide (DMSO, Sigmal-
Aldrich) as vehicle controls. Total RNA was isolated and subsequently analyzed via qRT-PCR. 
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2.6.4 siRNA Transfection 
       HSPA5 (GRP78) targeting siRNAs were purchased from Ambion (Carlsbad, USA). Two 
different siRNAs; Silencerâ Select Pre-designed siRNA s6979 (5’ UUC UGG ACG GGC UUC 
AUA Gtt 3’) and s6980 (5’ UCU AGU AUC AAU GCG CUC Ctt 3’) targeting exons 6 and 8 of 
GRP78 mRNA, respectively, were tested. For control, the Silencerâ select negative control No. 2 
siRNA was used (Ambion).  siRNA transfections were performed using a modified reverse 
transfection technique 69 using  a cocktail containing equimolar quantities of each GRP78 siRNA 
to maximize silencing potential. The GRP78 siRNA cocktail (or siRNA control) was diluted in 
Opti-MEM reduced serum medium and incubated with the TransIT-X2 dynamic delivery system 
(Mirus Bio) according to the manufacturer’s protocol. The siRNA-TransIT-X2 complexes were 
added to wells of either a 6- or 24- well plate upon which either MM or PC3 cells seeded in 
complete growth medium at a cell density of 7.5-9x105 cells/well (6 well plate) or 0.75-1x105 
cells/well (24 well plate).  GRP78 siRNA cocktail or control siRNA were used at a final 
concentration of 50 nM for PC3 and 100 nM for MM cell lines.  
2.6.5 RNA Isolation and qRT-PCR 
       Total RNA was isolated following transfections (48 hrs) from TriZol (Ambion) preserved 
cells using a TriRNA Pure Kit (Geneaid), following the manufacturer’s instructions. The collected 
RNA was quantitated on a Qubit 3.0 fluorimeter using the Qubit Broad Range (BR) assay kit 
(Thermo Fisher Scientific). RNA (200 ng) was reversed transcribed into cDNA using a high 
capacity cDNA kit (Applied Biosystems). RT-PCR was performed using pre-developed 
TaqManTM gene expression primer-probes for GRP78 (assay ID Hs99999174_m1), N-cad (assay 
ID Hs00983056_m1), GRP94 (assay ID Hs00437665_g1), GRP75 (Hs00269818_m1), and 
GAPDH (Hs99999905_m1) and TaqManTM fast advanced master mix. qPCR fast assay was 
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carried out on a StepOnePlus RT-PCR system (Applied Biosystems). Fold changes were calculated 
with the ΔΔCt method using GAPDH as endogenous control and the negative siRNA as the control 
sample. 
2.6.6 Western Blot  
         Total protein was isolated from the cell cultures following transfection (72 hrs). Protein 
lysates were prepared by lysing the cells in ice-cold RIPA buffer (G-Biosciences) supplemented 
with a protease inhibitor cocktail (P2714, Millipore Sigma) which was diluted 1:10 as per the 
manufacturer’s recommendations. Cell debris was removed by centrifugation at 16,000xg at 4°C 
and protein concentrations were determined using a PierceTM BCA kit (Thermo Fisher Scientific). 
A sample (20-35 µg) of the supernatant protein was mixed with LDS buffer and DTT, incubated 
at 70 °C for 10 min and resolved on a 4-12% Bis-Tris PAGE gradient gel before being transferred 
to a PVDF membrane. Following transfer, the membrane was blocked in 5% skim milk for 1 h, 
washed and incubated at 4 °C overnight with a rabbit 1° mAb against human GRP78, GRP94, 
GRP75, N-cad, E-cad, TGF-b1, Slug, B-catenin or GAPDH (all purchased from Cell Signaling 
Technology) at a 1:1000 dilution. The membrane was subsequently washed and incubated with an 
anti-rabbit HRP-conjugated 2° Ab (Cell Signaling Technology) for 1 h at room temperature at 
1:2000 dilution. The bands were visualized using a SignalFireTM ECL reagent (Cell signaling 
Technology) on a ProteinSimple FluorChem E imager. No changes in GAPDH band intensity 
between control siRNA and GRP78 siRNA were detected, therefore target protein bands were 
normalized against the loading control GAPDH. 
2.6.7 Flow Cytometry and Cell Viability 
        Cell viability was assessed using an Annexin V/PI kit (Biolegend).  Annexin V and PI were 
added to the cell samples post-transfection at 24, 48, and 72 hrs according the manufacturer’s 
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recommendation, incubated for 15 min at room temperature in the dark, and followed by 
immediate analysis by flow cytometry (FC500 flow cytometer, Beckman Coulter).  Data was 
processed with Kaluzaâ (Beckman Coulter) flow analysis software. 
2.6.8 Cell Morphology Assay 
         For cell morphology analysis, PC3 cells were transfected with GRP78 siRNA and harvested 
48 h later or treated overnight with 20ug/mL of a N-cad neutralizing monoclonal antibody, clone 
CG-4 (N-cad NAb, Sigma-Aldrich) prior to analysis. The cells were counted on Z2 Particle 
Counter and Size analyzer (Beckman Coulter) and re-seeded at cells/well in a standard 96 well 
plate and left to culture for an additional 18 h. The wells were subsequently washed and imaged 
under bright field on a Cell Insight CX5 high content screening instrument (Thermo Fisher 
Scientific). Images were analyzed using ImageJ software package (NIH). Fields of view (15 total, 
5 each from 3 independent experiments) of control cells or cells treated with GRP78 siRNA were 
analyzed using the ImageJ software package (NIH).  Cells with a clearly defined spherical and 
darker border (under bright field) were considered as rounded. Morphology was calculated as 
rounded: Nrounded cells/Ntotal cells or elongated: [Ntotal cells-Nrounded cells]/Ntotal cells and represented as a 
mean percentage ± SD. 
2.6.9 Adhesion Assay 
      To determine the effects of GRP78 KD on PC3 cells adhesion to bone, PC3 cells were 
transfected with GRP78 siRNA and harvested 48 hrs later and cultured with hFOB 1.19 cells plated 
in a 96 -well plate until confluent. To track the PC3 cells in co-culture, transfected cells were 
labeled with the Vybrant CFDA SE (green) Cell Tracer Kit (5 M) (Thermo Fisher Scientific) 
counted on a Z2 particle counter and size analyzer (Beckman Coulter), and then seeded at 10,000 
cells/well onto confluent OSB. For comparison, parallel co-cultures were treated overnight with 
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20 ug/mL of a N-cad NAb, clone CG-4 (Sigma-Aldrich). Number of fluorescently labeled cells 
[Ncoculture] were counted by high content screening (Cell Insight CX5, Thermo Fisher Scientific) 
following an 18 hr co-incubation period. Supernatants were then transferred from co-culture wells 
into empty ones to determine the number of fluorescently labeled floating cells [Nsupernatant]. 
Adherence was calculated as %Nsupernatant/ Nco-culture. 
2.6.10 Statistical Analysis  
         All data was plotted and analyzed using the GraphPad Prism software, V 7.0d (La Jolla, CA). 
Each experiment was performed in triplicates (N=3). Data is represented as the mean ± SD. 
Comparisons between two groups were analyzed using unpaired student’s t-tests. A probability 
(P) value of less than 0.05 was considered statistically significant. 
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Chapter 3: Biological Activity of Higher-Order siRNA Nanostructures and 
their Bioconjugates1-4 
 
3.1 Abstract 
The biological action of higher-order siRNA motifs and their bioconjugates have recently gained 
widespread attention in the development of new and improved gene therapeutics. In cancer gene 
therapy applications, these siRNA motifs target and silence important oncogene targets leading to 
potent cell death in a wide range of cancer models. In this study, we have developed an efficient 
method for the construction of higher-order RNA structures, including those adopting V-, and Y- 
and >-< shape RNA templates. Self-assembly of complementary RNA to the template strands led 
to higher-order siRNA nanostructures which produced a significant increase in the knockdown 
efficiency (50-95%) at low nanomolar concentrations (5 nM) of multiple oncogene targets 
simultaneously. In an effort to extend the repertoire of functionally diverse siRNAs, we have also 
developed bioconjugation strategies for incorporating bio-active probes such as fatty acid 
appendages and fluorescent reporters on to our V- and Y-shape templates allowing for the 
incorporation of up to three probes per molecule of siRNA. Our results indicate that introducing 
multiple fluorescent reporters significantly increased the in vitro limit of detection of the siRNA 
in a model prostate cancer (PCa) cell line with comparable knockdown efficiency to the control 
siRNA. Conversely, multiple fatty acid appendages yielded a mild silencing effect in the absence 
of a transfection reagent. Taken together, these results highlight the ability to generate higher-order 
siRNAs and their bioconjugates for exploring the influence of modified siRNA structure on anti- 
cancer activity.  
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3.2 Introduction 
Among the many nucleic acids currently employed as gene therapy agents, short-
interfering RNAs (siRNAs) are widely used  as potent regulators of gene expression and for  
mitigating the progression of various diseases.5-7 Structurally, siRNAs are short double stranded 
RNA duplexes composed of hybrid antisense (guide) and sense (passenger) strands which 
contain19-25 base pairs with nucleotide overhangs on the 3’ ends.8-10 These molecules trigger a 
regulatory system of genetic expression known as the RNA interference (RNAi) pathway. In the 
natural mechanism, long double stranded RNAs are cleaved into siRNAs by an RNAse III 
dependent endonuclease referred to as “Dicer”. The siRNAs are then incorporated into the RNA 
Induced Silencing Complex (RISC), a multimeric protein complex with endonuclease activity 
mediated by the Argonaute (Ago) protein which uses the guide strand to target and cleave 
complementary mRNA, thus preventing protein translation.11-14 Conversely, siRNA can be 
synthesized exogenously and then introduced into the cell target where it is immediately 
incorporated into RISC and leads to the degradation of mRNA transcripts. 
In spite of their therapeutic promise, siRNAs are still plagued by poor pharmacokinetic 
properties,15 including poor metabolic stability, off-target gene silencing and immunostimulatory 
effects. These effects increase toxicity, limits cell permeability and limits their duration of action 
which restricts their therapeutic potential and raises the need for more potent constructs. One 
approach to improve siRNA potency is to use an “siRNA cocktail” which incorporates multiple 
siRNAs that target the same or multiple mRNA sequences in one treatment. However, effectively 
delivering or expressing multiple siRNAs comes with a caveat, they are inherently more difficult to 
transfect and have shown limited in vivo applicability.16 Alternatively, chemically derived siRNAs 
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can facilitate the incorporation of modifications and/or functional probes which can enable self-
assembly into higher-order structures for improving RNAi activity.17-19  
RNAi nanotechnology has led to the evolution of functional siRNA materials for a variety 
of applications, including the development of nanomedicines and nanoparticle formulations for gene 
therapy.18,19 siRNA nanostructures have been formulated for silencing single or multiple gene 
targets. For example, a tripodal-interfering RNA (tiRNA) (Figure 1, a) and related supramolecular 
RNA nanostructures with polyethyleneimine (PEI) and galactose-functionalized PEI were self-
assembled to promote silencing efficiency in-vivo.17 The resultant siRNA nanoparticle produced an 
increase in stability and delivery efficiency while also accumulating in specific tissues (i.e. liver) 
leading to a much more robust and long-lived gene silencing effect. Likewise, DNA-RNA and RNA-
RNA nano-cubes (Figure 3.1, b), the latter of which contained as many as six double-stranded 
dsRNA Dicer substrates, promoted the release of multiple siRNAs in breast cancer cells.20 The 
siRNAs resulted in a significant increase in the duration of action due to the prolonged knockdown 
of enhanced green fluorescent protein, (eGFP) for up to twelve days. These nano-cube formulations 
have proven to be effective in biomedical studies as well.  They induced potent suppression of the 
viral Gag proteins, p55 and p24, in HIV-1 pseudotyped with VSV-g 293T cells, which resulted in 
potent antiviral activity. These constructs were also found to be immunogenic, which ultimately 
limits their applicability due to the risk of toxic immunostimulatory responses. In another proof-of-
concept study, the siRNA nanostructures composed of self-assembled three- and four-way junctions 
(Figure 3.1, c), triggered potent knockdown of multiple luciferase gene targets for up to five (5) 
days in HeLa cells.21 Due to the impressive increases in the stability, potency, length of action, and 
flexible design, siRNA nanostructures have become an interesting tool of enhancing siRNA activity. 
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Figure 3.1. Schematic representations of siRNA self-assembly and nanotechnology. A) Design of 
a non-linear tripartite siRNA tripod based on the complementary base pairing of three independent 
siRNA sequences. B) Structural assembly of RNA and RNA-DNA “nanocubes” for delivery of up 
to six siRNAs after Dicer cleavage.  C) Sequence dependent assembly of 3- and 4- way siRNA 
junctions. D) Design of V- and Y-shape siRNAs containing up to three siRNA sequences within 
the same molecular scaffold. Reprinted with permission from Wiley and Sons: Cultrara, C. N.;  
Shah, S.;  Kozuch, S. D.;  Patel, M. R.; Sabatino, D. Chem. Bio. Drug Des. 2018, 1-12 
 
Similar in action to nanostructure formulations, siRNA bioconjugates have shown the 
potential to improve the physicochemical and pharmacokinetic properties of siRNAs in preclinical 
and clinical studies.22-24 The generation of amphiphilic siRNA with lipid-like moieties including 
fatty acids, steroids, or terpene derivatives have seen great use due to their inherent stability, longer 
duration of action, and improved penetration across cell membrane.25-28  The appeal of these 
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lipophilic siRNAs are in their potential to act as self-delivering formulations through the 
interactions with lipoprotein particles, receptors, and transmembrane proteins embedded within 
the cell membrane. 
 Furthermore, the combination of therapy and diagnostics termed “theranostics” has led to 
the development of new and improved gene therapeutics for the diagnosis and treatment of 
cancers.29 Specifically, siRNA bioconjugates containing reporter probes such as fluorophores, 
near-infrared (near IR) dyes and photosensitizers as well as those containing contrast agents and 
radiolabels (Figure 3.2, B) have been extensively used as theranostic agents in oncology.30,31 
These molecules have the capabilities of not only producing a therapeutic effect, but also allows 
for the mechanism of action to be studied. This is invaluable information when deducing new drug 
targets or determining the potential side effects when altering specific molecular pathways. 
However, most bioconjugates can only incorporate a single moiety and those covalent 
conjugations are limited to either the 3’ or 5’ end of the oligonucleotide. The latter can be 
problematic as both ends are important for siRNA incorporation into RISC and mRNA target 
recognition as well as being susceptible to RNA degradation by endogenous exonuclease. 
Therefore, new prototypes are still in demand to produce exceptionally efficient multi-functional 
siRNA conjugates.  
 
Figure 3.2. Representative examples of siRNA bioconjugates. A) lipid-siRNA bioconjugates. 
Figure adapted with permission from ref. 23, Kubo, T.; Yanaghara, K.; Sato, Y.; Nishimura, Y.; 
Kondo, S.; Seyama, T. Bioconjugate Chem. 2013, 24(12), 2045-2057. Copyright 2013, American 
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Chemical Society. B) Fluorescent-siRNA conjugated polymers used to image live cells. Figure 
adapted with permission from ref. 29, Liu, Y. Gunda, V.; Zhu, X.; Xu, X.; Wu, J.; Askhatova, D.; 
Farokhzad, O.C.; Parangi, S.; Shi, J. Proc Natl Acad Sci U S A 2016, 113(28), 7750-7755. 
Copyright 2016, National Academy of Sciences. Reprinted with permission from Wiley and Sons 
:Cultrara, C. N.;  Shah, S.;  Kozuch, S. D.;  Patel, M. R.; Sabatino, D. Chem. Bio. Drug Des. 2018, 
1-12 
3.3 Chapter Objectives 
 This thesis chapter builds on the work of Mayurbhai Patel, Ph.D., Stephen Kozuch, 
Ph.D., and Sunil Shah, M.Sc. which describes the self-assembly of a linear, V-shape, and Y-
shape siRNA into novel nanostructures and further functionalization through bioconjugation. My 
contribution primarily involves siRNA formulation and biological testing in cell lines to evaluate 
the anti-cancer activity of the reported siRNA constructs.1-4 Hybridization and self-assembly of 
complementary RNA strands using linear, V-shape and Y-shape RNA templates generated a 
library of siRNA nanostructures targeting the GRPs in vitro. Moreover, bioconjugation with an 
FITC fluorescent probe or with a variety of fatty acids led to the creation of new multi-functional 
V- and Y-shape siRNAs which can incorporate two or three moieties, respectively, to be tested 
for their unique structure-activity relationship in a model prostate cancer (PCa) cell line. 
Significantly, this work demonstrates the bio-activity of novel siRNA nanostructures, and their 
bioconjugates as potent multi-functional gene therapy tools in a variety of selected cancer cell 
lines. This work has been adapted and reprinted with permission from the following authored 
publications: Wiley and Sons: Cultrara, C. N.;  Shah, S.;  Kozuch, S. D.;  Patel, M. R.; Sabatino, 
D. Chem. Bio. Drug Des. 2018, 1-12. Copyright 2018, American Chemical Society.  Kozuch, S. 
D.;  Cultrara, C. N.;  Beck, A. E.;  Heller, C. J.;  Shah, S.;  Patel, M. R.;  Zilberberg, J.; Sabatino, 
D. ACS Omega 2018, 3, 12975-12984.  <https://pubs.acs.org/doi/10.1021/acsomega.8b01999> 
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  Patel, M. R.;  Kozuch, S. D.;  Cultrara, C. N.;  Yadav, R.;  Huang, S.;  Samuni, U.;  Koren, J. I.; 
Chiosis, G.; Sabatino, D. Nano Lett. 2016, 16, 6099-6108.  Shah, S.;  Cultrara, C. N.;  Kozuch, S. 
D.;  Patel, M. R.;  Ramos, J.;  Samuni, U.;  Zilberberg, J.; Sabatino, D. Bioconj. Chem. 2018, 29, 
3638-3648. Copyright 2016, American Chemical Society   
3.4 Results and Discussion 
3.4.1. Self-Assembly of siRNA Nanostructures 
Based on our previous work which produced linear, V and Y shape RNA templates using 
an orthogonally protected 5’-OLv 2’-OMMT rU phosphoramidite as branchpoint synthon,32 we 
developed a self-assembly strategy for the generation of siRNA nanostructures targeting GRP 75, 
78 and 94 (Figure 3.3). In our self-assembly approach, equimolar (200 pmol) quantities of purified 
linear, V- and Y-shape RNA templates along with their complementary RNA strands were used to 
form the siRNA hybrids and nanostructure formulations in annealing buffer (10 mM Tris, 50 mM 
NaCl, 1 mM EDTA, pH 7.5–8.0, 13-15 μL). Self-assembly into siRNA nanostructures which 
resembled circles, squares, rectangles, pentagons, hexagons and porous spheres were designed and 
detected using TEM imaging.3 Furthermore, a native PAGE analyses confirmed the formation of 
more retained, self-assembled higher-order siRNA hybrids, whereas TEM and DLS provided 
additional structural information related to the varying geometric shapes and sizes (10-150 nm) of 
the observed self-assembled siRNA nanostructures.    
 
  67 
 
 
Figure 3.3 Design and self-assembly of siRNA nanostructures.  
 
3.4.2. Activity siRNA Nanostructures in Various Cancer Cell Lines 
 The self-assembled siRNA hybrids (24 samples) were screened for their biological activity 
within the AN3CA human endometrial cancer cell line.3 The RNAi screen investigated the 
influence of the siRNAs on the proliferative activity of the AN3CA cells. Among this library of 
siRNAs, a set of lead samples demonstrating the most potent anti-proliferative activity were 
evaluated for their RNAi activity. These samples demonstrated GRP78 KD and upregulation of 
cleaved PARP (cl-PARP), a marker of apoptosis (Figure 3.4).33 Four lead siRNAs were selected, 
two V-shape (A12:S1:S:2, A12:S12) and two Y-shape (A123:S1:S2:S3, A123:S123) targeting 
GRP78 mRNA and transfected with the RNAiMAXTM transfection reagent.  
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Figure 3.4 Biological evaluation of the V- and Y-shape siRNA targeting GRP78 in the AN3CA 
cell line. A) Western blot of the total GRP78 and Cl-PARP levels following siRNA transfections. 
The loading control, GAPDH, was used to normalize the detected bands for quantitative 
densitometry using NIH imager (ImageJ). (D) The percent GRP78 knockdown and the percent Cl-
PARP levels were normalized according to the NS RNA control and quantitated following 
densitometry of the Western blot. The linear (r2 = 0.9243) correlation diagram in between the 
percent GRP78 knockdown and the percent Cl-PARP levels is provided as an inset. All 
experiments were replicated in triplicate, with average values presented with their standard 
deviations about the mean. Statistical analyses produced error bars with acceptable variance ± 
SEM; N = 3; p < 0.05.		
The V- and Y-shape siRNAs exhibited more potent GRP78 KD according to western blot 
when compared to the linear siRNA controls ( >80% vs ~75%) (Figure 3.4, A). Significantly, this 
result suggests that the higher order siRNA constructs are able to synergistically enhance the 
knockdown effect. Furthermore, the expression levels of Cl-PARP (cleaved 85-kDa protein 
poly(ADP-ribose) polymerase) were monitored as a molecular marker of apoptosis.33 There is a 
direct correlation between GRP78 KD and upregulation of Cl-PARP, suggesting that 
downregulation of GRP78 results in cell apoptosis (Figure 3.4, B). Similarly, the V- and Y-shape 
siRNAs significantly increased the levels of Cl-PARP as compared to the linear controls (>65% 
vs 10-65%) implicating that the higher order siRNAs exhibit more potent, synergistic anti-cancer 
effects relative to the linear siRNA controls.   
A) B)
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 The lead V- and Y-shape siRNAs were then tested in the HeLa (ATCC CCL-2) cervical , 
MDA-MB-231 (ATCC HTB-26) breast cancer cell lines known to overexpress the GRPs34,35 and 
a non-tumorigenic lung fibroblast cell line MRC5 (ATCC- CCL- 171) which was used as a control 
cell line with expressing basal GRP levels.36 Moreover, the V- and Y-shape were re-designed to 
target multiple GRPs (GRP78, GRP94, GRP75). In this assay, a control non-specific siRNA (NS 
RNA), was tested against the control linear GRP siRNAs (78 + 94 + 75), and the lead Y-shape 
siRNA targeting all three GRPs (GRP757894) in combination. The siRNAs (5 nM) were 
transfected using RNAiMAX (7 μL) within the AN3CA, HeLa and MDA-MB-231 cancer cell 
lines and within the MRC5 normal human cell line as control. The RNAi activity of the siRNA 
samples was evaluated according to GRP KD and release of LDH as a measure of cell cytotoxicity 
(Figure 3.5).  
  70 
 
 
Figure 3.5 RNAi screening. (A) Grp mRNA levels detected by RT-PCR. HeLa cells were 
transfected with NS RNA, linear GRP (78 + 94 + 75), and Y-shape GRP(789475) siRNA (5 nM) 
using RNAiMAX (7 μL). Grp78, Grp94, Grp75, and GAPDH mRNA levels were normalized 
according to GAPDH and quantitated with respect to NS RNA. (B) LDH release assay. The percent 
LDH released was measured following transfections of all treated cell lines (MRC5, AN3CA, 
MDA-MB-231, and HeLa). The LDH levels were quantitated and normalized according to the NS 
RNA. (C) Western blots measuring GRP78, GRP94, and GRP75 (percent protein) levels following 
siRNA (5 nM) transfections in normal lung, MRC5, endometrial, AN3CA, breast, MDA-MB-231, 
and cervical HeLa cancer cells. The GRP78, GRP94, and GRP75 levels were normalized 
according to GAPDH and quantified with respect to the NS RNA. Data represents knockdown 
efficiency of V-shape siRNAs (GRP7894, GRP7875, and GRP9475), Y-shape siRNA 
(GRP789475), and the linear siRNAs (GRP78 + GRP94 + GRP75) added in combination. All 
experiments were replicated in triplicate, with average values presented with their standard 
(A123−S1−S2−S3 and A123−S123) siRNA nanostructures
were selected to validate the potency of their RNAi activity
relative to their corr sponding linear NS RNA and the siRNA
(A1−S1, A2−S2, A3−S3, A1S1, A1−S1 + A2−S2, A1−S1 + A2−
S2 + A3−S3) controls (Figure 4). The siRNA nanostructures,
which xhibited the most pronoun ed anticancer eﬀects,
determined based on GRP78 knockdown, Cl-PARP levels, and
cell growth inhibition in our siRNA screen (Figure S17) were
selected as leads. As anticipated, the self-assembled siRNA
hybrids inhibited the AN3CA cells’ growth to about a 40%
greater extent relative to the siRNA controls (Figure 4A). A LDH
release assay conﬁrmed the cytotoxicities of the siRNA
formulations, even at low dosages (5 nM), with the Y-shape
A123−S1−S2−S3 siRNA exhibiting the most lethal (∼10%)
eﬀects (Figure 4B). Moreover, Western blot validated their
potent GRP78 knockdown eﬃciencies, with ≥80% knockdown
observed for the V- and Y-sha e siRNA hybrids, and the linear
controls exhibited at most ∼75% GRP78 knockdown when
added in combination (Figure 4C,D). Western blot also
conﬁrmed that the Cl-PARP levels indicative of ap ptosis were
found at signiﬁcantly increased levels in the cases of the V-shape
(A12−S1−S2, ∼75% and A12−S12, ∼65%) and the Y-shape
(A123−S1−S2−S3, ∼77% and A123−S123, ∼69%) si As
relative to their linear controls (∼10−∼65%).
Interestingly, a direct correlation was observed in between
GRP78 knockdown and increased levels of Cl-PARP, indicating
that GRP78 knockdown may be directly contributing to
apoptosis in the AN3CA EC cells. Taken altogether, this study
Figure 5. RNAi screening. (A) Grp mRNA levels detected by RT-PCR. HeLa cells were transfected with NS RNA, linear GRP (78 + 94 + 75), and
Y-shape GRP(789475) siRNA (5 nM) using RNAiMAX (7 μL). Grp78, Grp94, Grp75, and Gapdh mRNA levels were normalized according to Gapdh
and quantitated with respect to NS RNA. (B) LDH release assay. The percent LDH released was measured following transfections of ll treated cell lines
(MRC5, AN3CA, MDA-MB-231, and HeLa). The LDH levels were quantitated and normalized according to the NS RNA. (C) Western blots
measuring GRP78, GRP94, and GRP75 (percent protein) levels following siRNA (5 nM) transfections in normal lung, MRC5, endometrial, AN3CA,
breast, MDA-MB-231, and cervical HeLa cancer cells. The GRP78, GRP94, and GRP75 levels were normalized according to GAPDH and quantiﬁed
with respect to the NS RNA. Data represents knockdown eﬃciency of V-shape siRNAs (GRP7894, GRP7875, and GRP9475), Y-shape siRNA
(GRP789475), and the linear siRNAs (GRP78 + GRP94 + GRP75) added in combination. ll experiments wer r plicated in triplicate, with average
values presented with their standard deviations about the mean. Statistical analyses produced error bars with acceptable variance± SEM;N = 3; p < 0.05.
Nano Letters Letter
DOI: 10.1021/acs.nanolett.6b02274
Nano Lett. 2016, 16, 6099−6108
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deviations about the mean. Statistical analyses produced error bars with acceptable variance ± 
SEM; N = 3; p < 0.05.  
 The knockdown efficiency of the siRNAs proved to vary among the cancer cell lines tested. 
The AN3CA cell line was the most sensitive to treatment yielding GRP silencing efficiencies of 
>85% for the Y-shape siRNA hybrid. Conversely, the HeLa and MDA-MB-231 lines showed 
variable levels of GRP knockdown. However, in general, the V- and Y-shape siRNAs exhibited a 
more potent GRP knockdown effect compared to the control linear siRNA targeting GRP 75, 78 
and 94 as a cocktail mixture. This result validates the synergistic silencing effect of the siRNAs  
embedded within the same molecular scaffold as opposed to separate siRNAs (Figure 3.5, C). 
Interestingly in the AN3CA line, silencing of GRP94 and 75 with the V-shape siRNA hybrid had 
a separate silencing effect on GRP78 which was not the primary gene target. Moreover, silencing 
of GRP78 and 94 had little effect on GRP75 and these trends varied in the HeLa or MDA-MB-
231 suggesting that the cell lines have a varying dependence on the GRPs. For example, there may 
be a compensation effect in the GRP expression levels to offset loss or downregulation of a related 
GRP.37 Significantly, a modest KD effect of the GRPs was observed in the non-cancerous MRC5 
cell line either with all of the siRNA samples, suggesting that the cancer cells are more sensitive 
to GRP activity. This trend was also extended to cell viability, in which the tumor cells exhibited 
a more pronounced cell death effect (as a result of LDH release) presumably due to GRP KD when 
compared to the control MRC5 cell line (Figure 3.5, D). Importantly, this result underscores the 
potential use of the multi-GRP silencing siRNAs in a selective cancer treatment strategy. This 
work also demonstrates the utility of higher order self-assembled siRNA constructs as potent gene 
therapy tools and probes to elucidate the role important oncoproteins on cancer cell biology. 
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3.4.3. Rational design of fluorescently labeled V- and Y-shape siRNAs 
 The linear, V- and Y-shape RNA templates were also applied to a simple bioconjugation 
strategy to tag a fluorescent reporter, fluorescein (FL), onto the 5’ ends of the siRNA constructs 
(Figure 3.6A). Moreover, a self-assembly strategy was developed to hybridize complementary, 
linear FL-RNA strands with the linear, V- and Y-shape RNA templates to afford the multi-labeled 
siRNA constructs (Figure 3.6B). In this application, the incorporation of multi-fluorescent labels 
within a single molecular scaffold was hypothesized to increase signaling detection in cells in order 
to monitor siRNA cell biology.2 Fluorescently labeled siRNAs are especially useful in studying 
cellular uptake, trafficking and localization in order to optimize siRNA KD efficiency. The latter 
forms the main objectives of the current study.  
 
Figure 3.6 Design of fluorescently labeled linear, V-, and Y-shape siRNAs. A) Single probe 
bioconjugate or B) multi probe bioconjugate. Reprinted with permission from Kozuch, S. D.;  
Cultrara, C. N.;  Beck, A. E.;  Heller, C. J.;  Shah, S.;  Patel, M. R.;  Zilberberg, J.; Sabatino, D. 
ACS Omega 2018, 3, 12975-12984. Copyright American Chemical Society 2018.  
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Figure 3.2. Rational design of FL-siRNA bioconjugates. Linear, V-shape and Y-branch GRP 
silencing siRNAs with A) single and B) multiple FITC probes. Drawn in ChemDraw. 
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3.4.4. Internalization studies of the FL-siRNA bioconjugates  
 The FL-siRNA served as bifunctional probes, signaling the detection of siRNA activity in 
human cancer cells and mediating GRP KD post-transfection ultimately leading to potent anti-
cancer effects. The V- and Y-shape siRNAs had been previously validated as lead constructs in 
our GRP silencing approach across a panel of cancer cell lines. In this application, the single and 
multi-labeled FL-siRNAs belonging to the linear, V- and Y-shape constructs were transfected in 
PC3 PCa cells using the Trans-IT X2 dynamic delivery system known to work efficiently in 
suspension and adherent cell lines.38 High FL-siRNA doses (100 nM) of either a linear, V-, or Y-
shape hybrid with a single FITC moiety was used to effectively track cell uptake within the PC3 
cells at 3 and 20 hours by flow cytometry. Typically, transfection reagents rapidly shuttle siRNAs 
within cells during the first 4hrs. In our case, the FL-siRNAs showed a complete shift in 
fluorescence intensity in the flow histogram at 3 hours, which continued to persist up to the 20 
hour time point (Figure 3.7A). This indicates rapid uptake and prolonged residency time of the 
siRNAs  within the PC3 cells. Interestingly, when the cells were treated with a smaller 50 nM dose 
of FL-siRNA containing double (V-shape FL-siRNA) or triple (Y-shape FL-siRNA) FITC labels, 
the signal increases over time, hits a maximum at 4 hrs, and persists up until 72 hours (Figure 3.7 
B). Therefore, by increasing the number of FITC molecules per siRNA construct, the ability to 
track robustly siRNA uptake in live cells over extended (72 hours) duration of time is significantly 
improved (Figure 3.7). Together, this data provides mechanistic insights into the cellular uptake 
of FL-siRNAs while validating their extended localization times (72 hours post-transfection) in 
PC3 cells.   
  74 
 
 
Figure 3.7 Uptake efficiency monitored by flow cytometry. A) 100nM dosage of a single-FITC 
linear, V-, and Y-shape hybrid and B) Time dependent study of a linear, V-, and Y-shape hybrid 
containing 1, 2, or 3 FITC labels, respectively, at a 50nM dosage. Images reprinted with permission 
from Kozuch, S. D.;  Cultrara, C. N.;  Beck, A. E.;  Heller, C. J.;  Shah, S.;  Patel, M. R.;  Zilberberg, 
J.; Sabatino, D. ACS Omega 2018, 3, 12975-12984. Copyright American Chemical Society 2018.  
 
  
 To validate the cell uptake activity detected by flow cytometry, fluorescence imaging of 
the cells was used to visualize cell uptake and residency time. The images (Figure 3.7) supported 
the flow cytometry data, indicating that at least 4hrs was needed to visualize the FL-siRNAs within 
the cells. Moreover, in all cases, the signal intensity increased with time and also as a function of 
the number of FITC labels incorporated within the FL-siRNA construct, with the tri-FITC labeled 
Y-shape siRNA providing the most vibrant and detailed images (Figure 3.8 C). 
 
 
 
 
 
 
that upon GRP 78 mRNA knockdown, a marked upregulation
of GRP 94 expression was observed, with a lower eﬀect on the
GRP 75 mRNA levels (Figure 5A). Presumably, this
compensatory eﬀect may be linked to the maintenance of
the UPR under the stress-induced conditions, potentially
linking the activity of these GRP chaperones.25 A similar trend
was observed for the V-shaped siRNA targeting GRP 78 and
94 mRNA, with a noticeable upregulation of GRP 75, albeit to
a smaller extent (Figure 5A). The Y-shaped siRNA targeting all
three GRP chaperone proteins displayed the most synergistic
mRNA knockdown (40−70%) of GRP 75, 78, and 94 (Figure
5A). Comparison with the FITC-labeled siRNA constructs
demonstrated GRP knockdown (20−70%) in a sequence-
dependent manner albeit to a lesser extent when compared to
the native, unconjugated siRNAs (40−80%) (Figure 5A). The
decrease in GRP-silencing activity of the FL-labeled siRNAs
can be partially attributed to detrimental eﬀects of function-
alizing the 5′ terminus of the antisense siRNA strand, which
may inhibit incorporation into RNA induced silencing complex
and mRNA processing as part of the RNAi pathway.27
Interestingly, when the sense strands were FITC-labeled and
hybridized to the complementary Y-shaped RNA template, the
FITC-labeled Y-shape siRNA displayed comparable GRP
knockdown (55−95%), as the non-FITC-labeled Y-shape
Figure 3. siRNAs’ uptake eﬃciency in PC-3 cells monitore by ﬂow cytometry. (A) Cell internalization of linear, V- and Y-shaped FITC-labeled
siRNA. (B) Time-dependent cell internalization of linear, V- and Y-shaped siRNA containing single, double or triple FITCs, respectively.
Figure 4. Time-dependent (4 and 24 h post-transfection) ﬂuorescent and bright-ﬁeld images of PC-3 cells transfected with (A) linear FITC-labeled
siRNA and (B) Y-shape FL−siRNA containing multiple (3×) FITC probes.
ACS Omega Article
DOI: 10.1021/acsomega.8b01999
ACS Omega 2018, 3, 12975−12984
12980
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Figure 3.8 Fluorescence microscopy of the FL-siRNA. 50 nM of A) FL-linear (1 FITC), B) FL-
V-shape (2 FITC), and C) FL-Y-shape (3 FITC) were transfected into PC3 cells and imaged at 4hr 
and 24 h post transfection. Images reprinted with permission from Kozuch, S. D.;  Cultrara, C. N.;  
Beck, A. E.;  Heller, C. J.;  Shah, S.;  Patel, M. R.;  Zilberberg, J.; Sabatino, D. ACS Omega 2018, 
3, 12975-12984. Copyright American Chemical Society 2018.  
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Figure 3.13 Fluorescent microscope images of FL-siRNA transfected PC-3 cells at 4 and 24 hours 
post transfection. (A) FL-linear, (B) V-FL-siRNA containing 2 FITC probes, (C) Y-FL-siRNA 
containing 3 FITC probes 
 
 
C 
Y-FL-siRNA  
4 hours post transfection  24 hours post transfection 
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3.4.5. Gene Knockdown Efficiency of the FL-siRNAs 
 With optimized transfection conditions in hand, the FL-siRNAs were assayed for their 
ability to track the knockdown effects of the target GRP (GRP78, GRP94, GRP75) mRNA 
transcripts. Briefly, the FL-siRNA (50 nM) were transfected into the PC3 cells and analyzed by 
qRT-PCR for 48hrs for mRNA silencing and by western blot at 72 hrs for protein knockdown.  
Figure 3.9 qRT-PCR analysis of GRP75, 78 and 94 mRNA knockdown. FL-siRNA (50 nM) 
samples were transfected into PC-3 cells and relative mRNA levels were normalized to a control, 
non-specific siRNA. (A) Total mRNA levels were analyzed 72 h post transfection for the antisense 
strand labeled FL-siRNA constructs. (B) Total mRNA levels were analyzed 48 h post transfection 
of the sense-strand labeled FL- siRNA constructs containing 1, 2 and 3 FITC probes (B).  
 
An initial screen of the antisense (guide) labeled linear and V-shape siRNA showed a 
diminished silencing effect of the GRP transcript levels with the FL-siRNA (20-70%) compared 
to their naked controls (40-80%). The inability to acquire sufficient yields of pure FL-Y-shape 
siRNA (Figure 3.6 A) prevented it from being included in this assay. Instead, a single labeled 
sense (passenger) strand was hybridized to the antisense Y-shape RNA template (Figure 3.6 B) to 
self-assemble the Y-shape FL-siRNA construct. This sample triggered similar knockdown 
efficiencies when compared to the unlabeled Y-shape siRNA confirming that sense strand 
modification was more tolerant (with respect to anstisense strand modifiers) to RNAi activity in 
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Figure 3.11 qRT-PCR analysis of GRP75, 78 and 94 gene knockdown. 50nM siRNA samples 
were transfected into PC-3 cells and relative mRNA levels were normalized to a control siRNA. 
(A) Total mRNA levels were analyz d 72 h post transfecti n of the antisense FL-siRNA 
constructs. (B) Total mRNA levels were analyzed 48 h post transfection of the sen e-strand FL-
siRNA constructs containing 1, 2 and 3 FITC probes (B).  
 
3.4.8  Internalization Efficiency via Flow Cytometry and Fluorescent Microscopy 
Incorporation of the FITC within the siRNA constr cts provid d the ability to monitor 
cellular uptake quickly and efficiently. PC-3 cells were treated with FL-siRNA nd cell uptake 
measurements were etermined by flow cytometry 3 h post transfection. Analysis of the linear, V- 
and Y-shaped FITC-labeled siRNA revealed a slight shift in fluorescence intensity vs the total 
gated cell population post transfection (Figure 3.13A). This data suggested that 3 hours may not 
be sufficient for complete siRNA uptake. To determine the optimal cell uptake time, a new set of 
siRNA samples were prepared (50 nM). PC-3 cells were transfected as previously described 
analyzed 20 hours post transfection by flow cytometry and revealed that FL-siRNA treatment at 
higher concentrations (100 nM) and treatment time (20 h) elicited the greatest shift in cell-based 
fluorescence intensity (Figure 3.12A). Interestingly, multiple incorporation of FITC upon 
A B 
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PC3 cells (Figure 3.9, A). The reduced silencing effects of the FL-labeled linear and V-shape 
hybrids when compared to the unlabeled siRNAs can be partially attributed to the FITC 
conjugation at the 5’ end of the sequence.40 This position has been shown to play an important role 
in the incorporation of siRNA into RISC and mRNA processing in the RNAi pathway. Conversely, 
when the guide, antisense siRNA strands were left unmodified and the FITC label (single, double 
or triple FITCs for the linear, V-, and Y- shape siRNAs , respectively) was incorporated within the 
passenger, sense strands the knockdown efficiencies improved ( 55-95%) which were comparable 
to the control, unlabeled siTNA sequences (40-80%) (Figure 3.9, B). These siRNA constructs also 
proved to be most useful in the cellular uptake and imaging studies (Figures 3.6 and 3.7). As 
previously seen, silencing one or two GRPs can elicit an upregulation of the non-targeted one (i.e 
GRP94 when silencing GRP78 with the FL-linear and GRP75 when silencing GRP78 and GRP94 
with the FL-V, Figure 3.9, A). However, this was not observed when treating the cells with the 
Y-shape hybrids suggesting the synergistic silencing of all three (3) targeted GRPs is maintained 
even with FITC labeling.  
 Based on the qRT-PCR results, we selected the Y-shape hybrid containing 3 FITC probes 
as our lead siRNA construct for further analysis. Similarly, the FL-Y-shape siRNA hybrid (50 nM) 
was transfected into the PC3 cells and analyzed for mRNA and protein knockdown. A significant 
knockdown of GRP78 and GRP94 mRNA (40-60%) was observed by qRT-PCR with little effect 
on GRP75. These mRNA knockdown effects translated differently at the protein level, with 
diminished levels of GRP78 and GRP75 (30-35%) observed with little effect on GRP94 (Figure 
3.10). This is not uncommon as post-transcriptional regulation can alter the protein expression 
levels despite little to no changes observed at the mRNA level.41 Furthermore, the expression 
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levels of the GRPs varies significantly among cell lines, further compounding the siRNA KD 
effects.  
 
Figure 3.10 Protein and mRNA knockdown levels of GRP75, 78 and 94 determined by Western 
Blot (A), and RT-PCR (B). *P< 0.05 in PC-3 and **P<0.01. 
 
 3.4.6. Cell Viability after treatment with the FL-siRNAs 
 Given the observed GRPs silencing effects of the FL-siRNAs, their cytotoxicity to the PC3 
cells was next determined. In this assay, PC3 cells were stained with propidium iodide (PI), a 
fluorescent DNA intercalator that is not cell permeable in living, healthy cells and permeable in 
cells with compromised cellular and nuclear membranes.42 The extent of cytotoxicity was 
measured by the release of PI fluorescence intensity (636 nm), 72 hrs post transfection. Brightfield 
microscopy showed populations of PC3 cells that were both adherent (live) and in suspension 
(dead). The PC3 cells are designated as an adherent epithelial cell line that grows and thrives when 
adhered to the culture plate and are generally considered compromised when detached and found 
in suspension. Flow cytometry revealed significant increases in the populations of dead cells in 
suspension over time, peaking at 48 hrs (Figure 3.11). At 72 hrs, the cells still adhered to the 
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3.4.9  Western Blot 
 Following the qRT-PCR screening analysis of the FITC-siRNA samples, the lead Y-shaped 
siRNA containing three FITC probes was selected for further analysis. The Y-shaped siRNA 
sample (50nM) was prepared and transfected into PC-3 cells as described earlier. Cells were 
collected 72 h post transfection and subjected to qRT-PCR and western blot. RT-PCR showed 
mRNA knockdown of GRP78 (~40%), increased knockdown of GRP94 (~60%) and no visible 
knockdown of GRP75. However, western blot indicated protein level knockdown of GRP78 and 
75 (~30-35%) in both instances, but no visible knockdown of GRP94 at the protein level, which is 
known to vary from the mRNA tr script levels. 
 
Figure 3.14 Protein and mRNA knockdown levels of GRP75, 78 and 94 determined by Western 
Blot (A), and RT-PCR (B). *P< 0.05 in PC-3 cells and *P<0.01 in PC-3 cells. 
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culture plate appeared to have recovered and the viability returned to a comparable level observed 
within the first 24hrs. Conversely, the percentage of compromised cells was maintained at high 
levels in the supernatant suggesting that the FL-siRNAs were capable of eliciting cancer cell death 
upon GRP KD. In this assay, the FL-labeled Y-shape siRNA construct yielded the most potent cell 
death effects following synergistic GRP (GRP75, 78 and 94) knockdown. 
Figure 3.11 Cell viability determined using PI on flow cytometry, adhered cells (A) and 
supernatant cells (B). 
 
3.4.7 Rational Design of Fatty Acid Labeled siRNA Bioconjugates. 
 In this related application, fatty acid conjugated siRNAs were designed to address the lack 
of cell permeability associated to siRNAs. The hydrophilicity and net anionic charge of RNA 
prevents its passive diffusion across the cell membrane and requires the use of a transfection vector 
or reagent to facilitate cell uptake.43 In spite of their promise in preclinical and clinical siRNA 
applications, these reagents are limited in utility due to their cytotoxicity, immunogenicity, and 
variable efficiency based on the cell type being studied.44, 45 Previous work has shown that the 
bioconjugation of fatty acids and related lipid moieties can improve siRNA metabolic stability as 
well as facilitate passive diffusion across cell membranes in the absence of a transfection   
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3.4.10 Cell Viability 
Cell viability of the FITC-labeled siRNAs treated PC-3 cells was measured using 
propidium iodide (PI) staining. PI is a fluorescent intercalating agent that stains dead cells and is 
commonly used in flow cytometry to evaluate cell viability. PI cannot cross the membrane of live 
cells, making it useful to differentiate necrotic, apoptotic and healthy cells.70 PC-3 cell viability 
was determined at 24, 48 and 72 h post transfection to determine which construct exhibited the 
most potent cell death activity. (Figure 3.15 A, B) Following the 24 h incubation, it was noted that 
the supernatant contained PC-3 cells, as an initial indicator of cell death due to loss in adhesion. 
Both the supernatant cells as well as the cells still adhered to the bottom of the well were tested 
for viability. PI staining showed an increase in cell death over a 72h period for all samples. The 
Y-shape targeti g all three GRPs elicit d the most potent cell dea h in both cases.  
 
   
Figure 3.15 Cell viability determined using PI on flow cytometry, adhered cells (A) and 
supernatant cells (B) 
 
 
 
 
A             B 
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Reagent.25-27 To build on this, we designed a simple strategy to expand the scope of fatty acid-
siRNA (FA-siRNA) bioconjugation with its application to the higher order V-, and Y-shape RNA 
templates.  
In this application, a fatty acid conjugation strategy was adapted for the incorporation of 
lengthy (C18) and shorter chain (C12) saturated {lauric acid (12:0), palmitic acid (16:0), stearic 
acid (18:0)} and unsaturated {oelic acid (18:1), linoleic acid (18:2), and linolenic acid (18:3)} fatty 
acids.4 Moreover, the development of a self-assembly strategy was designed, in order to 
functionalize the 5’-terminus of the sense RNA strand with palmitamide followed by hybridization 
with the complementary RNA template strand (Scheme 3.1). In this manner, self-assembled linear, 
V-shape, and Y-shape siRNAs respectively containing a single, double and triple palmitamides 
were designed and developed to investigate the effect of fatty acid conjugation on siRNA cell 
permeability and RNAi activity in PC-3 cells.  
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Scheme 3.3. Self-assembly of the linear, V-, and Y-shape siRNA templates to generate hybrids 
containing 1, 2, or 3 fatty acid moieties, respectively. 
 
3.4.8. GRP Knockdown Efficiency of the FA-siRNAs 
 The linear and V-shape guide strand labeled FA-siRNA hybrids and a Y-shape hybrid 
containing a single FA molecule to maintain consistency across this assay (Figure 3.12, B, C) 
were transfected with the Trans-IT X2 dynamic delivery system (Figure 3.12, A) and directly 
(Figure 3.12, B-D) within PC-3 cells to determine the extent of GRP (GRP75, GRP78 and GRP94) 
knockdown efficacy at the mRNA levels of expression. In this assay, the FA-siRNAs incorporating 
a single (linear), double (V-shape) and triple (Y-shape) palmitamides were also screened to 
determine whether multiple FAs effect knockdown efficiency (Figure 3.12, D). 
GRP-75, 78, and 94 expressions in human cancer cells.7,8 The
linear, V-, and Y-shaped RNA functionalized with a reactive 5′-
hexamethylene amino linker within the antisense (A) or sense
(S) single strands were synthesized by automated solid-phase
RNA synthesis. Using our previously reported procedure, the
orthogonally protected 5′-OLv 2′-OMMT ribouridine phos-
phoramidite was incorporated with the V- and Y-shaped RNA
templates as branchpoint synthon.9,10 A O-(1H-6-chlorobenzo-
triazole-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate
HCTU-coupling strategy which has been found to be
especially useful in a previou study, designed and optimized
for the incorporation of a hydrophobic phthalocyanine onto an
oligonucleotide vector, has also been adopted in our solid
phase RNA bioconjugation approach.30 More speciﬁcally, short
and long-chain (C12−C18) fatty acids containing saturated,
unsaturated, and polyunsaturated hydrocarbons were coupled
onto the amino-linked linear RNA template strands using
HCTU as activator, N,N′-diisopropylethylamine (DIEA) as
base and N,N′-dimethylformamide (DMF) as reaction solvent
(Scheme 1). Following solid phase bioconjugation, samples
were cleaved and deprotected from the solid support and
analyzed by reverse phase ion pairing high p rformance liquid
chromatography (RP IP HPLC) to determine reaction
conversions. The conjugation reactions were found to proceed
smoothly (52−75%) in the case of antisense linear RNA
functionalization targeting GRP78 mRNA. Subsequently, the
V-shaped RNA template, targeting GRP78 and GRP94 mRNA,
as well as the Y-shaped RNA targeting GRP 75, 78, and 94,
were subjected to the same HCTU/DIEA coupling procedure
for the incorporation of palmitic acid at the 5′-terminus. In
these cases, good conversions were detected by RP IP HPLC
for the V-shaped RNA bioconjugate (69%); however, little
product (<5%) was detected in the case of the Y-shaped RNA
template. The latter was attributed to diﬃculties associated
with conjugation onto more complex, higher-order RNA
templates. In order to circumvent this limitation, an alternative
strategy was developed in which palmitic acid was initially
conjugated to the 5′-ends of the linear, complementary sense
strands targeting GRP 75, 78, and 94 mRNA, followed by their
hybridization to the RNA templates (Scheme 2). In this
manner, linear, V-, and Y-shaped GRP targeting siRNAs
containing single, double, and triple palmitamides were self-
assembled to directly improve transfection eﬃciency for more
potent knockdown and cell death eﬀects in cancer. Analytical
RP IP HPLC (Figure 1), denaturing (urea) polyacrylamide gel
electrophoresis (PAGE) (Supporting Information, Figure S1)
and electrospray ionization mass spectrometry (ESI MS)
(Supporting Information, Table S1) were used to conﬁrm
Scheme 2. Self-Assembly of i. Linear, ii. V-, and iii. Y-Shaped Multi-Palmitamide Labeled siRNA Constructs
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.8b00580
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Figure 3.12 qRT-PCR analysis of GRP mRNA levels in PC-3 cells following (A) transfection of 
linear, V-, and Y-shaped siRNAs with the Trans-IT X2 dynamic delivery system, (B) direct 
transfection of saturated, unsaturated and polyunsaturated fatty acid-siRNA bioconjugates, (C) 
direct transfection of palmitamide conjugated linear, V-, and Y-shaped siRNA bioconjugates, (D) 
direct transfection of linear, V-, and Y-shaped siRNA bioconjugates, respectively, containing a 
single, double, and triple palmitamides. Target mRNA levels are relative to a control siRNA and 
represented as the mean fold change ± SD of 3 separate trials. *P < 0.05 and ***P < 0.001 in PC3 
cells for GRP78 KD.  
 
The direct transfections of the various linear FA-siRNAs into our model PC-3 cell line yielded 
mild knockdown (20-40%) of the GRP78 mRNA levels, when compared to a control siRNA hybrid 
transfected with the Trans-IT X2 dynamic delivery system (80%) according to qRT-PCR. Direct 
transfection of the V- and Y-shape hybrids containing a single palmitamide elicited modest 
knockdown of GRP78 (~40%) without any effect on the other GRP mRNA targets, GRP94 and 
GRP75. Direct transfection of the multi-palmitamide siRNA hybrids improved the GRP78 
knockdown efficiency (5-65%) compared to the siRNA constructs containing a single palmitamide 
(20-40%); albeit to a lesser extent when compared to the Trans-IT X2 dynamic delivery system 
(80%).  
3.4.9. Cell Uptake of the FA-siRNAs by Flow Cytometry 
Interestingly, the length of the hydrophobic fatty acid tail and
the degree of unsaturation did not have any signiﬁcant eﬀect in
potentiating siRNA KD activity. Thus, palmitic acid (C16)
which has been found to be well tolerated in siRNA
Figure 4. qRT-PCR analysis of G P mRNA levels in PC-3 cells following (A) transfection of linear, V-, and Y-shaped siRN s with the Trans-IT
X2 dynamic delivery system, (B) direct transfection of saturated, unsaturated and polyunsaturated fatty acid-siRNA bioconjugates, (C) direct
transfection of palmitamide conjugated linear, V-, and Y-shaped siRNA bioconjugates, (D) direct transfection of linear, V-, and Y-shaped siRNA
bioconjugates, respectively, containing a single, double, and triple palmitamides. Target mRNA levels are relative to a control siRNA and
represented as the mean fold change ± SD of 3 separate trials. *P < 0.05 and ***P < 0.001 in PC3 cells for GRP78 KD.
Figure 5. Time dependent (6−24 h) ﬂow cytometry analysis of linear, V-, and Y-shaped FITC labeled siRNAs transfected with the Trans-IT X2
dynamic delivery system (A-C). Direct transfection of linear, V-, and Y-shape FITC-labeled siRNA containing single (D-F) and multiple (G-I)
palmitamides within the PC-3 prostate cancer cell line.
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.8b00580
Bioconjugate Chem. 2018, 29, 3638−3648
3644
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 FACS analysis was used to gain a better understanding of the knockdown effects observed 
by qRT-PCR. In this assay, the FA-siRNA bioconjugates were additionally labeled with FITC 
(FL) to produce the bifunctional FA-FL-siRNA bioconjugates which were hypothesized to enable 
tracking of cell uptake in PC-3 cells. Linear, V-, and Y-shape FA-FL-siRNA bioconjugates (50 
nM) containing either a single or double FA appendages and a single FITC probe were treated 
directly within PC-3 cells and tracked by flow cytometry at 3, 6, and 24 hrs (Figure 3.13). The 
control FITC-siRNA transfected with the Trans-IT X2 dynamic delivery system resulted in a 
fluorescent spike at 6hrs which persisted into the next day (Figure 3.13, A-C). Conversely, the 
FA-FL siRNA bioconjugates exhibited a fluorescent spike at 6 hrs and then complete loss in 
fluorescent intensity by 24 hrs. We hypothesize that the FA-containing siRNA may be interacting 
with the cells during that period, but are unable to completely penetrate into the cytosol. However, 
this analysis was set to only show the effects on the bulk population of cells and not smaller subsets 
wherein cell penetration may be occurring and subsequent mild knockdown seen by qRT-PCR. 
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Figure 3.13 Time dependent (6−24 h) flow cytometry analysis of linear, V-, and Y-shaped FITC 
labeled siRNAs transfected with the Trans-IT X2 dynamic delivery system (A-C). Direct 
transfection of linear, V-, and Y-shape FITC-labeled siRNA containing single (D-F) and multiple 
(G-I) palmitamides within the PC-3 prostate cancer cell line.			
3.4.10. Size and Morphology Characterization by DLS and TEM 
 To fully characterize the dynamics of the FA-siRNA bioconjugates, we analyzed their size 
and morphological properties by dynamic light scattering (DLS) and transmission electron 
microscopy (TEM). Given the spike in fluorescence intensity observed only within 6 hrs for the 
FA-FL-siRNA, we reasoned that the lack of cell penetration may be due to the aggregation of the 
lipid tails and formation of large, amorphous aggregates.   
Interestingly, the length of the hydrophobic fatty acid tail and
the degree of unsaturation did not have any signiﬁcant eﬀect in
potentiating siRNA KD activity. Thus, palmitic acid (C16)
which has been found to be well tolerated in siRNA
Figure 4. qRT-PCR analysis of GRP mRNA levels in PC-3 cells following (A) transfection of linear, V-, and Y-shaped siRNAs with the Trans-IT
X2 dynamic delivery system, (B) direct transfection of saturated, unsaturated and polyunsaturated fatty acid-siRNA bioconjugates, (C) direct
transfection of palmitamide conjugated linear, V-, and Y-shaped siRNA bioconjugates, (D) direct transfection of linear, V-, and Y-shaped siRNA
bioconjugates, respectively, containing a single, double, and triple palmitamides. Target mRNA levels are relative to a control siRNA and
represented as the mean fold change ± SD of 3 separate trials. *P < 0.05 and ***P < 0.001 in PC3 cells for GRP78 KD.
Figure 5. Time dependent (6−24 h) ﬂow cytometry analysis of linear, V-, and Y-shaped FITC label d siRNAs transfected with the Trans-IT X2
dynamic delivery system (A-C). Direct transfection of linear, V-, and Y-shape FITC-labeled siRNA containing single (D-F) and multiple (G-I)
palmitamides within the PC-3 prostate cancer cell line.
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.8b00580
Bioconjugate Chem. 2018, 29, 3638−3648
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Figure 3.14 Figure 3. Representative DLS derived size distribution and corresponding TEM 
images of (A) saturated (C16), (B) unsaturated (C18:3), and (C) palmitic acid (C16) conjugated V 
shaped siRNA bioconjugates. Palmitic acid (C16) conjugated sense strands were used to generate 
the multifunctionalized Linear, V-, and Y-shaped RNA bioconjugates (D−F).  
 
As expected, the TEM analysis showed large aggregates, especially with the V- and Y-shape 
templates containing 2 or 3 FA-siRNAs despite the average individual particle sizes ranging only 
from ~250-350 nm (Figure 3.14). Interestingly, the linear palmitamide-siRNA bioconjugate 
showed the least amount of aggregation and most uniformity which translated into a bioconjugate 
that was able to elicit GRP knockdown. Therefore, future derivatives of these compounds must be 
nm. DLS measurements of these samples showed multimodal
size distribution suggesting formation of large aggregates. Zeta
potential measurements of these samples showed an overall
reduction as compared to the native, unconjugated RNA
template (see Supporting Information, Table S2). Similarly,
palmitic acid conjugated to higher order V-shaped RNA
displayed a propensity for aggregation, however, without
formation of a well-deﬁned structure (Figure 3C). The
palmitic acid conjugated to sense strand showed formation
of spherical aggregates having size about 300 nm (Figure 3D)
similar to the ones observed for the palmitic acid-RNA
bioconjugate (Figure 3A), whereas sense strands conjugated
wit double palmitamides incorporated into V-shaped siRNA
(Figure 3E) and with triple palmitamides incorporated into the
Y-shaped siRNA (Figure 3F) show large irregular amorphous
aggregates (>300 nm). Thus, the incorporation of fatty acids
within siRNA triggers formation of larger, and typically
undeﬁned aggregates that may have profound eﬀects on
siRNA cell biology. Furthermore, the tabulated average data
for particle size, polydispersity index, and zeta potentials from
triplicate measurements are provided in Table S2 of the
Supporting Information.
Biological Activity of siRNA Bioconjugates. Following
evaluation of the chemical and physical properties, the
biological activity of the fatty acid conjugated linear, V-, and
Y-shaped siRNAs was examined in a metastatic prostate (PC-
3) cancer cell line amenable to standard siRNA transfection
protocols.33 The Trans-IT X2 dynamic delivery system was
used as suitable siRNA transfection reagent34 in order to
establish the baseline activity of the control, unconjugated
linear, V-, and Y-shaped siRNAs, respectively, targeting
GRP78, GRP 78 and 94, as well as GRP 75, 78, and 94. In
this assay, the control sequences exhibited potent (60−80%)
GRP mRNA knockdown (KD) according to RT PCR (Figure
4A). Comparatively, the antisense fatty acid functionalized
linear siRNAs (Scheme 1, Samples 1−5) transfected directly
and without the use of an additional transfection reagent
triggered GRP78 mRNA KD, albeit to a lesser extent (20−
40%) relative to the linear siRNA control (80%) tranfected
with the Trans-IT X2 dynamic delivery system (Figure 4B).
Figure 3. Representative DLS derived size distribution and corresponding TEM images of (A) saturated (C16), (B) unsaturated (C18:3), and (C)
palmitic acid (C16) conjugated V shaped siRNA bioconjugates. Palmitic acid (C16) conjugated sense strands were used to generate the
multifunctionalized Linear, V-, and Y-shaped RNA bioconjugates (D−F).
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.8b00580
Bioconjugate Chem. 2018, 29, 3638−3648
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designed to limit size and aggregation potential while allowing for an amphiphilic FA-siRNA 
complex to interact and penetrate efficiently the cell membrane for RNAi activity.  
 
3.5 Conclusions 
 In this chapter the design and biological activity of unique RNA templates and their siRNA 
nanostructure formulations as well as the multi-functional siRNA bioconjugates have been 
described. The novel V-, and Y-shape RNA templates were capable of self-assembly with 
complementary RNA strands into nanostructure formulations that elicited potent knockdown of 
multiple GRP gene targets while also facilitating the incorporation of functional probes (FL and 
FA) that can track and trigger RNAi activity in cells. The siRNA nanostructure formulations were 
found to be active in a variety of cancer cell lines including breast, endometrial, and cervical which 
highlights their broad scope. Moreover, a covalent bioconjugation approach was designed and 
developed to attach fluorophores or various fatty acids to impart theranostic or self-delivering 
capabilities. This approach was then expanded to allow for the incorporation of multiple bio-active 
moieties on the V- and Y-shape siRNAs. This drastically improved the diagnostic capabilities of 
the FL-siRNAs as the Y-shape hybrids containing 3 FITC molecules provided the most intense 
and persistent fluorescent signal while maintaining gene silencing activity within a model prostate 
cancer cell line. Conversely, the FA-siRNAs did not produce as significant knockdown effects, 
presumably due to the limited cell permeability detected by flow cytometry. TEM and DLS 
analyses revealed large, amorphous aggregates which likely limited cell uptake of the FA-siRNA 
biconjugates. Despite this, the V- and Y-shape siRNAs have been shown to be a unique and potent 
class of synthetic siRNAs that can be expanded further into a myriad of biochemical probes for a 
wide scope of biomedical applications.  
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3.6 Materials and Methods 
3.6.1 siRNA Hybridization 
 Purified complementary RNA strands were mixed in equimolar concentrations (10 uM ) in 
annealing buffer ( 10-30 µL, 10 mM Tris, 50nM NaCl, 1 mM EDTA, pH 7.5-8.0). The solution 
was heated at 95°C for 5 minutes and left on a heating block to slowly cool to room temperature 
(25°C) over 40 minutes to afford the RNA hybrids. The hybrid mixture was subsequently used 
immediately or stored at 4°C overnight. 
3.6.2 Dynamic Light Scattering (DLS) Analysis of the FA-siRNA Bioconjugates 
A Malvern Zetasizer, Nano-ZS (Malvern Instruments, UK) employing a 173° scattering 
angle and a 4 mW incident He−Ne laser (633 nm) was used to measure the particle sizes 
(hydrodynamic diameter), size distributions, and zeta potentials of the siRNA hybrid control and 
siRNA-fatty acid bioconjugates. Samples were measured in triplicate at 25 °C. All samples were 
loaded into folded capillary cells (DTS1070) equipped with electrodes on both sides to allow 
measurement of their zeta potentials and by extension, the stability and degree of aggregation. 
Particle suspensions with highly positive or highly negative zeta potentials were considered stable 
because the electrical repulsion between the particles tends to counter the van der Waals forces 
that would otherwise result in aggregation and precipitation.  
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3.6.3 Transmission Electron Microscopy (TEM) Imaging of the FA-siRNA 
Bioconjugates 
TEM analyses of the linear, V-, and Y-shaped siRNA bioconjugates were performed with 
a JEOL 1200EX Transmission Electron Microscope (JEOL Ltd., Japan) at an accelerating voltage 
of 80 kV. A mixture of 1:1 volume ratio 1% uranyl acetate and sample suspension was prepared 
and 10 μL of this solution placed on a TEM carbon-film-coated copper grid of 300 mesh (Electron 
Microscopy Sciences Inc., Hatfield, PA). Each sample was allowed to sit for 5 min on the grid 
before wicking the excess liquid followed by storage of 1 week to allow the samples to dry. Images 
were taken with a SIA-L3C CCD camera (Scientific Instruments and Applications, Inc.) using the 
software Maxim DL5 (Diffraction Limited, Ottawa, Canada). 
3.6.4 Cell Culture 
 The MRC5 (ATCCÒ CCL-171ä ) normal lung cell line, AN3CA (ATCCÒ HTB-111ä )  
endometrial cancer, MDA-MB-231(ATCCÒ HTB-26ä )  breast cancer, HeLa (ATCCÒ CCL-2ä ) 
cervical cancer,  and PC3 (ATCCÒ CRL-1435ä )  prostate cancer cell lines were all purchased from 
ATCC. The MDA-MB-231, HeLA, and MRC5 cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM), the AN3CA cells in Minimum Essential Medium (MEM), and the PC3 cells 
in RPM1 1640 complete growth media. All media was supplemented with 10% (v/v) fetal bovine 
serum (FBS) and 1% (v/v) penicillin/streptomycin. The cells were cultured at 37°C in a CO2 
incubator set to 5% CO2. The cells were subcultured using 0.25% trypsin and resuspended in fresh 
complete growth media.  
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3.6.5 siRNA Transfection in AN3CA, MDA-MB-231, HeLa, and MRC5 Cell Lines 
 Briefly, the cell lines were plated in separate 6-well culture plates containing complete 
growth media at a density of 1x105 per well. Cells were then cultured for 48 h to a confluency ~60-
80% prior to transfection. On the day of transfection, the siRNA hybrids (5-12.5 µL) were diluted 
in 250 µL of complete growth media and mixed with the Lipofectamine RNAiMAX transfecting 
reagent (2.5-7 uL, Thermo Fischer) according the manufacturer’s protocol. The solutions were 
incubated at room temperature for 10min before being added to the cell cultures. The cells were 
then cultured in 5% CO2 at 37°C.  
3.6.6 siRNA Transfection in the PC3 Cell Line 
 The PC3 cell line was transfected using a modified reverse transfection protocol.46  Briefly, 
on the day of transfection, the cells were suspended in complete growth media, counted, and plated 
in 24-well culture plates at a density of 9x105 cells per well. Simultaneously, the siRNA hybrids 
(25-50 pmol)  were diluted in 50 µL of Opti-MEM reduced serum media and mixed with the Mirus 
TransIT-X2Ò dynamic delivery system transfecting reagent (3 µL, MirusBio) according the 
manufacturer’s protocol. The samples were incubated at room temperature for 15 minutes before 
being added to the PC3 cell culture. The cells were then incubated in 5% CO2 at 37°C.  
3.6.7 Cell Cytotoxicity  
 The cytotoxicity of the siRNA hybrids in the AN3CA, MDA-MB-231, and HeLA cancer 
cell lines were assayed using the Cytotoxicity Detection Kit (ThermoFisher). Following 
transfection of the GRP specific siRNAs, the rate of cell death was monitored by the release of 
LDH into the medium and quantified spectroscopically at 492 nm by the detection of the resultant 
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chromophore, red formazan. The cytotoxicity of the siRNA hybrids in the PC3 cancer cell lines 
were assayed using a Propidium Iodide (PI) assay. Following siRNA transfection, the cells were 
isolated and stained with PI according to the manufacturer’s protocol and incubated for 15 min in 
the dark. The stained cells were diluted in PBS containing 1% BSA and then analyzed by flow 
cytometry. The data was processed using the Kaluza, Flow Cytometry Analysis Software 
(Beckman Coulter).  
3.6.8 Cell Uptake by Flow Cytometry 
 Following transfection of the FL-siRNA and FA-siRNA into the PC3 cells, the cells were 
detached from the wells using 0.25% trypsin, isolated, and resuspended in 300µL of RPMI 1640 
complete growth media. The samples were then analyzed on a Cytomics FC 500 flow cytometer 
(Beckman Coulter). Time dependent cell uptake studies of the FL-siRNA bioconjugates containing 
1, 2, or 3 FITC probes over 72 hrs with data points being measured in triplicate at 2, 4, 8, 24, 48, 
and 72 hrs. Similarly the time dependent uptake study of the FL-FA-siRNA bioconjugates 
containing 1 or 2 fatty acid moieties and the FITC fluorophore (FL) over a 24 hr time span with 
data points being measured in triplicate at 3, 6, and 24 hrs. The data was processed using the 
Kaluza, Flow Cytometry Analysis Software (Beckman Coulter).  
3.6.9 Cell Imaging 
 Following transfection of the FL-siRNA bioconjugates, the cells were imaged directly in 
the culture plate using a CellInsightä High Content Screening (HCS) Platform (ThermoFisher). 5 
random field of views from 3 separate wells were imaged under brightfield and then again after 
the cells were excited by a 480 nm LED filter within the platform at time points of 2, 4, 8, 24, 48, 
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and 72 hrs. The images were analyzed using Thermo Scientificä HCS Studioä Cell Analysis 
Software. 
3.6.10 qRT-PCR 
Total mRNA was isolated following transfection (48 hrs) from TriZol (Ambion) preserved 
cells using a TriRNA Pure Kit (Geneaid), following the manufacturer’s instructions. The collected 
mRNA was then quantitated on a Qubit 3.0 fluorimeter using the Qubit Broad Range (BR) assay 
kit (Thermo Fisher Scientific), mRNA (200 ng) was reversed transcribed into cDNA using a high 
capacity cDNA kit (Applied Biosystems). RT-PCR was performed using pre-developed 
TaqManTM gene expression primer-probes for GRP78 (assay ID Hs99999174_m1), GRP94 
(assay ID Hs00437665_g1), GRP75 (Hs00269818_m1), and GAPDH (Hs99999905_m1) and 
TaqManTM fast advanced master mix. qPCR fast assay was carried out on a StepOnePlus (Applied 
Biosystems). Fold changes were calculated with the ΔΔCt method using GAPDH as endogenous 
control and the negative siRNA as the control sample.  
3.6.11 Western Blot 
Total protein was isolated from the cell cultures following transfection (78 h). Protein 
lysates were prepared by lysing the cells in ice-cold RIPA buffer (G-Biosciences) supplemented 
with protease and phosphatase inhibitors (Millipore Sigma) which were diluted 1:10 as per the 
manufacturer’s recommendations. Cell debris was removed by centrifugation at 16,000g at 4°C 
and protein concentrations were determined using a PierceTM BCA kit (Thermo Fisher Scientific). 
A sample (20-35 mg) of the supernatant protein was mixed with LDS buffer and DTT, incubated 
at 70 °C for 10 min and resolved on a 4-12% Bis-Tris PAGE gradient gel before being transferred 
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to a PVDF membrane. Following transfer, the membrane was blocked in 5% skim milk for 1 h, 
washed and incubated at 4 °C overnight with a rabbit 1° mAb against human GRP78, GRP94, 
GRP75 or GAPDH (all purchased from Cell Signaling Technology) at a 1:1000 dilution. The 
membrane was subsequently washed and incubated with an anti-rabbit HRP-conjugated 2° Ab 
(Cell Signaling Technology) for 1 h at room temperature at 1:2000 dilution. The bands were 
visualized using a SignalFireTM ECL reagent (Cell signaling Technology) on a ProteinSimple 
FluorChem E imager.  
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Chapter 4: Targeting the Prostate Specific Membrane Antigen Receptor for 
Targeted siRNA Delivery 
4.1 Abstract 
 In this study, oligoarginine peptides are conjugated to a short cancer-targeting peptide 
(CTP) selective for the prostate-specific membrane antigen (PSMA) receptor. The PSMA receptor 
is present on the cell surface of metastatic and castrate resistant prostate cancer (PCa) cells and 
functions as a clinically relevant biomarker for cancer-targeting strategies. In our cancer-targeting 
gene therapy approach, the PSMA-Rn (n= 6 and 9) peptides were synthesized by solid phase 
peptide synthesis (SPPS), isolated and characterized by LCMS and condensed with the Glucose 
Regulated Protein (GRP) silencing siRNAs. Native gels revealed formation of stable CTP:siRNA 
ionic complexes at low mole ratios (1:25). Furthermore, siRNA release was affected by heparin 
competition, underscoring the capabilities for the peptides to act as effective condensing and 
releasing agents. DLS and TEM studies revealed the importance of size and shape of the 
CTP:siRNA particles for cell biology applications. The CTP:siRNA formed large anionic 
complexes which were prone to aggregation and limited cell uptake for RNAi activity when 
compared to the control siRNA complex formed with the commercial Trans-IT dynamic delivery 
system. Therefore, the development of efficient peptide based siRNA delivery systems is 
contingent on the formulation of discrete, neutral nanoparticles that can effectively condense, and 
release siRNA across the cell membrane for RNAi action.    
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4.2 Introduction 
4.2.1 Targeted Delivery Ligands 
 A major limitation in the development of siRNA-based drugs is the non-specificity of the 
various delivery methods. Not only can this lead to off-target silencing of genes, but also 
widespread distribution in healthy tissues potentially resulting in cytotoxicity.1 Conversely, 
selective delivery systems can increase the specificity and potency of siRNA therapies.2-4 Ligands 
that can target cell surface receptors have been functionalized to condense siRNAs  and facilitate 
their selective delivery across cell membranes for RNAi activity. These ligands encompass both 
small and large molecules that have binding affinity and selectivity for their target receptors. They 
are typically functionalized with a cell penetrating domain, that can effectively condense siRNA 
cargo and facilitate its translocation across cell membranes, typically by receptor mediated 
endocytosis (Figure 4.1). Once internalized, the siRNA is released in the cytosol of the cell and 
recruits the RISC complex for gene silencing activity. 
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Figure 4.1 Illustration of ligand targeted delivery of cargo into cells. Image reprinted with 
permission from Elsevier: Svensen, N.; Walton, J.G.; Bradley, M. Trends Pharmacol Sci. 2012, 
33(4):186-925 
 
The folate and cholesterol receptors are common targets whose ligands, folate and 
cholesterol (or cholesterol analogs) respectively, are readily available and conjugate easily to 
siRNA based delivery systems (i.e. transfection reagents). The folate receptor is highly expressed 
among a variety of cancer types yet has minimal expression in healthy tissues except the kidneys. 
One study has shown molecular folate conjugated to polycationic polymers polyethylenamine and 
polylysine (PEI/PLL) formed siRNA carrier formulations for transfection into nasopharyngeal 
carcinoma cells which resulted in potent gene silencing.2,6,7 Similarly, cholesterol conjugated 
siRNA was introduced intrasystemically in an in vivo mouse model. The cholesterol-siRNA 
bioconjugate was found to accumulate only lightly in the kidneys and heart, but highly into target 
hepatocytes where the cholesterol receptors present on these cells helped endocytose the ligand. 
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Moreover, the naked siRNA was not found to localize or accumulate in any specific tissue and the 
siRNA-cholesterol bioconjugate was able to elicit upwards of 60% knockdown of the target 
protein, apoB.8  
 The larger macromolecular targeting ligand class is typically represented by peptides, 
proteins, and antibodies. Antibodies, in particular, are particularly interesting as they are among 
the most selective receptor targeting ligands, including representative examples of antibody-based 
siRNA delivery in vivo. For example, siRNA targeting ku70 mRNA has been complexed to a 
fusion protein that contains the antibody binding domain for the ErbB2 receptor and successfully 
delivered siRNA into ErbB2+ breast cancer.9 Likewise, an antibody conjugated cationic liposome 
was able to deliver siRNA targeting Cyclin D1 as a treatment against inflammatory bowel 
disease.10 Yet, antibodies are not without their drawbacks as they are large molecules that are not 
readily cell permeable, susceptible to denaturation and proteolytic degradation which greatly 
reduces their therapeutic effect, while raising toxicity concerns by stimulating immune responses.  
 Peptide based ligands are also highly favorable as targeting ligands due to their flexibility 
in size and composition as well as ease in synthesis. One of the most highly studied and useful 
peptide ligands for targeted delivery is the RGD sequence. This peptide can bind to transmembrane 
integrins which are commonly overexpressed receptors on the surface of cancer cells.11 This 
peptide has been conjugated to various delivery system, such as PEI based formulations, which 
facilitate the selective accumulation of siRNA into integrin presenting cancerous cells ultimately 
leading to targeted cytotoxicity.12 Another example is the use of a homing peptide to target the 
VEGF receptor – another commonly targeted cellular receptor overexpressed on the surface of a 
panel of cancer cell lines.13 In a representative application, a 6-mer homing peptide, A1, 
(WFLLTM) was conjugated to the TAT cell penetrating peptide (RKKRRQRRR) to effectively 
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condense and internalize siRNA selectively into the targeted VEGF receptor 1 overexpressing 
cancer cells in a co-culture model.14 Furthermore, these cancer-targeting peptides (CTPs) are also 
applicable in vivo. For example, a short 29-mer peptide derived from the rabies virus glycoprotein 
conjugated to a nona-D-arginine sequence was used to target the acetylcholine receptor, and 
deliver siRNA targeting Cyclophilin B and HMGB1selectively into dendrites and macrophages to 
help suppress an overactive immune system in the blood and brain.15, 16 These examples highlight 
peptides as a highly interesting and promising siRNA delivery ligands.  
 
4.2.2 Cell Penetrating Peptides  
 Cell penetrating peptides (CPPs) have also been used to facilitate intracellular delivery of 
siRNA. There are three conventional designs for CPPs : 1) poly-cationic in which the sequence 
contains dense regions of basic amino acids such as lysine or arginine, 2) amphiphatic which 
contains alternating sequences of polar and hydrophobic amino acids, such as arginine and 
tryptophan and 3) completely hydrophobic sequences such as poly(histidine) peptides. These 
peptides have been used in many cell uptake studies, however, their mechanism of uptake can vary 
depending on CPP type and sequence.17 Moreover, these peptide motifs are important for siRNA 
encapsulation and release based on a combination of competing ionic and aromatic interactions. 
Therefore, CPPs are bifunctional in their ability to condense and deliver siRNA across cell 
membranes. Furthermore, CPPs have been functionalized with targeting ligands (small molecules, 
peptides and antibodies) to facilitate selective cell uptake of siRNA and other payloads (Table 
4.1).   
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Table 4.1 List of various CPPs used to deliver siRNA into cells and ranging in size and 
composition. Image adapted with permission from Elsevier: Tai, W.; Gao, X., Adv. Drug Del. Rev. 
2017, 11, 157-168.17 
 
 The first CPP was derived from the short transduction region of the HIV-1 TAT protein. 
This 9-mer peptide sequence (RKKRRQRRR) can rapidly translocate across the cell membrane 
and is considered a universal carrier for cellular delivery.14 In particular, this peptide has been 
covalently conjugated to a fluorescently labeled siRNA which tracked localization within cellular 
endosomes and  transport into the perinuclear space for release, RISC assembly and RNAi 
activity.18, 19 However, direct conjugation of TAT peptides to the siRNA may hinder assembly  
within the RISC complex, reducing the overall effectiveness of the RNAi response.17 Therefore, 
the CPP:siRNA based delivery systems are typically formulated as reversible ionic complexes for 
more effective cell biology applications. 
 The oligoarginine and polyarginine peptides are another important class of CPPs capable 
of siRNA delivery. This type of CPP is a short 6 to 16-mer sequence comprised solely of arginine. 
Oligoarginine peptides are hydrophilic cationic CPPs with a high polycationic charge density and 
penetration. The ﬁrst study in cell lines stably transfected with GFP
demonstrated that the R9/siRNA com lexes can efﬁciently reach the
perinuclear regions and reduce eGFP expression [22]. In vivo application
has also been explored by using a longer arginine oligomer R12 for bet-
ter siRNA condensation. Treatment of a mouse tumor xenograft model
with anti-Her2 siRNA/R12 complexes resulted in a marked reduction
of tumor growth [23].
The delivery of siRNAbynoncovalent condensationwith hydrophilic
cationic CPPs is a simple and effective strategy. However, excess CPP
(regarding N/P molar ratio) is required for efﬁcient siRNA condensation
and delivery. For example, in the case of the R9/siRNA complex, the pep-
tides and siRNA were mixed at a 12:1 N/P ratio [22]. Although the N/P
ratio can be decreased to 3:1 by elongating the arginine oligomer to
15 mer, the number of positive changes is still overwhelmingly high
[23]. The excessive cationic CPP is efﬁcient in siRNA condensation and
cell entry, but at the same time promotes nonspeciﬁc interactions
with other anionic molecules and cells, thereby affecting the colloidal
stability of the CPP/siRNA complexes and targeting during in vitro trans-
fection and in vivo circulation. A common strategy to address this issue
is to conjugate the CPP to polymers, which not only enhance the CPP's
condensation ability through multivalency, but also reduce nonspeciﬁc
binding with serum proteins. For example, block copolymers anchored
with Tat peptides (MPEG-PCL-Tat) can form stable nanoparticles (60
to 200 nm) with siRNA and efﬁciently deliver siRNA to brain tissues
via intranasal administration [24]. Similarly, treatment with an anti-
Ataxin siRNA and Tat-tagged PEG-chitosan successfully suppressed
Ataxin-1 gene expression in an establishedmodel of ND spinocerebellar
ataxia (SCA1) [25]. Increasing the hydrophobicity of cationic CPPs has
also been proposed to overcome the inherent instability of CPP/siRNA
complex. It was demonstrated that simple modiﬁcation of octaarginine
Table 1
siRNA delivery by CPPs.
Peptide Subgroup Sequence Ref.
Hydrophilic CPPs
Tat – RKKRRQRRR [17,18,24,25]
Arginine oligomer – Rn; 6 b n b 16 [22,23,26,27]
Amphiphilic CPPs
MPGΔNLS Bipartite peptide GALFLGFLGAAGSTMGAWSQPKSKRKV [30–35]
MPG-8 Bipartite peptide bAFLGWLGAWGTMGWSPKKKRK-Cya [36]
MPGα Bipartite peptide Ac-GALFLAFLAAALSLMGLWSQPKKKRKV-Cya [37,38]
BPrPp Bipartite peptide MVKSKIGSWILVLFVAMWSDVGLCKKRPKP-amide [39]
Pep-1 Bipartite peptide Ac-KETWWETWWTEWSQPKKKRKV [40]
Penetratin α-Helical peptide RQIKIWFQNRRMKWKK-amide [18,39,44–46]
CADY α-Helical peptide Ac-GLWRALWRLLRSLWRLLWRA-cysteamide [36,49,50]
KALA α-Helical peptide WEAKLAKALAKALAKHLAKALAKALKACEA [52,53]
Targeting ligand–CPP conjugates
Fab-protamine Antibody-based Fab-ARYRCCRSQSRSRYYRQRQRSRRRRRRSCQTRRRAMRCCRPRYRPRCRRH [55,56]
scFv-dR9 Antibody-based scFv-dRdRdRdRdRdRdRdRdR [57]
mAb-R9 Antibody-based mAb-RRRRRRRRR [58]
A1-Tat Homing peptide-based WFLLTM-RKKRRQRRR [68]
RVG-R9 Homing peptide-based YTIWMPENPRPGTPCDIFTNSRGKRASNGGGG-RRRRRRRRR [69–73]
Activatable CPPs
ACPP Enzyme activated EEEEEEE-GALGLP-RRRRRRRRKKR [78]
Fig. 1. CPP-mediated siRNA intracellular delivery. A). Schematic illustration of formulation schemes for CPP-mediated siRNA cell entry. (1) CPP–siRNA conjugate; (2) CPP–siRNA
nanocomplex; (3) siRNA anchored on an antibody-CPP conjugate; (4) hairpin-structured activatable CPP conjugated with siRNA. B) The helical wheel showing the amphiphilicity of
α-helical CPPs: penetratin, CADY, and KALA. Amino acids are color coded (red: charged; orange: apolar; yellow: polar; gray: hydrophobic).
159W. Tai, X. Gao / Advanced Drug Delivery Reviews 110–111 (2017) 157–168
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have a higher cell penetrating potential due to the strong affinity of the guanidinium group for the 
phospholipids in the cell membrane. The charged side chains can infiltrate into the lipid bilayer 
and essentially create a pore within the membrane through which the CPP and its cargo can 
penetrate into the cell.20, 21 The R9 -siRNA complexes have been used to silence eGFP expression 
in human gastric carcinoma cells.22 Moreover, an in vivo application of an R12 CPP – siRNA 
complex was found to reduce subcutaneous tumor growth in a mouse xenograft model via the 
silencing of the Her2 protein.23 Furthermore, substituting L/D-Rn has been found to improve 
peptide stability and the siRNA silencing effect. However, these peptides are not without their 
limitations, as the oligoarginine CPPs can be difficult to use as they need to be used in large excess 
compared to their siRNA cargo. While this may not affect all tissue models, the large excess can 
elicit nonspecific interactions with other anionic components in the cellular microenvironment and 
circulatory system. This can lead to a loss in stability of the formulation as well as off target 
silencing or inefficient in vivo circulation. Often, these hydrophilic cationic peptides are combined 
with a targeting ligand to offset this limitation.17 
 
4.2.3 Targeting the PSMA Receptor with anti-PSMA Peptides 
 The prostate specific membrane antigen, PSMA, is a type-II transmembrane protein which 
functions as a surface carboxypeptidase enzyme, an exopeptidase with folate hydrolase activity 
because it progressively liberates glutamates from glutamate rich sources.24 Moreover, this 
receptor has been shown to have an internalization signal which, once activated, allows for the 
internalization of the enzyme from the membrane into the cell via an endosome formed from 
clathrin dependent endocytosis.25 In cancer, PSMA is expressed in all prostatic tissues including 
primary prostate adenocarcinomas, prostate tumors metastatic to bone and in the tumor 
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neovasculature of many solid cancers but not normal tissues.26,27 In prostate cancer, PCa, PSMA 
is highly expressed in poorly differentiated, highly metastatic prostatic cells and in castrate-
resistant models.28 In fact, PSMA-based PET and CT imaging is an emerging field in the diagnosis 
and treatment of advanced and resistant PCa, rendering PSMA a valuable biomarker for targeted 
forms of therapies.28  
 The phage display selection of PSMA binding peptides has resulted in the identification of 
three peptide sequences: GDHSPFT, SHFSVGS and EVPRLSLLAVFL, capable of targeting, 
binding and internalizing within PSMA expressing PCa cells.29 The selected lead PSMA binding 
peptides were based on the consensus sequences, SHSFSVGSGDHSPFT and 
GRFLTGGTGRLLRIS. These peptides were labeled with the 5-FAM fluorophore and were shown 
to bind selectively to PSMA expressing PCa cells, and accumulated intracellular by the 
observation of disperse fluorescent punctuate regions found within the cells. Similarly, a separate 
phage display study was used to identify another PSMA binding peptide. This 12-mer peptide, 
GTIQPYPFSWGY, was shown to have good binding affinities (8-9 µM) to PSMA+ LNCaP and 
C4-2 PCa cell lines and attachment of a fluorophore allowed for the surface staining of these cells 
for microscopy.30 Moreover, this peptide was capable of delivering the D-(KLAKLAK)2 cytotoxic 
peptide to LNCaP cells and induce cell death. This peptide also had favorable in vivo distribution 
where it selectively accumulated in a C4-2 mouse xenograft with minimal uptake in any other 
major organ. These key lead peptides highlight the potential in targeting this receptor as a potential 
diagnostic and for the specific delivery of therapeutics against PCa.  
 Recently, a folate targeted cyclodextrin-based nanoparticle formulation had been 
developed to selectively deliver siRNA targeting the RelA gene in PSMA+ cell lines, LNCaP and 
VCaP. The formulation silenced mRNA levels by 22% and 44%, respectively, while no significant 
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knockdown was observed with complexes absent of the folate ligand.31 Moreover, gold 
nanoparticle (AuNPs) containing a folate ligand selectively delivered RelA siRNA into PSMA+ 
LNCaP resulting in a moderate 35% decrease in transcript levels.32 While these examples highlight 
the interest in targeting the PSMA receptor as a means of selective siRNA delivery, they are limited 
in only using small molecule ligands as the targeting agent. As described, there are multiple 
examples of PSMA-specific peptide ligands for cell delivery, yet none describe their use in siRNA 
uptake in PCa cells. Therefore, the generation of peptide-based delivery systems targeting PSMA 
may enhance the uptake and gene silencing of siRNA therapies. 
 
4.3 Chapter Objectives 
 This chapter will focus on the design and development of a novel targeted delivery siRNA 
vector based on the PSMA receptor. In this application, oligoarginine CPPs (R6 and R9) and a 
model PSMA cancer targeting peptide (CTP), GRFLTGGTGRLLRIS, were combined to afford 
an amphiphilic peptide with two main functional domain: a PSMA targeting domain with the 
potential to trigger receptor mediated endocytosis, and a poly-cationic domain which functions to 
complex siRNA facilitate translocation into the cell (Figure 4.2). The peptides will be synthesized 
by Fmoc-solid phase peptide synthesis (Fmoc-SPPS) with and without an N-terminal FITC label 
to track peptide cell biology. The crude peptides will be purified by RP-IP HPLC and identity 
confirmed by ESI-MS. The siRNA condensation and release studies will be optimized by native 
PAGE analysis while the size, shape and charge distributions of the CTP:siRNA formulation will 
be evaluated by DLS and TEM. Cell biology will be next accomplished in PSMA+/- cell lines to 
determine binding and knockdown efficiency by flow cytometry, qRT-PCR, and western blot. 
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Taken together, this study is expected to yield a new peptide based siRNA delivery system in 
PSMA+ PCa cells for targeted gene therapy applications. 
 
Figure 4.2 Representation of the PSMA-Rn siRNA delivery system. Drawn in ChemBioDraw. 
 
4.4 Results and Discussion 
4.4.1 Rational Design and Synthesis of PMSA-Rn Peptides 
 The PSMA binding peptide chosen for this work was based on the phage display selection 
reported by Shen, et. al.29 Among the PSMA binding peptides reported in this study, the sequence 
GRFLTGGTGRLLRIS (PSMA-1) was selected for our work due to its potential synthesis 
efficiency and aqueous solubility given its amphiphilic nature for cell biology. To the PSMA-1 
sequence, a hexa-arginine peptide, R6, was incorporated at the C-terminus to generate the CTP, 
PSMA-1-R6. The R6 sequence was selected to complex siRNA and facilitate cell delivery as 
+
PSMA CTP Oligo Arginine CPP
G
R
P78 siR
N
A
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polyarginine peptides have been classified as cell penetrating peptides (CPPs) for cell based and 
in vivo studies.22,23 Furthermore, PSMA-1 does exhibit some cell permeability, potentially via a 
receptor-mediated endocytotic mechanism which should also contribute to cell penetration. 
 
 
Scheme 4.1 Synthesis of the lead PSMA-1 -R6 CTP. Drawn in ChemBioDraw, 
 
 Peptide synthesis of the lead CTP, PSMA-1-R6 (Scheme 4.1) was accomplished using classical 
Fmoc-SPPS conditions.33 The hydrophilic poly(ethylene glycol) PEG resin was selected for 
making the polar PSMA-1-R6 sequence and its related controls, FITC-PSMA-1, to track PSMA 
binding on PCa cells and FITC-PSMA-1-R9 to track the influence of the nona-arginine sequence 
on siRNA delivery in PCa cells. Fmoc-protected amino acids were efficiently coupled using 
HCTU as activator followed by Fmoc deprotections with basic piperidine conditions. For FITC 
labeling, the peptide N-terminus was functionalized with an aminohexanoic acid (Ahx) linker 
followed by direct couple of FITC in the dark. Following synthesis, the peptides were cleaved and 
deprotected from the solid support and subjected to RP-IP HPLC purification (>90%) and 
characterization by ESI-MS (Table 4.2) 
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Peptide Isolated 
Puritya 
Expected Mass 
(g/mol) 
Found Mass (g/mol) M/Zb 
FITC-PSMA1 >95% 2106 702.7 +3 
PSMA1-R6 90% 2541 509 +5 
FITC-PSMA1-R9 95% 3510 461.7 +8 (+22) 
Table 4.2 Purity and MS characterization of the isolated PSMA-1 peptides. a Purity as determined 
by RP-HPLC. 20-80% MeCN gradient over 18min.b Denotes charge state of the mass fragments 
found. +22 indicates a sodium adduct for that fragment   
 
4.4.2 PSMA-1-R6 Can Efficiently Complex siRNA 
 The poly(arginine) domain of the peptides have the capability of interacting with and 
complexing to RNA electrostatically through the negatively charged phosphate backbone of the 
RNA and the positively charged side chain guanidium groups of the arginines. Native PAGE shift 
assays were used to determine the extent of CTP:siRNA complexation by optmization of the 
stoichiometric mol ratios. Figure 4.3 highlights the optimization conditions of the CTP:siRNA 
complexes. The PSMA-1-R6 CTP was used to probe the extent of siRNA complexation as the R9 
variant was rationalized to interact with the siRNA in similar fashion. In order to optimize the 
stoichiometric ratios of the CTP:siRNA complexes, excess CTP (1-100 eq.) was added to the 
hybrid siRNA (250pmol) in (describe annealing buffer conditions), followed by incubation at 37°C 
for 30 min prior to addition of the gel loading sucrose buffer for native PAGE analysis (Figure 
4.3 B). CTP:siRNA complex formation was identified by a shift to more retained bands on the gel 
with a decrease in intensity when compared to the untreated siRNA controls. In this case, it is 
expected that the CTP:siRNA formulation moves to a more retained higher-order complex with 
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much slower electrophoretic mobility due to RNA charge masking and with limited signal 
detection due to the limited capabilities of the staining dye to stain RNA in the CTP:siRNA 
complex form. These trends were also observed in the time and temperature optimization studies 
(Figure 4.3, A) which indicates CTP:siRNA complex formation within 15 min  at 25oC and 37oC. 
At 50 eq of CTP, incubated at 37 °C for 30 min, the most efficient CTP:siRNA complex was 
detected for the linear and V-shape siRNA (Figure 4.3, D). Furthermore, the CTP:siRNA complex 
at these optimized conditions was challenged by a heparin release assay to validate the bifunctional 
siRNA complex and release capabilities of the CTP. In this assay (Figure 4.3, C), a concentration 
dependent study (0.1-10 eq.) of heparin was used to determine the extent of CTP:siRNA complex 
stability and the optimal heparin concentration for siRNA displacement. PAGE analysis revealed 
that at 10 eq heparin, siRNA (250pmol) was displaced from the CTP (12.5nmol) and stained as a 
dark violet band by the Stains-All dye solution. This result confirmed to important reversibility of 
the CTP:siRNA complex formulation for cell uptake and RNAi activity.   
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Figure 4.3. Optimization conditions of the CTP:siRNA complexes. A) Time (0-60 min) and 
temperature (25 and 37 oC) dependence. B) siRNA:CTP stoichiometric mol ratios (1:25-100 eq.). 
C) Concentration dependent (0.0163-1.63 mg/mL) heparin release assay at 37 oC for 30 min. D) 
CTP:siRNA complexes with linear and V-shape siRNA (250pmol) in combination with PSMA-1-
R6 (12.5nmol) 
    
4.4.3 The PSMA-1 Peptide Binds to PSMA+ PCa cells via Flow Cytometry 
 The PSMA-1 peptide’s ability to bind to PSMA+ PCa cells was next investigated. An FITC 
labeled version of the PSMA-1 peptide was used for this assay to ensure applicability to flow 
cytometric cell surface detection of PSMA+ PCa cells. The PSMA-1-R6 peptide was not analyzed 
in this study due to its expected cell permeability which would restrict cell surface PSMA detection 
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on the PCa cells. Two PCa (PSMA+ LNCaP and a PSMA- PC3) cell lines were tested for FITC-
PSMA-1 binding by flow cytometry (Figure 4.4). Surface expression of the PSMA receptor was 
confirmed on the LNCaP cells using a PE-conjugated PSMA mAb. No mAb binding was observed 
on the PC3 cells, validating that this cell line is PSMA-. A distinct increase in the fluorescent 
intensity for the FITC-PSMA-1 peptide was detected on the LNCaP cells (Figure 4.4 C) relative 
to the PC3 cells (Figure 4.4. F) indicating PSMA binding on the LNCap cells with some small 
degree of nonspecific binding detected on the PC3 cells. Of note, the peptide was used in higher 
concentrations (~1 mg/mL) when compared to the anti-PSM mAb ( ~10-100 ug/mL) which may 
account for the observed non-specific binding to the PC3 cells. 
 
Figure 4.4. Flow cytometric analysis of FITC-PSMA-1 binding to LNCaP and PC3 PCa cell lines. 
Binding was measured after 15 minutes for the PSMA mAb (B and E) or 60 minutes for the 
peptide (C and f). 
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4.4.4 Cell Uptake of the FITC-PSMA-1-R9 by Fluorescent Imaging 
 
 The FITC-PSMA-1-R9 was first assayed to determine whether the peptide would 
effectively condense and deliver siRNA in LNCaP cells. The peptide (1.25 uM) was incubated 
with siRNA (25 nM) and introduced to a monolayer of LNCaP cells at ~60-70% confluency and 
imaged over a 24 h. Little to no fluorescence was observed at any time points along the surface of 
the cells or intracellularly indicating a lack of binding and uptake as detected by flow cytometry 
(Figure 4.5). 
 
Figure 4.5 HCS imaging of LNCaP cells incubated with FITC-PSMA-1-R9: siRNA complexes 
over time. Top: brightfield channel, Bottom: LED filter (485/520 ex/em). 
 
 
4.4.5 GRP78 Knockdown in LNCaP and PC3 Cells 
 The initial lead peptide, PSMA-1-R6 was also probed for its ability to potentially function 
as a selective transfection vector. The peptide (1.25 µM) was mixed with siRNA (25 nM) and 
incubated with a monolayer of either LNCaP or PC3 cells at ~60-70% confluent. Likewise, the 
siRNA was complexed with the Trans-IT X2 transfection reagent and also transfected separately 
2hr 4hr 6hr 24hr
Linear GRP78 siRNA + FITC-PSMA1-R9
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into the cells. The knockdown efficiency was monitored by qRT-PCR and western blot at 48 hrs 
or 72 hrs post transfection, respectively.  
 
Figure 4.6 GRP knockdown in the LNCaP or PC3 cell lines using the PSMA-1-R6 peptide or the 
Trans-IT X2 system as the transfection reagents. The cells were transfected with 25 nM siRNA  
with relative mRNA levels analyzed by qRT-PCR at 48 hrs and total protein levels analyzed at 
72hrs. All knockdown levels were normalized against a negative siRNA control. mRNA 
knockdown comparison by qRT-PCR of the knockdown efficiency between the peptide or the 
trans-IT X2 reagent of A) linear siRNA against GRP78 and B) V-shape siRNA against GRP78 
and GRP94. C) Protein expression change comparison between the peptide or the Trans-IT X2 
reagent 
 
No changes in the mRNA levels (Figure 4.6, A) or the protein expression levels (Figure 4.6, B) 
were observed when transfecting a linear siRNA against GRP78 into either cell line as compared 
to 30-70% knockdown when using the Trans-IT X2 reagent. Similarly, peptide-based transfection 
of higher order V-shape siRNA against GRP78 and GRP94 into the LNCaP cells resulted in no 
knockdown of the target genes compared to the Trans-IT X2 control.  
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4.4.6 DLS and TEM Analysis of the CTP:siRNA Complexes  
 One advantage of using transfection reagents to shuttle siRNA into cells is their ability to 
condense the siRNA molecules into small discrete particles of similar size and shape. DLS analysis 
and TEM imaging were used to determine if the PSMA-1-Rn peptides were capable of effecting 
siRNA condensation. The R6 and an R9 variant of the PSMA-1 peptide were assayed to determine 
whether the length of arginine had an effect on the peptide’s ability to condense the siRNA. These 
were compared to the size and morphology of the complexes generated when mixing the siRNA 
with the Trans-IT X2 transfection reagent. Table 4.3 summarizes the relative sizes of the 
complexes along with their effective net charge determined as its zeta potential. The siRNA:Trans-
IT X2 complexes had a uniform size ~400nm with a net charge hovering around neutral. This was 
in stark contrast to that observed with the PSMA-1- Rn peptide complexes. 
 
 
Sample Effective Diameter (nm) Zeta Potential (mV) 
siRNA : Trans-IT X2 411.8 ± 55.8 
456 ± 60.6 
0.768 ± 1.24 
siRNA: PSMA-1-R6 1450 ± 332.3 
878 ± 40.23 
-2.16 ± 0.387 
siRNA: PSMA-1-R9 2135 ± 357.1 
1041 ± 222.2 
-5.88 ± 0.251 
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Table 4.3 Size and Zeta potential analysis by DLS of the siRNA: PSMA-1 complexes compared 
to that of an siRNA: Trans-IT X2 transfection reagent complex. The top diameter represents the 
relative aggregate sizes while the bottom represents individual particle sizes. 
 
Both the R6 and R9 PSMA-1 variants showed individual particle sizes ranging from ~800-1000 
nm with slightly negative net charges, (-5mV – -2mV). However, the relative sizes of the 
complexes  ranged from 1.5-2 µm in diameter, roughly 4-5x larger than the complexes generated 
with the transfection reagent. This indicates that the complexation observed by native SDS-PAGE 
were simply an ionic interaction that does not result in a condensation of the siRNA into sizes 
amenable for cellular uptake regardless of the mechanism of uptake. The TEM images (Figure 
4.7) confirm these results and give an indication of the extent of aggregation and the resulting 
morphology. Interestingly, the more amphiphilic peptide sequence, PSMA-1-R9 was the least 
efficient in condensing the siRNA and, in fact, generated large porous networks of peptide bound 
siRNA. Conversely, the R6 variant was able to produce particles of similar morphology which 
were, on average, 200-300 nm larger than those of the siRNA: Trans-IT X2 complexes. 
Interestingly, the aggregation is proportional to the arginine sequence length which may be related 
to the overall amphiphilicity of the peptide sequence and its behavior in solution. Moreover, as the 
CTP-siRNA complex becomes more neutral in charge, their relative hydrophobicity may play a 
more pronounced effect as both the siRNA and peptides’ aqueous solubility come from their ability 
to be charged in solution. As the charge is reduced and the system becomes more organic in nature, 
the complexes may then be aggregating through hydrophobic interactions to reduce the non-
favorable solvating effects of the aqueous medium. Nevertheless, this data confirmed that the 
peptides ability to complex siRNA, albeit with limited capabilities of forming small, discrete 
nanoparticles for targeted cell delivery. 
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Figure 4.7 DLS and TEM analysis of the siRNA: PSMA-1 complexes as compared to an siRNA: 
transfection reagent complex. 
 
4.5 Conclusions 
 This chapter highlights a method of creating unique cell targeting and cell penetrating 
peptides for the delivery of siRNA. Native PAGE of the R6 and R9 -PSMA-1 peptide hybrids, they 
were not efficient in condensing the siRNA complexes into discreet particles. The large particles 
and aggregates were not suitable for cell uptake and no downstream gene silencing was observed 
at either the transcript or protein levels. Complex aggregation likely sterically inhibited the PSMA 
peptide from binding to its receptor and triggering an endocytosis for siRNA uptake in the cells. 
Moreover, they were too large to passively diffuse through the membrane as is typical with 
oligoarginine delivery systems. However, our approach in developing these multifunctional 
peptide hybrids can expand the scope of peptides for the delivery of siRNA to include targeting 
peptides that have not previously been suitable for targeted siRNA-based cancer gene therapy. 
siRNA + Trans-IT X2 siRNA + PSMA1– R6 siRNA + PSMA1– R9
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4.6 Materials and Methods 
4.6.1 Materials 
Amino acids for the synthesis of all peptides, were purchased from Novabiochem (San 
Diego, CA, USA). Peptide syntheses were conducted on a Rink Amide ChemMatrix (0.47 mmol/g) 
(Biotage Inc., Charlotte NC, USA). 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate, HCTU, was purchased from Advanced ChemTech 
(Louisville, KY, USA). Fluorescein isothiocyanate, FITC, was purchased from ThermoScientific 
(Rockford, IL, USA) as a single isomer and used in the dark to fluorescently label all peptides. 
Trifluoroacetic acid (Biograde) was purchased from VWR (Radnor, PA, USA); N-N-
dimethylformamide, acetonitrile, methanol, and dichloromethane were all purchased from 
MACRON (Center Valley, PA, USA). Piperidine, triethylsilane (98+%) and pyridine (ACS, 99%) 
were purchased form Alfa Aesar (Ward Hill, MA, USA). N-methylmorpholine (99%) was 
purchased from Acros Organics (Pittsburg, PA, USA). Diethyl ether (99%, ACS), Et2O, used to 
precipitate peptides was purchased from Sigma Aldrich (St. Louis, MO, USA). All chemicals were 
used directly as received.  
 
4.6.2 Peptide Synthesis  
All peptides were synthesized by stepwise manual solid phase peptide synthesis using 
Fmoc-chemistry. Fmoc-amino acids (3eq, 0.3 mmol) were coupled on a Rink amide linker 
poly(ethylene glycol) solid support (0.47 mmol/g, 0.1 mmols) for 1 h using [HCTU (3eq 0.3 
mmol), NMM (6eq, 0.6 mmol) in DMF (3.5 mL). Fmoc deprotection was done with a 20% 
piperidine in DMF solution (3 mL, 2x10 min). Amino acid couplings and Fmoc deprotections were 
  118 
 
repeated until the desired sequences were completed. Upon completion of the PSMA-1 and 
PSMA-1-R9 sequences, solid support was subjected to FITC labeling. A slurry of FITC (1.1 equiv., 
0.33 mmol) in pyridine/DMF/DCM (12:7:5 v/v) was prepared and added to the reaction cartridge 
and left on a shaker for 16-18hrs. After FITC-labeling was completed, the resin was washed with 
DMF (3 x 3 mL), MeOH (3 x 3 mL), and DCM (3 x 3 mL). Peptide cleavage and deprotection 
from the solid support was accomplished using a mixture of TFA:TES:H2O, (95:2.5:2.5 v/v/v) for 
4hrs. Peptide samples were concentrated under nitrogen to a viscous oil, precipitated with cold 
Et2O, and centrifuged to a white pellet. The supernatant was decanted and the peptide pellets were 
dissolved in MeCN/H2O for LCMS analyses. 
 
4.6.3 RP IP HPLC and ESI-MS 
 Sample analyses were performed on an Agilent 1100 series ESI-LCMS with single 
quadrupole mass analyzer and LC conditions which used an isocratic binary solvent system (85% 
MeOH/H2O, 0.1% FA, 2min) in positive mode. Analytical RP-HPLC was performed using a 
Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 µm particle size) using a gradient of 20-
80% MeCN/H2O, 0.1% TFA, over 18 min at 25°C, with a 1 mL/min flow rate and detection at 220 
nm or 480nm for FITC labeled samples. Purified peptides were lyophilized to a fine powder before 
being dissolved in TE buffer (10 mM Tris, 50 nM NaCl, 1 mM EDTA, pH 7.5-8.0) to confirm 
purity. 
 
4.6.4 Native PAGE Shift Assay 
 Linear GRP78 siRNA (250pmol) was incubated with the PSMA-1-R6 peptide (25-100 eq, 
6.25-25 nmol) over 60 minutes at either 25°C or 37°C. Aliquots were taken at 15-minute intervals, 
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mixed with a 30% sucrose buffer, and loaded into wells of an 18% polyacrylamide gel. V-shape 
siRNA were incubated separately with 50 eq of peptide for 30 min at 37°C before being loaded 
into the gel. The assay was run at 300V, 100mA, 12W for 5 hours following subsequent staining 
with a Stains-All solution. For the heparin titration assay, the linear siRNA were incubated with 
50 eq. of peptide for 30min at 37°C and let cool to room temperature. Heparin (0.1-10eq) was 
titrated into the siRNA: peptide complexes and incubated for 30min at 37°C before being loaded 
into a separate 18% polyacrylamide gel and run at 300V, 100mA, 12W for 5 hours following 
subsequent staining with a Stains-All solution. 
4.6.5 Dynamic Light Scattering 
A Malvern Zetasizer, Nano-ZS (Malvern Instruments, UK) employing a 173° scattering 
angle and a 4 mW incident He−Ne laser (633 nm) was used to measure the particle sizes 
(hydrodynamic diameter), size distributions, and zeta potentials of the siRNA hybrid control and 
siRNA-fatty acid bioconjugates. Samples were measured in triplicate at 25 °C. All samples were 
loaded into folded capillary cells (DTS1070) equipped with electrodes on both sides to allow 
measurement of their zeta potentials and by extension, the stability and degree of aggregation. 
Particle suspensions with highly positive or highly negative zeta potentials are considered stable 
because the electrical repulsion between the particles tends to counter the van der Waals forces 
that would otherwise result in aggregation and precipitation.  
4.6.6 TEM Imaging  
TEM analyses of the linear, V-, and Y-shaped siRNA bioconjugates were performed with 
a JEOL 1200EX Transmission Electron Microscope (JEOL Ltd., Japan) at an accelerating voltage 
of 80 kV. A mixture of 1:1 volume ratio 1% uranyl acetate and sample suspension was prepared 
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and 10 μL of this solution placed on a TEM carbon-film-coated copper grid of 300 mesh (Electron 
Microscopy Sciences Inc., Hatfield, PA). Each sample was allowed to sit for 5 min on the grid 
before wicking the excess liquid followed by storage of 1 week to allow the samples to dry. Images 
were taken with a SIA-L3C CCD camera (Scientific Instruments and Applications, Inc.) using the 
software Maxim DL5 (Diffraction Limited, Ottawa, Canada)  
4.6.7 Cell Culture 
        PC3 (bone metastatic PCa cell line, ATCCÒ-CRL-1435) LNCaP (Clone FGC ATCCÒ-CRL-
1740) were purchased from ATCC. Both cells were cultured in RPMI-1640 medium containing 
10% FBS, 2.5mM of L-glutamine and 1% penicillin/streptomycin at 37°C in a humidified tissue 
culture incubator containing 5% CO2. 
 
4.6.8 Flow Cytometry 
 PSMA mAb (GCP-05) and PE conjugated IgG control were purchased from Thermo Fisher 
and used according to the manufacturer’s protocol. PC3 and LNCaP cells were dissociated mildly 
using TryplE, harvested, and resuspended in 1X PBS at a density of 5.0x105/mL. The antibodies 
were used at a 1:10 dilution and incubated in the dark for 15 minutes. The FITC-PSMA-1 peptide 
was used at a concentration of 1mg/mL and incubated in the dark at 37°C for 1hr. The samples 
were then analyzed on a Cytomics FC 500 flow cytometer (Beckman Coulter) and the data was 
processed using the Kaluza, Flow Cytometry Analysis Software (Beckman Coulter). 
 
4.6.9 siRNA Transfection 
 A monolayer of PC3 or LNCaP cells were grown in a 24-well culture plate in complete 
growth media until 60-70% confluent to ensure expression of the PSMA receptor. Linear GRP78 
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siRNA (12.5 pmol) was incubated with either the PSMA-1-R6 or the FITC-PSMA-1-R9 peptides 
(625 pmol) for 30min at 37°C in Opti-MEM before being added to the cells and diluted to a final 
siRNA concentration of 25nM. siRNA was also complexed with the Trans-IT X2 transfection 
reagent in Opti-MEM according to the manufacturer’s protocol and added to the cells at a final 
concentration of 25 nM. The cells were then incubated at 37°C in a humidified tissue culture 
incubator containing 5% CO2. 
 
4.6.10 siRNA Uptake via Fluorescent Imaging 
 The uptake of the siRNA complexed with the FITC-PSMA-1-R9 peptide was monitored at 
2, 4, 6, and 24hrs post transfection. The cells were imaged directly in the culture plate using a 
CellInsightä High Content Screening (HCS) Platform (Thermo Fischer). Five random field of 
views from 3 separate wells were imaged under brightfield and then again after the cells were 
excited by a 480nm LED filter within the platform. The images were analyzed using Thermo 
Scientificä HCS Studioä Cell Analysis Software. 
4.6.11 qRT-PCR 
Total mRNA was isolated following transfection (48 hrs) from TriZol (Ambion) preserved 
cells using a TriRNA Pure Kit (Geneaid), following the manufacturer’s instructions. The collected 
mRNA was then quantitated on a Qubit 3.0 fluorimeter using the Qubit Broad Range (BR) assay 
kit (Thermo Fisher Scientific), mRNA (200 ng) was reversed transcribed into cDNA using a high 
capacity cDNA kit (Applied Biosystems). RT-PCR was performed using pre- developed 
TaqManTM gene expression primer-probes for GRP78 (assay ID Hs99999174_m1), GRP94 
(assay ID Hs00437665_g1), and GAPDH (Hs99999905_m1) and TaqManTM fast advanced 
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master mix. qPCR fast assay was carried out on a StepOnePlus (Applied Biosystems). Fold 
changes were calculated with the ΔΔCt method using GAPDH as endogenous control and the 
negative siRNA as the control sample.  
4.6.12 Western Blot 
Total protein was isolated from the cell cultures following transfection (78 h). Protein 
lysates were prepared by lysing the cells in ice-cold RIPA buffer (G-Biosciences) supplemented 
with protease and phosphatase inhibitors (Millipore Sigma) which were diluted 1:10 as per the 
manufacturer’s recommendations. Cell debris was removed by centrifugation at 16,000g at 4°C 
and protein concentrations were determined using a PierceTM BCA kit (Thermo Fisher Scientific). 
A sample (20-35 mg) of the supernatant protein was mixed with LDS buffer and DTT, incubated 
at 70 °C for 10 min and resolved on a 4-12% Bis-Tris PAGE gradient gel before being transferred 
to a PVDF membrane. Following transfer, the membrane was blocked in 5% skim milk for 1 h, 
washed and incubated at 4 °C overnight with a rabbit 1° mAb against human GRP78, GRP94, 
GRP75 or b-Actin (all purchased from Cell Signaling Technology) at a 1:1000 dilution. The 
membrane was subsequently washed and incubated with an anti-rabbit HRP-conjugated 2° Ab 
(Cell Signaling Technology) for 1 h at room temperature at 1:2000 dilution. The bands were 
visualized using a SignalFireTM ECL reagent (Cell signaling Technology) on a ProteinSimple 
FluorChem E imager.  
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Chapter 5: Conclusions and Contributions to Knowledge 
5.1 Conclusions and Contributions to Knowledge Made in this Thesis 
5.1.1 Investigating the Role of GRP78 in Cell Adhesion  
 RNAi is a powerful tool that has found wide applicability in disease gene therapies as well 
as in basic research to investigate the role of specific genes in complex molecular pathways. The 
main research objectives of this thesis revolve around improving the utility of synthetic siRNAs 
in cancer gene therapy by targeting and silencing the Glucose Regulated Proteins (GRPs) that play 
key roles in the development, progression and spread of cancer. Chapter 2 highlights a novel role 
that GRP78 has in cell-cell adhesion and its implication in tumors (multiple myeloma, MM and 
prostate cancer, PCa) that target the bone as a primary metastatic site. By silencing GRP78 via 
siRNA, a concomitant downregulation of a mesenchymal cell-adhesion marker, N-cadherin, was 
observed in multiple myeloma and prostate cancer cell lines (Figure 2.1). N-cadherin, and its 
epithelial counterpart E-cadherin, are two major adhesion proteins involved in the EMT pathway, 
for epithelial tumors to transition to mesenchymal form during a metastatic event which leads to 
adhesion to a secondary tumor site. Upon further investigation with an epithelial prostate cancer 
cell line, PC3, it was noted that the GRP78 silencing led to concomitant downregulation of E-
cadherin and subsequent upregulation of TGF-b1 and Snail-2 (Figure 2.5). Interestingly, TGF-b1 
expression has been correlated with EMT and the upregulation of N-cadherin, suggesting that our 
findings indicate a novel function of GRP78 in which it can modulate the expression of adhesion 
molecules in a manner that supersedes the natural pathways that regulate their expression in PCa. 
We also show that this action is not related to the other GRPs, GRP94 and GRP75, as their 
expression levels remained unchanged after GRP78KD despite a known compensatory mechanism 
that alters the expression of one GRP in response to another (Figure 2.4, A). Furthermore, the PC3 
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cells treated with GRP78 siRNA produced drastic changes in their morphology from their normal 
elongated shape to a more rounded shape (Figure 2.6). This change in cell phenotype is important 
because cells tend to be less adhesive in a rounded shape. This resulted in a reduction in their 
adhesion to an osteoblast (bone cell) monolayer in an N-cadherin dependent manner (Figure 2.7). 
These results help establish a novel correlation between GRP78 and N-cad in MM and PCa cells 
and present GRP78 as an ancillary regulator of markers associated with the EMT pathway and its 
implications in the adhesion properties of PCa to the bone. Aside from the extensively described 
roles in tumor progression, our data suggest that downregulation of GRP78 may represent a 
suitable therapeutic intervention strategy for modulating tumor-microenvironment adhesive 
interactions leading to tumor progression. 
 
5.1.2 Development of Higher Order siRNA hybrids and their Bioconjugates for RNAi Activity in Cancer 
 Chapter 3 discussed the application of a synthetic methodology that led to the production 
of linear, V-shape and Y-shape RNA templates, the latter two by the incorporation of a unique 
branchpoint ribouridine synthon. In this application, the RNA templates were used to hybridize 
complementary RNA strands that self-assembled into higher order nanostructure formulations. 
These formulations were designed to adopt genetically encoded shapes that resulted in siRNA 
hybrids that targeted multiple GRPs (Figure 3.4). The first generation of these siRNA 
nanoparticles targeted multiple regions of the GRP78 mRNA and produced a much more 
pronounced knockdown effect and induction of apoptosis in an endometrial AN3CA cancer cell 
line when compared to the control transfection with linear siRNAs targeting the same GRP78 
mRNA sites (Figure 3.4). The second generation lead Y-shape siRNA targeted all three GRPs, 
GRP78,94,75, and was capable of inducing a synergistic knockdown of the GRPs in multiple 
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tumor types (endometrial, breast, cervical) yet proved relatively inert in a non-cancerous lung cell 
line (Figure 3.5). This established that the self-assembled siRNA nanostructures as a more potent 
anti-cancer gene therapy tool as compared to a cocktail of linear siRNAs, administered separately. 
These results highlight the novelty of these siRNAs in enhancing their gene therapy potential and 
also allows flexibility in screening the effects silencing multiple oncogenes on tumor progression 
and viability. 
 siRNA bioconjugates based on the V- and Y-shape RNA templates were designed to 
incorporate multi-functionality to the siRNA constructs and improve their scope. Theranostic 
agents, tools that combine therapy with diagnostics, are rapidly emerging in their utility and 
applications, including those involving siRNAs. In this chapter, a solid phase synthetic strategy 
was developed to covalently attach a fluorophore, FITC, onto chemically synthesized RNA 
templates. A self-assembly strategy was also developed for incorporating multiple FITCs within 
single molecular V- and Y-shape siRNA constructs. These siRNAs provided a unique opportunity 
to track cell uptake, localization, and mechanism of action with greater sensitivity (up to 72 hrs 
post transfection) due to the enhanced signaling effect of the multi-FITC containing siRNAs within 
the PC3 PCa model (Figures 3.7, 3.8). Sense strand functionalization provided the most potent 
GRP KD effects (50-95%) which translated to the most significant cell death effects (20-95%) 
within a model PC3 PCa cell line (Figures 3.9, B and 3.11).  
 A similar approach was used to conjugate fatty acids to the RNA templates on solid phase 
to generate amphiphilic siRNA bioconjugates that may have the potential to diffuse across the cell 
membrane without the need of a transfection vector, ultimately improving their clinical utility. 
Long and short chain fatty acids ( C12-C18) as well as C18 unsaturated fatty acids (w-3,6,9) were 
conjugated to the linear anti and sense sequences, yet only the C16 and C18 conjugated siRNAs 
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were able to elicit GRP78 knockdown, albeit a moderate one ( ~30-40%) (Figure 3.12, B). To 
potentially improve this modest effect, the sense strands were conjugated with palmitic acid (C16) 
and hybridized to the corresponding linear, V-, and Y-shape antisense RNA templates. This self-
assembly approach provided the opportunity to incorporate a single, double or triple palmitamides 
within the linear, V- and Y-shape siRNAs, respectively. However, this did not result in improved 
GRP KD effects (Figure 3.12, D). Cell uptake studies performed by flow cytometry with a 
chimeric fluorophore – fatty acid siRNA bioconjugate revealed that there is an interaction of the 
siRNA with the cells, which rapidly dissipates within 24hrs post transfection (Figure 3.13). 
Furthermore, DLS and TEM analysis revealed large aggregate particles with sizes upwards of 1 
µm (Figure 3.14). Taken together, these results suggest that the amphiphilic lipidated siRNAs may 
contribute to transient cell membrane binding affinity, which rapidly dissipates due to formation 
of large molecular aggregates which impede cell binding and uptake altogether. This effect may 
be applicable to other gene delivery strategies, making this discovery an important one. 
Furthermore, the siRNA bioconjugates effectively expand the scope and utility of the synthetic 
siRNAs, making them more effective therapeutic agents in cancer gene therapy applications.   
 
5.1.3 Development of Cancer Targeting and Cell Penetrating Chimeric Peptides for the Targeted 
Delivery of siRNA in PCa cells 
 A major limitation of siRNA therapies is their lack of cell selectivity, especially when 
delivered with a conventional transfection reagent into non-targeted cells leading to potentially 
deleterious off-target side effects. Chapter 4 of this thesis illustrates a unique method for targeting 
cells for siRNA delivery. The use of cell targeting peptides (CTPs) function to target and bind to 
a cell surface receptor, in this case PSMA, found on PCa cells. Moreover, the incorporation of 
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poly(cationic) cell penetrating peptides (CPPs), such as poly(arginine), can have dual functionality 
in condensing siRNA by favorable electrostatic interactions and facilitating cell uptake within the 
target cell lines. The PSMA receptor is a surface bound enzyme expressed in metastatic PCa, 
linked with poor prognosis and, most importantly, found on castrate-resistant PCa tumors. 
Recently, peptides were discovered from phage display to target and bind to the PSMA receptor 
on selected PCa cells leading to cell penetration by receptor mediated endocytosis. A lead model 
peptide sequence, PSMA-1, was functionalized with short oligo(arginine) sequences (R6 and R9). 
The peptides were synthesized on solid phase, purified by RP-HPLC, and characterized by ESI-
MS. (Scheme 4.1, Table 4.1). Furthermore, an FITC tag was included on the parent PSMA-1 
peptide as well as the PSMA-1-R9 peptide in order to track cell binding and uptake. The PSMA-1 
peptide was able to effectively bind to PSMA+ LNCaP cells with a limited amount of nonspecific 
binding to a PSMA- PC3 cell line (Figure 4.4). The R6 variant was shown to efficiently complex 
and release siRNA according to a gel shift assay (Figure 4.3), yet no GRP78 KD was detected at 
the mRNA and protein levels of expression within the PC3 or LNCaP cells (Figure 4.7). Cell 
uptake studies by flow cytometry revealed that the FITC-PSMA-1-R9 peptide showed limited 
uptake into the cells when bound with siRNA (Figure 4.5). DLS and TEM analysis showed large 
particle sizes (1-2 µm), polydisperse particle distributions, negative surface charge densities and 
aggregation which prevented cell uptake of the CTP:siRNA complexes when compared to siRNA 
complexed with a commercial transfection reagent. This suggests that although the peptides are 
capable of complexing and releasing siRNA, they do no efficiently condense the siRNA into small, 
monodisperse, neutral particles that can easily penetrate the cell membrane. Future work is aimed 
at improving the design and delivery characteristics of the peptide-based transfection reagent.  
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5.2 Future Work 
 While the results in this thesis highlight important accomplishments in the field of siRNA-
based gene silencing, there is still progress to be made. The V- and Y-shape siRNAs, to date, have 
been used to target only the GRPs. An important variation would be to generate siRNAs that target 
other oncogenes and investigate their activity. For instance, designing an siRNA to targets both 
GRP78 and N-cad may have an even more pronounced effect on E-cad and other EMT markers.  
Similarly, the bioconjugation strategies could be expanded to include different fluorophores and 
amphiphilic or cationic lipids. Different fluorophores would allow the siRNAs to be used in 
differential imaging and co-localization experiments particularly when being used to deduce 
molecular pathways or protein mechanism of actions. The addition of cationic or amphiphilic 
lipids to the siRNA would mimic the formulations used by many commercial transfection reagents 
and may allow for improved siRNA nanoparticle formulations for cell delivery.   
 Moreover, the CTP-CPP chimeras need to be designed to improve siRNA condensation in 
order for cell uptake to proceed efficiently. One design approach could be to create dendrimeric 
peptides in which the PSMA targeting peptide displays multiple oligo(arginine) sequences. In 
doing so, the chimeric peptide may be able to encapsulate the siRNA. Another approach would be 
to introduce linkers, such as polyethylene glycol (PEG), between the CTP domain and the 
oligoarginine domain. This may help to restore the ligand binding properties by reducing 
aggregation and steric block of receptor mediated endocytosis.  Regardless of the variations, we 
envision that the future iterations of the formulations presented in this thesis will significantly help 
to further enhance the functionality of siRNA in cancer gene therapy applications.  
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Figure 5.1 Future CTP-CPP variations. Top: dendrimeric peptides containing multiple oligo-
arginine moieties branching from a single PSMA CTP. Bottom: A linear peptide with a PEG linker 
separating the CTP and CPP domains. 
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Figure A1 Western Blot Analysis of Basal GRP78 and N-cad expression in PC3 and MM.1S 
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Figure A2 RP IP HPLC Analysis of FITC-PSMA-1 (220nm) 
 
 
           Minutes 
 
 RT % Area Area (µV*sec) 
1 10.018 100 979467 
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Figure A3 RP IP HPLC Analysis of FITC-PSMA-1 (480nm) 
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 RT % Area Area (µV*sec) 
1 10.018 100 156568 
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Figure A4 ESI-MS Analysis of FITC-PSMA-1 
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Figure A5 RP IP HPLC Analysis of PSMA-1-R6 (220nm) 
 
 
 
Minutes 
 
 RT % Area Area (µV*sec) 
1 6.466 6.88 53173 
2 6.874 88.09 473200 
3 9.469 5.03 38875 
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Figure A6 ESI-MS Analysis of PSMA-1-R6 
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Figure A7 RP IP HPLC Analysis of FITC-PSMA-1-R9 (220nm) 
 
 
 
        Minutes 
 
 
 RT % Area Area (µV*sec) 
1 9.707 3.18 149571 
2 9.973 96.82 3153448 
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Figure A8 RP IP HPLC Analysis of FITC-PSMA-1-R9 (480nm) 
 
 
 
 
 
          Minutes 
 RT % Area Area (µV*sec) 
1 9.707 7.22 28945 
2 9.973 92.78 371957 
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Figure A9 ESI-MS Analysis of FITC-PSMA-1-R9 
 
 
 
 
 
 
 
 
 
